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ABSTRACT
The co-chaperone protein Bcl-2-associated athanogene-3 (BAG3) is a central
mediator of cellular protein quality control through autophagy. In the heart, decreased
BAG3 activity through mutation or decreased expression are linked to dilated
cardiomyopathy (DCM). Unfortunately, though clinical data indicates BAG3 mutations
are a definitive cause of DCM, few mechanistic studies had been performed to decipher
the fundamental role of BAG3 in cardiomyocytes. However, several studies suggested
BAG3 was involved in maintenance of the sarcomere, the molecular contractile
structure in muscle cells. The goals of this dissertation were to: 1. Determine the
functional significance of BAG3 for the sarcomere, 2. Identify the mechanism(s) of
sarcomere maintenance by BAG3, and 3. Assess the impact of proposed BAG3targeting heart failure and cancer therapies on cardiomyocytes.
Using biophysical assays to assess sarcomere function in cardiomyocytes from
human DCM and mouse models of BAG3 deficiency/mutation, we identified BAG3 was
required for maximal sarcomere contractile strength. To determine the mechanism of
BAG3-dependent sarcomere maintenance, we employed a combination of molecular
biology, cell culture, super-resolution imaging, and proteomics approaches and found
that BAG3 maintained sarcomere function through chaperone-assisted selective
autophagy (CASA) with HSP70 and HSPB8. We further found this CASA complex
localized to the Z-disc in cardiomyocytes and mediated turnover of sarcomere proteins.
xiv

In a study of human myocardial samples, we found sarcomeric BAG3 decreased in
male DCM patients, indicating a potential sex-dependent mislocalization in disease.
Importantly, in male mice with heart failure secondary to myocardial infarction, BAG3
gene therapy restored CASA protein clearance and rescued sarcomere function.
However, exposure of cardiomyocytes to proposed small molecule cancer therapeutics
that disrupt the CASA complex resulted in reduced autophagy flux, increased apoptosis,
and sarcomere structural disintegration, suggesting such treatments will be cardiotoxic.
Sarcomere protein quality control mechanisms are poorly understood. Herein, we
have characterized a mechanism of sarcomere protein turnover in the heart. We hope
others will build on these findings to further advance our collective understanding of this
complex process. Finally, we hope our findings will help to inform future therapies for
both genetic and non-genetic cases of heart failure where reduced BAG3 activity is
implicated.
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CHAPTER 1
INTRODUCTION
The Co-chaperone B-cell Lymphoma-2-associated Athanogene-3 (BAG3)
The co-chaperone Bcl2-associated athanogene-3 (BAG3) is a multifunctional
adaptor protein that orchestrates cellular signaling pathways by serving as a scaffold for
the assembly of unique protein complexes. The capability of BAG3 to interact with
diverse protein binding partners stems from the co-chaperone’s four distinct binding
domains: the N-terminal tryptophan-tryptophan motif (WW), two isoleucine-prolinevaline motifs (IPV), a proline rich region near the center (PXXP), and the C-terminal
BAG domain, from which its name derives (Figure 1) [1]. Through regulation of its
binding partners, BAG3 has been identified as a fundamental modulator of apoptosis,
autophagy, development, and cytoskeleton remodeling [2–6]. BAG3 is also expressed
at the protein level in nearly every tissue, excepting only the spleen and lymph nodes,
with highest expression in striated muscle, nervous and endocrine tissues, and the
female reproductive organs (The Human Protein Atlas). Therefore, it is perhaps
unsurprising that dysregulation of BAG3 is implicated in several diseases, including
various cancers, neurodegenerative diseases, skeletal myopathies, and
cardiomyopathies.
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Figure 1. Unique Domains on BAG3 Facilitate Numerous Protein Interactions.
As a co-chaperone, BAG3 modulates several cellular processes (including
apoptosis, autophagy, cytoskeleton remodeling, and development) through its
multiple protein binding partners. Through the N-terminal tryptophan-tryptophan
(WW) domain, BAG3 interacts with proteins involved in autophagy and gene
expression. The two isoleucine-proline-valine (IPV) motifs facilitate interactions
between BAG3 and a handful of small heat shock proteins (HSPBs), including
HSPB1, HSPB5, HSPB6, and HSPB8. Between the two IPV motifs, phosphorylation
of serines 136 and 173 are promote interaction with 14-3-3 adaptor proteins, an
important step in substrate trafficking in BAG3-dependent autophagy. In the middle
of the protein, a proline rich region (PXXP) engages in interactions with
phospholipase C gamma, SRC, the molecular motor protein dynein, and likely
others. This domain is fundamental for BAG3’s cell protective effects. Finally, at the
C-terminus is the BAG domain, a triple alpha helix structure that interacts with Bcl-2
to prohibit apoptosis, from which BAG3’s name derives. This domain also interacts
with HSP70/HSC70 for which BAG3 is a nucleotide exchange factor and regulates
HSP70 client processing and autophagy.

Regulation of bag3 Gene Expression
Expression of the bag3 gene is regulated by several transcription factors.
Foremost among these is thought to be heat shock factor-1 (HSF-1), the primary
orchestrator of the stress response in most cell types [7]. HSF-1 localizes to the nucleus
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in response to cell stressors, including heat, oxidative stress, hypoxia, and with
exposure to some compounds, and binds to two heat shock elements in the bag3 gene
promoter to stimulate its expression [8–10]. While this stress-induced upregulation of
BAG3 levels is well described, it is not clear if basal regulation of bag3 gene expression
is through HSF-1, or if it is mediated by another factor. Another transcription factor,
NFκB, has been shown to regulate bag3 expression. The involvement of NFκB in
regulating bag3 expression is also stress-induced and was shown to occur after heat
stress or with proteasome inhibition by bortezomib [11,12]. The NFκB-dependent
regulation of bag3 expression following stress appears to require c-jun N-terminal
kinase (JNK), as inhibiting JNK prevented the upregulation of BAG3 levels [13,14].
BAG3 Post-translational Modification
Though very little is understood regarding the post-translational regulation of
BAG3, earlier work in skeletal muscle, neurons, and cancer cells identified several
phosphorylation sites. One study using the mouse C2C12 cell line, a model of skeletal
myocytes, used quantitative proteomics to identify how phosphorylation differs between
myoblasts and differentiated myotubes. They found that many proteins known to
associate with the sarcomere Z-disc, a signaling hub in striated muscle, displayed
unique phosphorylation signatures in the mature myotubes that were absent in
myoblasts [15]. One of these was BAG3, which they identified as being phosphorylated
on nine different serine residues (Table 1). Phosphorylation at two of these same
residues (S136 and S173) in Chinese hamster ovary (CHO) cells and A549 cells were
shown to regulate binding of BAG3 to 14-3-3 proteins, regulatory adaptor proteins that
facilitate the association of BAG3 and its cargo with dynein, an essential step in some
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BAG3-mediated autophagy processes [16]. Studies in cancer cells have identified two
other phosphorylation sites, S187 and Y457, which are involved in epidermal growth
factor signaling and tumor migration [17,18].
Table 1. BAG3 Post-translational Modifications
Site

PTM

Cell Type/Tissue

Role

Reference

K60
S136
S171
S173
S177
S180
S183
S185
S187
S194
S195
K249
S264
S268
S269
S274
S275
S279
S283
S284
T285
S289
S291
K349
S377
S381
S385
S386
S399
Y457
K445
K446
K493

Acetylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Acetylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Acetylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Phosphorylation
Acetylation
Acetylation
Acetylation

Heart
Heart, skeletal, CHO, A549
Heart
Heart, skeletal, CHO, A549
Heart
Heart
Heart
Heart
Thyroid cancer
Heart
Heart
Heart
Heart, skeletal
Heart, skeletal
Heart
Heart
Heart
Heart, skeletal
Heart
Heart
Heart
Heart
Brain
Heart
Heart, skeletal, WBC, HEK293
Heart
Heart, skeletal, HEK293
Heart
Skeletal muscle
Breast cancer
Heart
Heart
Heart

Unknown
14-3-3 binding
Unknown
14-3-3 binding
Unknown
Unknown
Unknown
Unknown
Cancer proliferation
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
BAG3 stability
Unknown
Stress response, ERK
Unknown
ERK signaling
Unknown
Unknown
EGF signaling
Unknown
Unknown
Unknown

My data
[15,16]
My data
[15,16]
My data
My data
My data
My data
[17]
My data
My data
My data
[15]
[15]
My data
My data
My data
[15]
My data
My data
My data
My data
[19]
My data
[15,20]
My data
[15,20]
My data
[15]
[18]
My data
My data
My data

Our own unpublished proteomics data using protein level immunoprecipitation of
BAG3, tryptic digestion, and bottom-up mass spectrometry on human myocardial
samples further extends the vast phosphorylation fingerprint of BAG3 (Table 1).
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Additionally, we have identified several lysine acetylation sites on BAG3 in the human
heart (Table 1). Interestingly, while we have identified 24 phosphorylation sites on
BAG3 in the human heart, only 4 of these (S377, S381, S385, and S386 in the PXXP
region) lie within one of BAG3’s domains. Thus, it seems unlikely that most of these
PTMs affect BAG3 interactions with its known substrates. However, the study of BAG3
PTMs is in its infancy, with very few studies (none in the heart) exploring the
mechanism leading to PTMs, the kinases mediating BAG3 phosphorylation, or the
subsequent effects of PTMs on protein function. In the cardiac field, perhaps the
primary reason for this gap in knowledge is that before we can study the effects of
BAG3 PTMs, we first need to establish a solid groundwork for BAG3’s role in the heart.
To date, there are an abundance of clinical studies on BAG3, however, basic
mechanistic studies of BAG3 in the heart are lacking.
Involvement of BAG3 in Anti-apoptotic Signaling Pathways
Apoptosis is a complex process involving several cellular signaling pathways and
numerous signaling molecules. It is generally accepted that there are two potential
origin stories for cell death by apoptosis: the extrinsic pathway through the tumor
necrosis factor alpha (TNFα) receptor and the intrinsic or mitochondrial pathway [21]. In
the extrinsic pathway, extracellular ligands bind to the TNFα receptor on the cell
membrane and trigger cell death through downstream TNFα receptor-dependent
signaling mechanisms [22]. The intrinsic pathway is often activated by stressors, such
as toxins or oxidative stress, which contribute to opening of the mitochondrial
permeability transition pore, altered mitochondrial transmembrane potential, and release
of pro-apoptotic signaling proteins that are normally sequestered in the mitochondria
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[22]. Studies over the last two decades indicate that BAG3 modulates and prohibits
apoptosis through each of these pathways.
Evidence for BAG3’s involvement in the extrinsic apoptosis pathway is limited.
However, one study in thyroid cancer found that BAG3 suppresses the apoptotic
response to TNF-related apoptosis-inducing ligand (TRAIL), which binds to the TNFα
receptor [23]. Many more studies have characterized the involvement of BAG3 in the
intrinsic pathway. Here, BAG3’s anti-apoptotic effects can be generally parsed into three
categories: 1. Activation and sustainment of anti-apoptotic NFκB signaling, 2.
Inhibition/sequestration of mitochondrial pro-apoptosis proteins, 3. Stabilization of antiapoptosis proteins. BAG3-mediated activation of the anti-apoptotic NFκB pathway
occurs through IKK-γ, an upstream regulator of NFκB, which BAG3 protects from
proteasomal degradation [24]. Upon apoptotic stimuli, the proteins Bax and Bak
oligomerize and translocate from the cytosol to the mitochondrial outer membrane to
mediate its permeabilization [25]. Studies have shown that BAG3 prohibits this process
by binding Bax and sequestering it in the cytosol [26], which prevents cytochrome C
release from the mitochondria and the apoptotic signaling cascade that follows [27].
Finally, BAG3 prevents apoptosis through stabilization of anti-apoptotic proteins,
including Bcl-2, survivin, and Mcl-1 [28–30].
Most studies on BAG3 in apoptosis regulation have been performed in cancer
cells, where its anti-apoptotic role is considered a potential target for therapy. However,
several studies indicate that the anti-apoptotic effects of BAG3 extend to the heart,
which has important implications for cardiomyocytes as they are post-mitotic cells. Su
and colleagues showed that culturing cardiomyocytes in a hypoxic environment results
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in decreased protein expression of BAG3, which is associated with reduced Bcl-2
expression and increased apoptosis [31]. Notably, this study and a study by another
group found that BAG3 overexpression in cardiomyocytes following hypoxic stimuli
resulted in attenuation of apoptosis [31,32]. BAG3 haplo-insufficiency in mice and
certain heart failure-associated BAG3 mutations have also been linked to increased
cardiomyocyte apoptosis [33,34]. Future studies are needed to determine if BAG3
suppresses apoptosis in cardiomyocytes through its previously described mechanisms
in cancer cells, or if these results are due to modulation of other processes such as
autophagy, as has been suggested [32].
Involvement of BAG3 in Autophagy Pathways
Organelles and misfolded proteins/protein aggregates that are too large to be
degraded by the proteasome are targeted to autophagy. First described by Christian de
Duve in 1967 [35], this process involves the formation of a lipid bilayer
(autophagosome) around the substrates, followed by fusion of the autophagosome with
a lysosome, where its contents are exposed to lysosomal hydrolases and rapidly
digested [36]. The involvement of BAG3 in autophagy stems from its association with
heat shock protein 70 (HSP70) via the BAG domain [37] and heat shock protein beta 8
(HSPB8) through two IPV motifs [38]. By extension, BAG3 is associated with the
misfolded protein cargo bound by the HSPs. Studies by Gamerdinger and colleagues
discovered that BAG3 facilitates the connection between the poly-ubiquitinated cargo
and the autophagic ubiquitin adaptor protein P62/SQSTM1 [39,40]. P62 is unique in that
it forms interactions with both the cargo and with LC3 proteins on the autophagosome
membrane, thus bringing the two together to promote autophagosome engulfment [41].
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The BAG3-HSP70-HSPB8 complex has also been shown to mediate autophagic
degradation of protein aggregates in models of neurodegenerative diseases [19,42–45].
Notably, without BAG3, HSPB8 fails to target substrates to autophagy [46], indicating
that BAG3 regulates an important autophagy pathway that is conserved across multiple
cell types [39,46–49]. While the BAG3-HSP70-HSPB8 complex is generally considered
to mediate selective macroautophagy of poly-ubiquitinated substrates, the complex has
also been shown to target un-ubiquitinated proteins through chaperone-mediated
autophagy [40].
The involvement of BAG3 in autophagy extends to the heart, though the specific
mechanisms have been poorly studied to date. Myers and colleagues showed that
cardiomyocyte-specific BAG3 haploinsufficiency reduces autophagic flux [33] and
others have described a role for BAG3-mediated protein quality control (PQC) for
specific clients in the nucleus (Lamin B) [50], gap junctions (Connexin 43) [51], and
mitochondria (TOM20) in cardiomyocytes [52]. Su et al. also showed that BAG3 siRNA
knockdown was associated with reduced expression of LAMP1, a lysosomal membrane
protein involved in lysosome biogenesis and integrity maintenance [53], which likely has
negative consequences for autophagy [31]. Other mechanistic studies on BAG3 and
cardiomyocyte autophagy are lacking, however, one consistent finding across multiple
studies is that reduced expression of BAG3 causes instability of HSPB8 and other
HSPBs [54–57]. Taken together with concurrent increases in misfolded protein
aggregates with BAG3 knockdown [54], this finding suggests that the BAG3-HSP70HSPB8 autophagy-mediating complex may be conserved in cardiomyocytes.
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BAG3 Mutations are Associated with Cardiac and Skeletal Muscle Myopathies
BAG3 Mutations and Dilated Cardiomyopathy
Mutations to BAG3 are among the leading causes for genetic dilated
cardiomyopathy (DCM), a syndrome characterized by decreased cardiac output and an
enlarged, weakened left ventricle [58]. Two recent clinical studies on the genetic
architecture of DCM concluded separately that there are 13 and 8 definitive monogenic
causes of genetic DCM, with BAG3 included on both lists [59,60]. Another study of
familial hypertrophic cardiomyopathy (HCM) and DCM suggested that BAG3 mutations
are also causative of HCM [61] and others have shown BAG3 mutations are associated
with Takotsubo cardiomyopathy [62,63]. However, there are fewer reports linking BAG3
mutations to these etiologies, suggesting they may be distinct to the specific cohort or
family studied and less representative of the general population. Disease-causing BAG3
mutations may be either missense or truncating variants, with numerous examples of
DCM arising in both cases [59,60,64–70]. In the largest study of BAG3 mutations to
date, Dominguez and colleagues studied 129 patients with BAG3 mutations across 18
European centers and found high disease penetrance in carriers >40 years-old with
likely development of progressive cardiac dysfunction and DCM [64]. Importantly, this
study also showed that there are sex differences in the disease penetrance of BAG3
mutations with males being much more likely to exhibit cardiovascular dysfunction [64].
Despite the prevalence of BAG3 mutations in the clinical literature, there have
been remarkably few basic mechanistic studies. The first was by Arimura and
colleagues who studied four BAG3 mutations (two DCM-causing: L462P, R218W; one
skeletal myopathy associated variant: P209L; and one genetic polymorphism: R258W)
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[34]. Using neonatal rat ventricular myocytes, they showed that the DCM-associated
mutations disrupted sarcomere Z-disc assembly and caused apoptosis in
cardiomyocytes [34]. Another study using iPSC-derived cardiomyocytes investigated the
mechanism of dysfunction resulting from the BAG domain mutation R477H. The authors
showed that R477H BAG3 had reduced binding to HSP70, myofibrillar disorganization
upon proteotoxic stress induction via proteasome inhibition, and reduced protein
expression of HSPBs. Interestingly, the negative effects of the mutation on myofibrillar
structure were partially restored with overexpression of HSF-1 [56].
To date, there has been only one in vivo study of a DCM-associated BAG3
mutation. Fang et al. studied another BAG domain mutant, E455K, in a cardiomyocytespecific genetic mouse model. They again found decreased HSP70 binding and
reduced stability of HSPBs with the BAG3 mutation, along with increased protein
aggregation [54]. The findings of these three studies suggest that the pathology arising
with BAG domain mutations, and likely truncating variants that do not contain this Cterminal domain, results from reduced binding to HSP70. Notably, a study of BAG3
truncating variants in zebrafish found that the pathology is reduced with activation of
autophagy by genetic haploinsufficiency of the mammalian target of rapamycin (mTOR)
[71]. However, further studies are needed to elucidate the disease mechanism with
mutations outside of the BAG domain.
In addition to disease-causing BAG3 mutations, a clinical study of left ventricular
structure/function among over 30,000 patients with heart failure found one BAG3
variant, C151R, is associated with an improved cardiac phenotype [72]. While this is an
exciting finding, the underlying mechanism for the protective effects of C151R are
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unknown. However, one might speculate that the mutation may promote BAG3 stability
by preventing digestion by cysteine proteases.
The Myofibrillar Myopathy-associated P209L BAG3 Mutation
BAG3 genetic variants are also a prominent cause of skeletal myopathy, which
may present alone or together with neuropathy and/or cardiomyopathy [73–75]. Among
these variants, missense mutations at amino acid 209 (P209L, P209S, P209Q) are the
most prominent, and are primarily associated adolescent onset myofibrillar myopathy
and increased mortality [75–80]. However, co-presentation with restrictive
cardiomyopathy, long QT syndrome, respiratory insufficiency, and peripheral
neuropathy are common. The mutation occurs within the second IPV motif, required for
HSPB binding, however it does not appear to affect the interaction of BAG3-HSPB8
[81,82]. Instead, mechanistic studies have shown that the P209 mutations disrupt
clearance of HSP70 clients by the BAG3-HSP70-HSPB8 complex by stalling the
complex and its ubiquitinated substrates at the perinuclear aggresome [82,83]. P209
mutations also reduce the refolding ability of HSP70 [82]. Others have shown structural
disintegration of the sarcomere Z-disc, protein aggregation, and signs of increased
apoptosis in skeletal and cardiac muscle biopsies from patients with P209L BAG3
mutations [75,84,85]. Additionally, studies of P209L BAG3 in zebrafish indicate that the
associated muscle pathology may be reduced with pharmacological activation of other
autophagy pathways [86,87]. The abundance of clinical data and basic science studies
of BAG3 P209 mutations support the importance of BAG3-HSP70-HSPB8 complexmediated autophagy in striated muscle.
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In the heart, there have been three in vivo studies of BAG3 P209L, each using a
different mouse model, and somewhat disparate conclusions. The first used a
transgenic mouse model with cardiomyocyte-specific expression of the human P209L
BAG3 [88]. The transgenic mice developed in vivo cardiac dysfunction by 8 months and
upon biochemical analysis displayed evidence of dysregulated autophagy and
proteotoxicity. However, this model did not perfectly replicate the progression of disease
in humans as in vivo cardiac structure (increased LV end diastolic diameter) was more
representative of DCM than restrictive cardiomyopathy. Moreover, the development of
dysfunction was relatively late (8 months) compared to adolescent onset in humans.
The second model was a genetic mouse model with a mutation of the analogous mouse
residue (P215L) [89]. However, there was no impact of the mutation on cardiac function,
leading the authors to conclude that the pathology of this mutation is likely specific to
the human BAG3. Finally, a third study was conducted using a human transgenic P209L
BAG3 mouse line [81]. This line phenocopies the human presentation of disease with
early-onset restrictive cardiomyopathy. Moreover, P209L BAG3 was found in this study
to be less soluble and prone to aggregation, while sequestering components of the
autophagy machinery. P209L BAG3 was also found in this study to causes sarcomere
structural disintegration, which has been observed clinically [75,85]. As the authors
discuss, the primary difference between this model and transgenic mouse used by
Quintana et al. [88] is most likely that the extent of human P209L overexpression was
much greater.
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Figure 2. BAG3 Protein Expression in the Left Ventricle Decreases in Patients
with Dilated and Ischemic Cardiomyopathies. (A). Representative western blot for
whole LV BAG3 in the non-failing (NF) and DCM left ventricle and BAG3 expression
normalized by total protein; n = 10 NF, 20 DCM. (B). Representative western blot for
whole LV BAG3 in the non-failing (NF) and ICM left ventricle and BAG3 expression
normalized by total protein; n = 10 NF, 10 ICM. (C). Representative western blot for
whole LV BAG3 in the non-failing (NF) and HCM left ventricle and BAG3 expression
normalized by total protein; n = 10 NF, 8 HCM. For all, the data were analyzed by
two-tailed t-test and are presented as the mean ± SEM.
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BAG3 in Non-genetic Heart Failure
BAG3 Expression Decreases in Ischemic and Dilated Cardiomyopathies
Beyond being a leading genetic cause of heart failure, decreased protein
expression of BAG3 has also been observed in humans with idiopathic cardiomyopathy
and in animal heart failure models. In a study of a small human cohort of DCM and
ischemic cardiomyopathy (ICM), Feldman et al. showed that LV BAG3 protein
expression decreases significantly in disease, while mRNA expression is not changed,
suggesting increased protein degradation and/or protein instability in disease [70]. Our
own unpublished data further validate this finding. We performed western blots for
BAG3 in LV protein lysates from non-failing rejected donor samples and compared
BAG3 protein expression with samples from patients with DCM, ICM, or HCM (Figure
2). Our data indicate that BAG3 is significantly reduced in DCM and ICM, while HCM
has no effect on BAG3 protein expression. Animal models of heart failure secondary to
trans-aortic constriction or MLP knockout (DCM models) and myocardial infarction (ICM
model) further support that BAG3 protein decreases in these two manifestations of the
disease [54,90,91]. Unfortunately, the mechanism underlying reduced BAG3 protein
expression in heart failure remains unknown.
While mechanisms remain to be elucidated, therapies that increase BAG3
expression in heart failure models or autophagy activity in BAG3 knockout models have
shown therapeutic promise. In a mouse model of heart failure eight weeks after left
anterior descending artery (LAD) ligation, three weeks of adeno-associated virus-9
(AAV9) driven BAG3 gene therapy was found to fully restore systolic function to sham
levels [91]. Moreover, this same approach was found to restore LV ejection fraction after
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ischemia/reperfusion injury, while reducing apoptosis and increasing autophagy flux
[31]. In a zebrafish model of BAG3 deficiency which presented with a DCM phenotype,
activation of autophagy was shown to have a similar effect on restoring LV ejection
fraction [71]. These studies support the therapeutic potential of targeting BAG3 and
suggest that the dysfunction associated with reduced BAG3 in heart failure may be due
to inadequate autophagy.
Serum BAG3 as a Biomarker for Heart Disease
Circulating protein levels, such as atrial natriuretic peptide (ANP) or troponin I,
are commonly used in the clinic as a first-pass screen in the diagnosis of heart failure
and myocardial infarction [92,93]. Work by Dr. M. Caterina Turco’s group suggests that
serum BAG3 protein and anti-BAG3 antibodies may also be useful biomarkers in
disease. One study of serum samples of 39 patients with acute decompensated heart
failure showed that BAG3 plasma concentrations above the median (336 ng/mL) was
associated with ~40% mortality by one year, while concentrations lower than the median
were associated with just ~15% mortality [94]. Further work by this group found that
circulating anti-BAG3 antibodies also significantly increase in chronic heart failure
compared to healthy subjects [95]. However, the use of serum BAG3 as a biomarker in
heart failure may be confounded by it also increasing with some cancers [96].
BAG3-dependent Regulation of Cardiomyocyte Contractility
While BAG3’s primary roles are generally considered to be in anti-apoptotic
signaling pathways and macroautophagy, another – potentially cardiomyocyte-specific –
role of BAG3 is the regulation of contractility through beta-adrenergic and calcium
signaling. Studies in isolated adult cardiomyocytes found that BAG3 associates with the
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β1-adrenergic receptor and L-type calcium channel, and downregulation of BAG3 is
associated with reduced cell shortening and calcium transient amplitude with
isoproterenol stimulation [97]. Decreased BAG3 levels were also associated with
reduced sarcoplasmic reticulum calcium stores in this study [97]. Myocytes isolated
from cardiomyocyte-specific BAG3 haploinsufficient mice showed reduced contractility
[33] and BAG3 overexpression in vivo in a heart failure mouse model was associated
with increased calcium transient amplitude in isolated cardiomyocytes [91]. Finally, in a
study employing microelectrode array technology in neonatal rat ventricular myocytes,
Tahrir and colleagues found that BAG3 also modulates signal propagation between
myocytes [98]. Future studies are needed to explore the specific mechanisms
underlying BAG3’s regulation of cardiomyocyte contractility.
BAG3 and the Sarcomere
BAG3 and Skeletal Myocyte Sarcomere
One of the earliest in vivo studies of BAG3, using whole body genetic BAG3
deletion in a mouse model, found that the mice developed severe skeletal myopathy
and died by three weeks of age [99]. Follow-up studies by two other groups had similar
findings [54,100]. Among the most prominent features of skeletal muscle was
sarcomere structural disintegration. Interestingly, sarcomere structure was normal in
embryonic mice, suggesting BAG3 is not needed for muscle development but has a role
in sarcomere structural maintenance [99]. Several studies by Dr. Jörg Höhfeld’s
laboratory explored the role of BAG3 at the skeletal sarcomere and found that the BAG3
together with HSP70 and HSPB8 is involved in a muscle-specific selective
macroautophagy pathway at the sarcomere [4,47,101]. In this pathway, termed
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chaperone-assisted selective autophagy (CASA), mechanically denatured filamin C (a
Z-disc actin cross-linking protein) is bound by the BAG3-HSP70-HSPB8 complex, which
localizes to the sarcomere Z-disc [102]. Filamin C is then ubiquitinated through the
HSP70-associated E3 ubiquitin ligase c-terminus of HSP70-interacting protein (CHIP),
tagging it for autophagic removal [103]. BAG3 then facilitates the association of this
cargo with the ubiquitin receptor P62, which connects the complex and filamin C to the
forming autophagosome membrane via interactions with LC3 proteins thereon. Another
protein, synaptopodin-2 (SYNPO2), which binds to the WW domain at the N-terminal
end of BAG3 is then thought to assist with full maturation of the autophagosome. After
autophagosome engulfment, the entire complex and its client are taken to the lysosome
and degraded [102]. The CASA pathway was first discovered in Drosophila [47], but it
has since been shown to play an important role in the skeletal sarcomere in humans
also [101]. Whether filamin C is the only client of CASA is not clear, though it seems
unlikely that such a complex process would evolve for the maintenance of a single
protein.
BAG3 and the Cardiomyocyte Sarcomere
Whether the CASA pathway operates at the cardiomyocyte sarcomere is
unknown, however, several studies implicate a role for BAG3 in sarcomeric
maintenance in the heart as well. Work by Hishiya and colleagues showed that in
neonatal rat ventricular myocytes, BAG3-HSP70 is important in maintaining the stability
of the actin capping protein CapZ at the sarcomere [104]. Additionally, they found that
shRNA knockdown of BAG3 prevented the mechanical stress-dependent maintenance
of sarcomere structure. Another study using iPSC-derived cardiomyocytes also showed
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that BAG3 was fundamental for structural maintenance of the sarcomere and went a
step further to show that the absence of BAG3 depresses cardiomyocyte contractile
force using atomic force microscopy [105]. Unfortunately, these studies each used
immature cardiomyocytes, which are structurally and functionally distinct from the adult.
However, work in a zebrafish model of BAG3 deficiency supports that BAG3 is
important for maintaining contractile function in adult myocytes as well [71].
Major Knowledge Gaps
Based on the available basic mechanistic studies of BAG3 in cardiomyocytes,
the roles of BAG3 in these cells may be broadly categorized into three camps:
stimulation of macroautophagy, anti-apoptosis signaling, and contractility maintenance.
Unfortunately, despite an abundance of evidence from clinical studies that BAG3 is
fundamental for cardiac function, we still know very little regarding the specific roles of
BAG3 in cardiomyocytes. Additionally, much of what has been established
mechanistically has come from studies using immature cardiomyocytes, which may not
reflect the physiology of mature cells. Indeed, that BAG3 knockout has no effect on
cardiomyocyte/sarcomere maturation in utero but has drastic effects once cells are
under mechanical load after birth, indicates just how important studies in adult myocytes
are [99]. Below, I summarize several major knowledge gaps regarding our
understanding of BAG3 in cardiomyocytes and how I intend to answer these questions
through this project.
What is the Role of BAG3 at the Cardiomyocyte Sarcomere?
Studies in skeletal myocytes indicate an important role for BAG3-mediated
selective autophagy (CASA) in maintenance of filamin C protein quality control at the
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sarcomere. Work in immature cardiac myocytes suggests an important structural and
functional role for BAG3 at the cardiomyocyte sarcomere. However, it is not clear to
what extent 1. Sarcomere protein quality control is impacted in human heart failure, 2.
Whether BAG3 localizes to the sarcomere in adult cardiomyocytes, 3. If BAG3 is
structurally and functionally significant at the mature sarcomere in cardiomyocytes, and
4. Whether CASA is conserved in cardiomyocytes/what the clients of BAG3-dependent
autophagy are.
How do Cancer Therapeutics that Target the BAG3-HSP70 Complex Impact
Cardiomyocytes?
While restoring BAG3 expression activity is under consideration as a potential
therapeutic target in heart failure, an equal emphasis has been placed on inhibiting
BAG3 and its regulation of HSP70 to treat cancer as increased BAG3 expression and
activity contribute to tumor growth and migration [106,107]. Promising small molecules
that disrupt BAG3 binding to HSP70 have proven efficacious in cell and animal cancer
models [106,108,109]. However, it is not known 1. How these therapies impact the
heart, where BAG domain mutations (which also disrupt HSP70 binding) are associated
with DCM, 2. Whether disrupting BAG3-HSP70 by this method will affect sarcomere
structure, as some BAG domain mutants do [34], and 3. If toxic, can co-treatment with
an autophagy inducing compound prevent toxicity as has been shown in models of
BAG3 deficiency and mutation [87].
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What Factors Regulate BAG3 Protein Expression and Localization in the Human
Heart?
As already described, one common theme in heart failure is reduced protein
expression of BAG3. Unfortunately, the underlying mechanism is almost completely
unknown. One study showed that overexpression of HSF-1 restored sarcomere
structure in iPSC-derived cardiomyocytes with a BAG domain mutation [56]. However, it
is not clear whether HSF-1 regulates BAG3 expression in cardiomyocytes, as has been
described for some other cell types. One factor that impacts BAG3 protein levels in
some cancer models is biological sex, where female sex is associated with increased
BAG3 levels. Given this information, it is interesting that BAG3 mutations have
increased penetrance in male patients. Whether sex affects BAG3 expression in the
heart and the impact of heart failure on BAG3 levels between males and females is
unknown.
Experimental Approach
1. Define the sarcomeric role of BAG3 in cardiomyocytes (Chapter 3)
2. Determine the effects of the proposed chemotherapy agent JG-98, an inhibitor of
BAG3-HSP70, on cardiomyocytes (Chapter 4)
3. Characterize factors regulating BAG3 expression in the human heart (Chapter 5)
At the conclusion of these studies, the mechanistic understanding of BAG3 in
cardiomyocytes – and specifically at the sarcomere – will be greatly advanced, which
will help to better inform future heart failure therapies both in genetic and non-genetic
manifestations of the disease.

CHAPTER 2
OVERVIEW OF PROTEIN QUALITY CONTROL AT THE CARDIAC SARCOMERE1
Abstract
The sarcomere is the basic contractile unit of striated muscle and is a highly
ordered protein complex with the actin and myosin filaments at its core. Assembling the
sarcomere constituents into this organized structure in development, and with muscle
growth as new sarcomeres are built, is a complex process coordinated by numerous
factors. Once assembled, the sarcomere requires constant maintenance as its
continuous contraction is accompanied by elevated mechanical, thermal, and oxidative
stress, which predispose proteins to misfolding and toxic aggregation. To prevent
protein misfolding and maintain sarcomere integrity, the sarcomere is monitored by an
assortment of protein quality control (PQC) mechanisms. The need for effective PQC is
heightened in cardiomyocytes as these cells are terminally differentiated and must
survive for many years while preserving optimal mechanical output. To prevent toxic
protein aggregation, molecular chaperones stabilize denatured sarcomere proteins and
promote their refolding. However, when old and misfolded proteins cannot be salvaged
by chaperones, they must be recycled via degradation pathways: the calpain and
ubiquitin-proteasome systems, which operate under basal conditions, and the stress-
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responsive autophagy-lysosome pathway. Mutations to and deficiency of molecular
chaperones and the associated factors charged with sarcomere maintenance common
lead to sarcomere structural disarray and the progression of heart disease, highlighting
the necessity of effective sarcomere PQC for maintaining cardiac function. This chapter
focuses on the dynamic regulation of assembly and turnover at the sarcomere with an
emphasis on the chaperones involved in these processes and describes the alterations
to chaperones – through mutations and deficient expression – implicated in disease
progression to heart failure.
Introduction
The sarcomere is the fundamental molecular unit of contraction in striated
muscle cells. It is a highly ordered structure containing myosin thick filaments and actin
thin filaments, which directly engage to facilitate contraction. The myofilaments are
accompanied by the contraction-tuning troponins (I, T, and C) and tropomyosin, which
regulate the thin filament, as well as many associated signaling and adaptor proteins
(Figure 3A). From its earliest histological description in the late 19th century [110], the
composition and unique structural organization of the sarcomere have held a central
focus in physiology. Long considered a rigid structure, with the advent of modern
molecular biology techniques it has become clear in recent decades that assembly and
turnover of sarcomere proteins is actually a highly dynamic process in constant flux
[111–114]. The coordinated assembly of sarcomere proteins into organized
paracrystalline structures in development (Figure 3B), and with muscle growth as new
sarcomeres are added, is essential for heart function. Effective assembly alone,
however, is insufficient, as the protein components of this contractile structure
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experience elevated stress and often denature, thus requiring regular turnover. Old and
misfolded proteins must be swapped out for newly synthesized proteins without
compromising mechanical function. Coordinating this task in cardiomyocytes, which
contract persistently throughout the lifespan, is a challenging endeavor assisted by
several protein degradation pathways and dozens of molecular chaperones. The need
for effective sarcomeric protein quality control (PQC) increases under elevated stress
conditions, such as occur over time with aging and the progression of heart disease with
mechanical stress from increased afterload. Stress may also stem from mutations to
sarcomeric proteins which promote misfolding and preclude adequate maintenance.
Therefore, a mechanistic appreciation of the factors involved is warranted in order to
characterize their functional significance for the sarcomere and manipulate their activity,
toward the goal of targeting sarcomere PQC to forestall heart disease progression and
restore cardiac function.
Newly synthesized polypeptides require folding into their unique threedimensional structures to achieve functional activity. Additionally, to maintain function
and prevent cytotoxicity, proteins denatured due to stress or misfolding must be
refolded or cleared from the cellular environment. Cardiomyocytes employ an
assortment of molecular chaperones to ensure these vital tasks are accomplished.
Chaperones promote proper protein folding, prevent protein misfolding through
stabilizing interactions, and are required for the assembly of macromolecular complexes
like the sarcomere [115]. They are essential at the dynamic sarcomere, where elevated
stress conditions facilitate protein misfolding, and newly synthesized proteins must be
rapidly incorporated. Unsurprisingly, mutations and deficiency of sarcomeric
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chaperones cause a failure of local PQC and aggregation of misfolded proteins, which
can disrupt sarcomere structure, lead to muscle dysfunction, and ultimately heart failure.
The structure and composition of the sarcomere are highly conserved between
skeletal and cardiac muscle, and from worms to mammals. As such, much of what we
know about sarcomere PQC has been inferred from muscle studies in worms (C.
elegans), flies (D. melanogaster), and fish (D. rerio) and will be included here. While
there is reason to expect that these mechanisms translate to higher organisms,
inferences should be made with care as critical differences may exist for species with
longer lifespans and higher cardiac hemodynamic load. In this review, we summarize
the current understanding of assembly and degradation processes at the cardiac
sarcomere, discuss the chaperones and PQC pathways involved, and highlight
emerging evidence for the dynamic remodeling processes that maintain sarcomere
structure and function.
Sarcomere Assembly and Maintenance
Integrin-ECM Interactions Initiate Myofibril Assembly
Cardiomyocytes are efficiently organized into dozens of contractile substructures
called myofibrils, which extend the length of the cell and are further organized into
dozens of sarcomeres arranged sequentially. In developing myofibrils, mechanical
tension communicated between myocyte cell surface proteins and the extracellular
matrix (ECM) is required for sarcomere formation [116]. Integrins and their associated
proteins are the first proteins to assemble with the regular periodicity characteristic of
sarcomeres and mediate the membrane association of immature Z-disc structures,
called Z-bodies [117–119]. These sites of high integrin concentration at the
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sarcolemma, termed protocostameres, recruit the Lim-domain binding protein
ZASP/cypher which serves as a nucleation site for Z-body assembly [116,120,121]. The
regional specificity of the integrin-rich protocostameres, which gives rise to the
characteristic sarcomere periodicity, relies on their receptor counterparts in the ECM
[122]. Genetic studies in invertebrates and a study of β1-integrin-KO mice support this
and indicate myofibril assembly is integrin-dependent and requires specific ECM
receptors [123–127]. Mutations to 18 proteins mediating myocyte-ECM interactions are
linked to muscular dystrophy and cardiomyopathy through disruption of myocyte
integrity [128–130].
Models of Sarcomerogenesis
The Titin Template Model. Titin is the largest known protein and extends from
the sarcomere Z-disc to M-line (Figure 3A). The Titin Template Model proposes titin
serves as a scaffold for sarcomerogenesis, establishing sarcomere length and
mediating thick filament integration. It was initially proposed due to titin’s length of
exactly one-half sarcomere and on evidence that titin associated with Z-bodies and
assembled prior to myosin filaments [131,132]. Early evidence for the model was largely
correlative, but support soon followed showing A-band titin assembly preceded myosin
incorporation [133,134]. Further evidence came from a knockout study of titin, where
myofibril assembly and thick filament formation were impaired [135]. Subsequent
studies in developing myocytes used targeted deletion of C-terminal titin domains and
found disrupted sarcomerogenesis [136–138]. The complexity of titin’s role is enhanced
by the recent finding that absence of the Cronos/T2 titin isoform, which lacks C-terminal
titin domains, also causes sarcomere disarray [139].
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Despite the prevalence of “titin template” in myofilament nomenclature, in the
decades since this model was proposed several lines of evidence have refuted its
accuracy. For one, titin is not required for Z-body formation, as these α-actinin
accumulations assemble prior to titin expression and titin I-band deletion does not
impact Z-disc structure [140,141]. While titin may mediate thick filament integration, it is
not required for assembly of the thick filament as myosin fibrils can form without titin
[142]. It was also noted that invertebrate sarcomeres form despite their titin analogs
only spanning the A-band region [143]. Thus, we speculate that titin is required for
maintaining sarcomere spacing, but not for initial patterning of the myofibril.
The Stitching Model. First described by Lu et al., in the Stitching Model
elements of the A-band (myosin fibers, myomesin) and I-Z-I bands (α-actinin, actin
fibers) assemble independently and are then “stitched” together by titin, which joins the
two large subunits through interactions with myomesin and α-actinin [144,145]. This is
supported by electron microscopy observations denoting independent sarcomere
subunit assembly, where Z-discs with associated thin filaments formed in myosindeficient muscle and A-band formation occurred in the absence of thin filament
components [144,146,147]. Further work in Drosophila found that myosin filaments
formed when various Z-disc components were deleted [148].
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Figure 3. The Cardiac Sarcomere and Assembly of the Myofilaments. (A).
Schematic diagram of the sarcomere and sarcomere-associated proteins. The
sarcomere is the basic contractile unit in striated muscle with the thin actin and thick
myosin myofilament proteins at its core. Sarcomeres are bounded at either end by αactinin-rich Z-discs and are arranged sequentially to form myofibrils. (B). Simplified
schematic of thin and thick filament assembly. GimC binds newly synthesized actin
as it is translated by the ribosome and mediates early stages of folding. GimC
passes now semi-folded actin to TriC, which assists in the assembly of the actin
filament. Thin filament assembly is further supported by FHOD3, which stabilizes
monomeric and filamentous actin and is crucial for actin filament nucleation and
polymerization. The small heat shock proteins (heat shock protein B family, HSPBs)
stabilize actin monomers and prevent protein aggregate formation. Actin capping
proteins, CapZ and tropomodulin (T-Mod), bind to the ends of actin filaments and
maintain stability. CapZ itself requires the BAG3/HSC70 chaperone complex to
maintain its stability. Unc45 is the key chaperone for thick filament assembly and
stability. It prevents myosin aggregation and assists with the folding of the myosin
ATPase domain. Unc45 is a co-chaperone for HSP90, which participates in the early
stages of myosin folding and myofibril assembly. The lysine methyltransferase
SmyD1 is proposed to interact with the HSP90/Unc45/myosin complex.

The study by Rui and colleagues proposed that rather than sequential assembly of the
sarcomere, multiple latent protein complexes are built simultaneously and then
combined. Unfortunately, with its many moving pieces this model is challenging to
assess using fluorescence-based approaches in live cells and is therefore largely based
on observations in fixed preparations.
The Premyofibril Model. The Premyofibril Model is the prevailing model of
sarcomere assembly. In this model, stress fiber-like structures composed of α-actinin,
actin, and non-muscle myosin-II (NMM-2) assemble at the cell periphery [141]. These
premyofibrils mature into nascent myofibrils, where NMM starts to be replaced by
muscle myosin, and then into mature myofibrils containing only muscle myosin
[141,149]. Prevention of NMM and muscle myosin co-polymerization in mature
myofibrils is attributed to myosin binding protein C (MYBPC), which assembles only in
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the mature myofibril [141]. In support of the Premyofibril Model, deletion of NMM mRNA
in myoblasts prevents actin stress fiber polymerization, and mice with germline KO of
the NMM-2B isoform display significant cardiac structural defects and die in
development [150–152]. The Premyofibril Model is not without contention, however, as
sarcomerogenesis is unimpaired with cardiomyocyte-specific deletion of NMM-2B or
NMM-2A [153,154]. Some suggest the two NMM isoforms serve overlapping functions
allowing the cell to compensate if one is mutated or deficient, which is supported by
studies in C. elegans [155–157]. Notably, NMM-2A expression increases in NMM-2Bdeficient mice [150]. While such redundancy may explain the mouse single isoform KO
results, whether NMM-2 isoforms have functional overlap in higher organisms or
cardiomyocytes is not known.
A recent study of sarcomerogenesis in iPSC-cardiomyocytes suggested that
aspects of each model are correct and proposed a unifying model of sarcomere
assembly. This study found sarcomeres assemble directly from actin stress fiber
templates and that assembly requires both NMM-2 isoforms and the actin nucleator
FHOD3 [158].
Thin Filament Assembly and Stability
As α-actinin is recruited to the maturing Z-disc by ZASP, it is organized into its
lattice structure by nebulin-related anchoring protein (NRAP) [159]. With Z-discs in
place, thin filament assembly proceeds with assistance from numerous chaperones
(Figure 3B).
GimC & TRiC. As it is translated, nascent actin is bound by GimC (prefoldin),
which promotes actin folding and prevents actin monomer aggregation [160]. GimC-
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bound actin is then targeted to TRiC (CCT), a general chaperone that localizes to the Zdisc [161]. TRiC is responsible for the final actin folding steps, and assists with actin
polymerization [162–164]. Zebrafish with missense TRiC mutations develop normally
but have impaired actin folding that precludes sarcomere assembly [161]. Mutations to
TRiC are associated with heart failure in humans and knockout of TRiC in Drosophila
resulted in disorganization of actin and myosin fibers [165,166]. However, whether this
is due to impaired actin folding/incorporation into the thin filament is not known. TRiC
has many different clients and has been proposed to interact with up to 10% of the
proteome, including myosin [167].
FHOD3. Recent studies have identified a role in thin filament assembly for the
formin family member FHOD3, which localizes to the sarcomere A-band [158].
Localization of FHOD3 to the A-band is dependent on MYBPC [168]. FHOD3 binds to
both monomeric and filamentous actin and facilitates thin filament nucleation and
polymerization; effects that are enhanced with GimC present [169]. As previously
discussed, FHOD3 localizes with NMM in developing myofibrils and is required for de
novo sarcomere assembly and organized A-band formation [158]. Notably, FHOD3 KO
does not completely prevent myofibril formation, but impairs cardiac development and
causes sarcomere disarray [170–172]. Mice expressing a mutant FHOD3 with disrupted
actin binding die by embryonic day 12, however, expression of wild-type FHOD3 in
these embryos rescued myofibril maturation by acting as an actin filament “reorganizer”
at the center of the sarcomere [173]. A FHOD3 mutation causes dilated cardiomyopathy
and FHOD3 expression decreases in human heart failure, likely one of many deficits
contributing to the sarcomere disarray characteristic of the failing heart [174,175].
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Regulation of actin polymerization. Once the thin filament is formed, its length
is dynamically regulated by two reciprocal factors, profilin and cofilin. The cofilin family
of proteins are actin disassembly factors expressed in all eukaryotic cells [176]. Cofilin-2
is the isoform expressed in striated muscle and mediates thin filament turnover by
promoting disassembly of actin at the pointed end [177,178]. Cofilin-2 binds to both
ADP- and ATP-actin filaments, which it cleaves to provide actin monomers for new
filament assembly [179–181]. Both cofilin-2 mutations and cofilin-2 deficiency are
associated with cardiomyopathy [182–184]. Profilin catalyzes ADP to ATP exchange on
monomeric actin and acts opposite to cofilin to enhance thin filament polymerization
[185,186]. Profilin ultimately passes monomeric actin to FHOD3 for filament
incorporation, though the site at which this occurs – Z-disc vs. A-band – is not clear
[187,188].
Thin filament stability is supported by the actin capping proteins CapZ and
tropomodulin. CapZ binds to the barbed end of the actin filament at the Z-disc and is
critical for cardiac performance [189]. Inhibition of CapZ impairs myofibrillogenesis by
disrupting actin filament assembly [190]. Tropomodulin binds to the pointed end of the
actin filament and prevents polymerization. Tropomodulin knockout impairs sarcomere
development and is embryonic lethal [191–193]. Its function is antagonized by
Leiomodin, a structurally similar actin nucleating protein that is expressed later in the
developing myofibril and maintains thin filament pointed end dynamics [194,195]. The
stability of actin capping proteins is essential for sarcomere structural maintenance. This
is emphasized by knockdown of the co-chaperone Bcl-2-associated athanogene 3
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(BAG3) in neonatal ventricular myocytes, which caused rapid degradation of CapZ and
sarcomere disarray [196].
The small heat shock proteins (HSPBs). The HSPBs are ATP-independent
chaperones and therefore do not have intrinsic folding activity. Instead, they operate as
“holdases” for misfolded proteins to prevent protein aggregation and connect clients
with the ATPase chaperones HSP70 and HSP90 [197]. Three HSPBs are implicated in
actin stability: HSPB1 (HSP27), αB-crystallin (HSPB5), and HSPB7. Morpholino
inhibition of HSPB1 translation in Xenopus embryo cardiac muscle impaired actin
filament organization and caused myofibril assembly defects [198]. αB-crystallin also
associates with actin and prevents formation of heat stress-induced actin aggregates
[199–201]. HSPB7 binds to monomeric actin and inhibits actin polymerization, which
likely prevents actin aggregation in vivo [202]. Cardiomyocyte-specific KO of HSPB7
resulted in abnormally long thin filaments with mislocalization of tropomodulin and was
embryonic lethal [202]. The severe phenotypes in the KO studies suggest that the
HSPBs serve non-overlapping roles where those still expressed are unable to
compensate.
Thick Filament Assembly and Stability
Contraction of the sarcomere is mediated by the molecular motor myosin, which
ratchets along actin filaments by converting energy from ATP into mechanical work.
Folding myosin polypeptides into their functional conformation, and assembly into the
hexameric myosin complex found only at the sarcomere, requires chaperones (Figure
3B).
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Unc45. Unc45 is the key myosin chaperone and is functionally conserved from
worms to mammals. The association of Unc45 with myosin is mediated by the Unc45 cterminal domain and prevents myosin aggregation [203,204]. Numerous studies show
Unc45 is essential for myosin maturation, specifically for folding the myosin ATPase
domain [205–213]. However, Unc45 expression must be tightly regulated as both
knockdown and overexpression result in defective myofibril organization [214]. The
association of Unc45 with myosin is enhanced with heat shock in vitro, suggesting
denaturation-dependent binding [205,215]. A similar effect has been shown for αBcrystallin, which prevents heat shock-induced myosin aggregation [216]. A study in
zebrafish found that physical cell stress triggers mobilization of Unc45 (and HSP90) to
the sarcomere A-band from a reserve pool at the Z-disc that is regulated by differential
affinity of Unc45 for denatured myosin [217]. The presence of a readily available myosin
chaperone pool at the sarcomere facilitates a rapid response to muscle damage. Biallelic mutations in Unc45 are associated with congenital myopathy and Unc45 mutants
impair sarcomerogenesis in zebrafish [218,219]. Notably, Unc45 mutations have not
been found to cause cardiomyopathy. While Unc45 is fundamental for muscle function
in lower organisms, it may be that other myosin chaperones are able compensate for
impaired Unc45 activity in mammals.
HSP70 and HSP90. HSP70 and HSP90 are general chaperones each with a
wide range of clients. Newly synthesized myosin is stabilized by forming a complex with
HSP70 or HSP90, where the chaperones participate in early stages of myosin folding
and myofibril assembly [220]. Less is known regarding HSP70-mediated stabilization of
myosin and it likely plays a secondary role to HSP90. Both HSP90 mutations and
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deficiency are associated with significant sarcomere disarray [207,221,222]. While
impaired myosin assembly contributes to the phenotype, careful interpretation is
warranted as HSP90 is also involved in quality control of other sarcomere proteins,
including titin [223–225]. The myosin folding activity of HSP70 and HSP90 are
enhanced with Unc45, which interacts with HSP70/90 through its co-chaperone helixturn-helix motif, though this association is dispensable for myosin folding in C. elegans
[226,227]. A recent study in skeletal muscle indicated that another HSP70 cochaperone, BAG3, also assists with myosin stabilization [228]. This suggests that, while
Unc45/HSP90 is the primary myosin chaperone complex, these complexes can exist in
at least one other chaperone/co-chaperone combination.
SmyD1. SmyD1 is a histone methyltransferase implicated in myofibril assembly.
Though not a confirmed chaperone, SmyD1 localizes to the sarcomere M-line where it
interacts with myosin and plays an essential role in thick filament integration [229–231].
A study in zebrafish found SmyD1 knockdown impaired myofibril maturation, disrupted
heart contraction, and prevented swimming activity [232]. Knockdown of SmyD1 also
inhibits myosin accumulation in the early sarcomere, causing instability and rapid
myosin degradation. This effect could be due to disruption of the Unc45/HSP90/myosin
complex, with which SmyD1 associates. In a probable attempt to compensate for
myosin instability, Unc45 and HSP90 expression increase with SmyD1 deficiency [233].
These data suggest SmyD1 is a third member of the canonical myosin chaperone
complex. SmyD1 levels are depressed in end-stage heart failure and a recently
identified de novo SmyD1 mutation causes hypertrophic cardiomyopathy [234,235].
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These studies add to the growing appreciation for the diversity of chaperone complexes
that regulate thick filament assembly.
Maintaining Titin and Desmin Stability
The factors maintaining titin stability are largely undefined but are known to
include αB-crystallin. At physiological sarcomere lengths, αB-crystallin binds to the N2B
region of titin in the I-band of the sarcomere and prevents ischemia/stretch-induced
misfolding [236,237]. In overstretched myofibrils, αB-crystallin also binds to and
stabilizes the I26/I27 Ig region of titin between the N2B domain and Z-disc titin [236].
This suggests increased affinity of αB-crystallin for the Ig region when it is mildly
denatured. Higher stretching forces are required to denature titin when αB-crystallin is
present and increased stiffness due to less distensible titin in failing ventricular tissue is
reversed by introducing αB-crystallin [236,238]. Notably, a missense mutation in αBcrystallin (R157H) that causes familial dilated cardiomyopathy prevents association of
αB-crystallin with titin [239]. The chaperones HSPB1 and HSP90 are also involved in
titin maintenance and translocate to titin to prevent toxic aggregation in response to
stress caused by genetic mutations to sarcomere proteins [224]. More research is
needed to determine if these chaperones cooperate with αB-crystallin or act
independently, and to identify additional chaperones involved in titin maintenance.
αB-crystallin is also the key chaperone for desmin, an intermediate filament
protein involved in mechanotransduction that associates with the Z-disc, sarcolemma,
and multiple organelles [240]. Nearly 70 desmin mutations and numerous αB-crystallin
mutations have been linked to cardiomyopathy [241,242]. αB-crystallin binds to
misfolded desmin and prevents aggregation [243]. The association of αB-crystallin with
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desmin in vitro increases with heat stress and pH changes, indicating
stress/denaturation-dependent binding [200]. The R120G αB-crystallin mutation has
received a lot of attention due to the severe phenotype it causes. This mutation
decreases the dissociation constant for desmin by half and causes toxic protein
aggregation, which leads to desmin-related cardiomyopathy [243–247]. Desmin- and
αB-crystallin-containing protein aggregates are common features of cardiomyopathy
and skeletal muscle myopathy tissue biopsies, even when mutations are not involved
[248]. These data indicate that both disrupted stability and degradation of desmin can
be pathogenic.
Maintenance of Myosin Binding Protein C
Cardiac myosin binding protein C (MYBPC), encoded by the mybpc3 gene, is a
flexible, thick-filament associated protein that regulates myosin crossbridge
cycling[249]. Mutations to MYBPC are the leading cause of hypertrophic
cardiomyopathy (HCM), accounting for up to 50% of cases[250]. Disease mechanisms
hypothesized in HCM include: 1. Point mutations in sarcomere proteins that directly
impair function (“poison peptide”), and 2. Protein haploinsufficiency caused by
truncating mutations[251]. Unlike disease-associated mutations in other sarcomere
proteins which are predominantly missense, truncations account for ~90% of MYBPC
mutations[252]. Interestingly, studies of HCM biopsy samples from patients with
MYBPC mutations failed to identify the truncated protein, suggesting that the protein
either is not synthesized or is quickly degraded via PQC mechanisms[253]. In support of
the latter, recent work by Glazier et al. found that HSC70 and HSP70 act as chaperones
for both wild-type and mutant MYBPC where knockdown of HSC70 in cultured
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ventricular myocytes impaired their degradation[254]. However, wild-type and mutant
MYBPC turnover was enhanced with a small molecule activator of HSP70/HSC70. In
cases of missense MYBPC mutants, the role of Hsp70 in regulating MYBPC
degradation may represent one mechanism in place to prevent the “poison peptide”
effect. To date, HSP70/HSC70 is the only identified MYBPC chaperone, though future
work may aim at determining the involvement of known HSP70 co-chaperones in
MYBPC turnover.
Sarcomeric Degradation
The regenerative capacity of cardiomyocytes is severely limited[255]. Sarcomere
proteins, however, have half-lives on the order of weeks to days and require continuous
turnover [256,257]. Sarcomeric protein turnover is thus essential to maintain function
and promote cardiomyocyte longevity. In this section, we review the three mechanisms
regulating sarcomere protein turnover (the calpains, the ubiquitin proteasome system,
and the autophagy-lysosome system (Figure 4A) and discuss how their dysregulation in
heart failure contributes to proteotoxicity and potentially sarcomere dysfunction (Figure
4B).
The Calpain System
Calpains are calcium-dependent cysteine proteases evolutionarily conserved
from bacteria to mammals. The human genome contains at least 16 different calpainencoding genes, three of which – calpain-1, calpain-2, and calpain-3 – are found in
striated muscle [258,259]. Calpain-3 expression is skeletal muscle-specific [260].
Cardiomyocytes do not have a tissue-specific calpain and instead express modest
amounts of calpains 1 and 2, each with many identified sarcomeric clients (Table 2)
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[261]. The susceptibility of sarcomere proteins to calpain proteolysis can be regulated
by chaperones, which prevent calpain proteolysis by binding to cleavage sites.
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Figure 4. Sarcomeric Protein Degradation in the Healthy and Failing Heart. (A).
Schematic representation of sarcomere PQC in the healthy heart. Three protein
degradation pathways are in place for the sarcomere. The calpains proteolyze
sarcomere proteins and release protein monomers to be degraded by the ubiquitin
proteasome system (UPS). The UPS also mediates the degradation of individual
misfolded proteins. Larger protein aggregates are removed by the
autophagy/lysosome pathway. (B). Schematic representation of the changes to
sarcomere PQC that occur in the end-stage failing heart. Proteins misfolded from
mechanical (stemming from increased afterload), thermal, oxidative, and genetic
stress aggregate in the end-stage failing heart. Aberrant protein misfolding as a
result of these stressors is accompanied by elevated calpain activity, which produces
excess proteolysis products. Compounding the issue of proteotoxicity, the activity of
the systems designed to recycle these proteins, the UPS and autophagy, are
downregulated in heart failure. Together, these factors culminate in toxic levels of
protein aggregation, which – presumably – contribute to the sarcomere structural
disarray and mechanical dysfunction commonly found in failing myocardium. Which
specific proteins aggregate and to what extent remains to be fully elucidated.

This was shown for HSPB1, which translocated to the Z-disc during oxidative stress and
prevented calpain-mediated proteolysis of desmin [262]. HSPB1 binding can also
prevent calpain cleavage of troponins I and T [263]. Calpain proteolysis of myofilament
proteins is enhanced with sarcomere stretch [264].
Calpain activation is associated with an increase in protein ubiquitination and is
thought to precede myofilament protein degradation by the ubiquitin-proteasome system
(UPS), which requires proteins to be in monomeric form. In this model, calpains release
the myofilament proteins from the sarcomere by proteolyzing several sarcomere
components, allowing for their subsequent targeting to the UPS (Figure 4A) [265,266].
This observation was first made in the heart by Galvez et al. who observed that
overexpression of calpain-1 resulted in increased ubiquitination and 26S proteasome
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activity while expression of the calpain inhibitor calpastatin decreased ubiquitination and
caused cardiac dysfunction [267].
Table 2. Summary Table of Sarcomere and Sarcomere-associated Proteins with
their Proposed Degradation Mechanisms.
Protein
Actin
α-Actinin
Ankyrin
Desmin

Function
Thin filament
Actin cross-linking
Cytoskeletal adaptor
Cytoskeletal adaptor

Dystrophin
FHL2
Filamin A and C

Cytoskeletal adaptor
Sarcomere/nucleus
crosstalk
Actin cross-linking

MYBPC
β-MHC
MLC-2
Myotilin
Nebulin/Nebulette
NRAP
Telethonin/T-cap
Titin
Tropomodulin/T-mod
Troponin C
Troponin I

Thick filament regulation
Thick filament
Thick filament regulation
Z-disc integrity
Thin filament stability
Thin filament stability
Titin stability
Strain-sensing, scaffold
Thin filament stability
Thin filament regulation
Thin filament regulation

Troponin T

Thin filament regulation

Tropomyosin

Thin filament regulation

Proposed Degradation Mechanisms
TRIM32 [283]
Fbxl22 [295], TRIM32 [284]
Calpains [310,404]
Calpains [262,405], TRIM32 [284,285],
Atrogin-1 [296], Cullin-5 [293,294]
Calpains [258,406]
MuRF-3 [277]
Calpains [15,407], Cullin-5 [293,294],
Fbxl22 [295], MuRF-3 [277], CASA [47]
Calpains [408,409], MuRF-1 [275]
MuRF1-3 [273,275], CHIP [287]
MuRF1-2 [273]
MuRF1-2 [273], TRIM32 [284]
Calpains [410,411], MuRF1-2 [273]
MuRF1-2 [273]
Mdm2 [291], MuRF1-2 [273]
Calpains [258,412], MuRF1-2 [273]
Calpains [413]
MuRF-1 [274]
Calpains [314,317,414,415], MuRF1-2
[273,274], TRIM32 [284], c-Cbl [297]
Calpains [314,414,415], MuRF1-2
[273], TRIM32 [284]
Calpains [258,410], TRIM32 [284]

These findings suggest calpain proteolysis at the sarcomere is upstream of the UPS
and is fundamental for cardiac function. However, the regulation of the UPS by calpains
is incompletely understood and not all studies support the requirement for calpains
upstream of the UPS [268]. More research is needed to characterize the calpain-UPS
relationship at the sarcomere.
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The Ubiquitin Proteasome System
UPS-mediated protein degradation is a concerted effort by multiple enzymes that
culminates in a reaction catalyzed by an E3 ubiquitin ligase, which transfers ubiquitin to
the protein of interest [269]. The ubiquitinated protein is subsequently degraded via the
26S proteasome, a large ATP-dependent protease complex with multi-catalytic activity
that localizes to the sarcomere Z-disc [114]. Evidence from many studies indicates the
UPS is fundamental for sarcomeric PQC and we focus our review on the E3 ligases
found at the sarcomere.
The muscle RING finger E3 ligases (MuRFs). The most well-characterized E3
ligases in striated muscle are the muscle RING finger (MuRF) proteins, which belong to
the TRIM family of ubiquitin ligases. These localize to the sarcomere Z-disc and M-line
and contribute to the proteasomal degradation of multiple sarcomere proteins [270–
272]. MuRF-1 and MuRF-2 are functionally similar and associate with troponins I and T,
NRAP, β-MHC, myosin light chain 2 (MLC2), telethonin (T-Cap), myotilin, titin, and
nebulin [273–276]. MuRF-3 was the first MuRF to be discovered, however, it has only
three identified sarcomere substrates: filamin C, β-MHC, and four-and-a-half LIM
domain protein-2 (FHL2) (Table 2) [270,277,278]. Genetic mouse studies have
contributed significantly to our understanding of the roles MuRFs serve in the
myocardium. Absence of MuRF-2 or MuRF-3 caused protein aggregation and impaired
cardiac function, while overexpression of MuRF-1 in a TAC heart failure model was
detrimental [279–281]. Uniquely, when mice lacking MuRF-1 were challenged with TAC,
they developed substantial hypertrophy which was not found in MuRF-2-deficient mice
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[282]. Together, these studies support that sarcomeric MuRFs share some redundancy
and are fundamental for muscle structure and function but require tight regulation.
TRIM32. Another TRIM family member, TRIM32, is involved in the UPSmediated degradation of thin filament-associated proteins. Work by Kuryashova et al.
found TRIM32 binds to the myosin head/neck region and mediates the ubiquitination of
sarcomeric actin [283]. More recently TRIM32 was shown to ubiquitinate the thin
filament-associated proteins troponin T, troponin I, tropomyosin, myotilin, and α-actinin
[284]. Studies of TRIM32 in muscle atrophy show that it is also an important mediator of
desmin turnover, where TRIM32 knockdown prevented desmin degradation [284]. It
seems TRIM32 is involved in an initial step of muscle atrophy requiring the disassembly
of desmin filaments [285]. To date, most studies on TRIM32 have been performed in
skeletal muscle, where TRIM32 mutations are associated with myofibrillar myopathy
[283]. Despite high expression in the myocardium, very little is known regarding cardiac
TRIM32. However, recent work with a mouse heart failure model indicated that TRIM32
has protective effects as TRIM32 overexpression prevented progression into heart
failure in mice subjected to TAC [286]. More studies are needed to determine whether
TRIM32 substrates identified in skeletal muscle are conserved in the heart.
Other E3 ligases at the sarcomere. Several other E3 ligases have been linked
to sarcomere PQC, with more surely yet to be identified. One of these is carboxylterminus of HSP70-interacting protein (CHIP). CHIP localizes to the sarcomere Z-disc
and A-band and assists with myosin turnover [287]. CHIP also mediates the
degradation of the myosin chaperone Unc45 via the UPS [288]. Mice lacking CHIP have
decreased survival and worsened myocardial injury following ischemia/reperfusion
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[289]. The E3 ligase murine double minute 2 (Mdm2) is canonically involved in the
turnover of p53 [290]. However, in the heart it also ubiquitinates the titin-capping protein
telethonin promoting its degradation [291]. Conditional knockout of Mdm2 in the heart
causes spontaneous cardiac hypertrophy and significant cardiomyocyte cell death,
though this is attributed to impaired degradation of a number of Mdm2 substrates [292].
Mdm2 gene expression decreases in heart failure [292]. Studies in recent years
implicate several other E3 ligases in sarcomere PQC. These include Fbxl22 (α-actinin,
filamin C), atrogin-1 (desmin), c-Cbl (troponin-I), and cullin-5/Asb2 (filamin A, filamin C,
desmin) [293–297]. The number of E3 ligases involved in sarcomere protein turnover
(Table 2) highlights the complexity of this process and suggests that proper turnover is
achieved by engaging many E3 ligases with somewhat overlapping roles.
The Autophagy-lysosome Pathway
Proteins that cannot be refolded by chaperones or processed by the UPS may be
degraded via macroautophagy, referred to hereafter as ‘autophagy’ (Figure 4A). In
autophagy, membrane-enclosed vesicles (autophagosomes) are formed around a
portion of the cytosol containing damaged organelles, protein aggregates, and/or other
toxic cellular components [298]. Like the UPS, selectivity in autophagy is mediated by
ubiquitin. Proteins carrying a K63-polyubiquitin tag, or aggregated proteins with K48polyubiquitination, are recognized by adaptors P62/SQSTM1 and NBR1 which facilitate
their association with proteins on the autophagosome membrane, or HDAC6 which first
targets them to the aggresome [299,300]. Autophagosomes recycle their cargo by
fusing with the lysosome, thus exposing autophagosome contents to lysosomal
hydrolases. While it is evident from several studies that autophagy is required for
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sarcomere structural maintenance, relatively little is known regarding the specific
involvement of autophagy in sarcomere PQC.
Impaired autophagy is associated with sarcomere structural abnormalities.
Autophagy related protein 5 (ATG5) is essential for the formation of the autophagosome
membrane and its knockout completely ablates autophagy [301]. One of the first studies
to implicate autophagy in sarcomere PQC was by Nakai et al. using cardiomyocyte
specific ATG5 knockout [302]. Baseline cardiac function was unaffected in ATG5-null
mice. However, after one-week of pressure overload, ATG5 KO caused significant left
ventricular dysfunction, chamber dilation, and sarcomere structural disarray [302].
Sarcomere disarray was also identified with ATG7 KO in skeletal muscle [303]. These
studies indicate the importance of autophagy for the sarcomere, but do not specifically
assess autophagy at the sarcomere level as autophagosome impairment affects global
myocyte autophagy.
Chaperone-assisted selective autophagy (CASA), an autophagy pathway
discovered in skeletal muscle, is thus far the only autophagy pathway that has been
explicitly shown to operate at the sarcomere (Figure 5A). In CASA, the co-chaperone
BAG3 operates as a scaffold for HSPB8 and HSC70/HSP70. The complex binds to
misfolded filamin C, preventing its aggregation. Filamin C is then ubiquitinated by the E3
ubiquitin ligase CHIP, which docks on the carboxyl terminus of HSP70. This promotes
client identification by the ubiquitin receptor P62/SQSTM1, which with synaptopodin-2
(SYNPO2) facilitates the association and engulfment of the complex by the
autophagosome [101].
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Figure 5. Chaperone-assisted Selective Autophagy at the Sarcomere. (A). The
co-chaperone BAG3 operates as a scaffold for HSP70 and HSPB8, which bind to
misfolded filamin C. The E3 ligase CHIP then ubiquitinates filamin C, allowing it to be
recognized by the ubiquitin receptor P62, which facilitates the association of the
CASA complex with LC3 on the autophagosome membrane. Through BAG3 this
complex also associates with SYNPO-2, which mediates interaction with a SNARE
protein on the autophagosome membrane that assists with autophagosome
formation. Autophagosome contents are recycled via autophagosome-lysosome
fusion. (B). BAG3 domains enable numerous binding activities. SYNPO2, which
assists in autophagosome formation, binds to the N-terminal WW domain. Several
HSPBs bind to two IPV motifs and the BAG domain associates with the ATPase
domain of HSP70/HSC70.
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CASA was first described in Drosophila, where the complex was shown to localize to
the sarcomere Z-disc and mediate the degradation of mechanically-misfolded filamin C
[47]. While it has not been shown directly, it is possible that multiple HSPBs are
interchangeable in the CASA complex (Figure 5B). This is supported in that multiple
HSPBs are established BAG3 binding partners (HSPB1, HSPB6, HSPB8, αB-crystallin),
some of which have also been implicated in filamin C maintenance [304–306].
Numerous BAG3 mutations and BAG3 deficiency have been linked to dilated
cardiomyopathy in humans [64,307]. Future research is needed to determine the extent
to which CASA operates in cardiomyocytes and whether it has additional sarcomeric
clients beyond filamin C.
Sarcomere Turnover in End-stage Heart Failure
In end-stage heart failure, there is a dysregulation of PQC mechanisms resulting
in old/misfolded protein aggregation that may cause sarcomere structural and functional
impairment (Figure 4B). Calpain activity increases in both ischemic and dilated
cardiomyopathy, causing an elevation in clients destined for degradation by the UPS
[150,201-210]. However, in the end-stage of heart failure there is diminished UPS
activity and thus the clients are not degraded rapidly enough [319]. In the healthy heart,
protein aggregates not removed by these first two lines of defense can be removed by
autophagy. Autophagy operates at low basal levels but is upregulated in response to
proteasome-insufficiency, elevated mechanical strain – such as occurs with increased
afterload –, and other stress conditions including those associated with genetic
mutations to sarcomere proteins [320]. However, autophagy activity is dysregulated in
heart failure [321]. Together, this dysregulation of sarcomeric PQC mechanisms in the
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progression of heart disease results in aberrant protein aggregation that may result in
impaired contractile function and ultimately cell death.
Clinical Implications
Manipulating sarcomere PQC separately from global cardiomyocyte PQC is not
feasible given our current understanding. However, as we gain mechanistic insight into
the signaling pathways that mobilize chaperones from the cytosolic pool to the
sarcomere, small molecule approaches targeting sarcomere PQC may become a
reality. For now, manipulating global cardiomyocyte PQC to affect changes at the
sarcomere appears the best option. Boosting HSP expression by exercise, caloric
restriction, or small molecule therapeutics has proven cardioprotective in animal models
of heart failure [322,323]. These therapies mostly target heat shock transcription factor1 (HSF1), the master regulator of HSP expression [324]. The expected benefits of
increasing HSP expression for the sarcomere extend from ensuring effective assembly
and protein stability, to maintaining adequate protein degradation. Autophagy inducing
drugs also show promise in restoring cardiac function in animal heart failure models,
though their impact on the sarcomere is poorly characterized [298]. For cases of
chaperone deficiency, which frequently occur in end-stage heart failure, we speculate
AAV-based gene therapy may be a promising approach to restore proteostasis. Gene
therapy has shown promise in restoring endoplasmic reticulum (ER) proteostasis, a
central node of global cardiomyocyte PQC [325,326]. However, gene therapy is
complicated in larger species by difficulties with delivering ample amount of virus.
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Summary and Future Directions
Protein quality control (PQC) at the sarcomere is fundamental for maintaining
cardiac function. In this chapter, we describe the proteins involved in sarcomere
assembly and stability, along with processes controlling protein degradation therein.
The exact mechanism of sarcomere formation (sarcomerogenesis), while controversial,
is thought to involve the formation of immature stress fiber complexes that are a
blueprint for the mature sarcomere. Sarcomerogenesis is supported by a variety of
chaperone and co-chaperone proteins, which stabilize sarcomere proteins and prevent
their aggregation. While the lifetime of a cardiomyocyte extends for many years, that of
the individual proteins is limited to days/weeks. Thus, new proteins must constantly be
incorporated into the sarcomere in place of old members without compromising
mechanical function. Protein turnover is accomplished via three different systems (the
calpain system, the ubiquitin-proteasome system, and the autophagy-lysosome
pathway), which assist in removal of old proteins to maintain sarcomere proteostasis.
The studies summarized in this review showcase the staggering complexity of
sarcomere PQC and highlight dozens of factors essential for sarcomere assembly and
maintenance. However, it is important to note that some of these studies came from
skeletal myocytes. Unlike cardiomyocytes, skeletal myocytes do not persistently
contract and are slowly turned over with age, and thus may not be faced with the same
PQC requirements. Regardless, it is increasingly evident that we still do not fully
understand many aspects of sarcomere PQC, which leads to key unanswered
questions. Foremost among these are questions regarding sarcomere assembly and
maintenance in the terminally differentiated adult cardiomyocytes: 1. What are the
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stimuli and mechanisms for de novo sarcomere assembly in adult myocytes? 2. Does
the addition of new sarcomeres in eutrophy and exercise-induced hypertrophy differ
from pathological hypertrophy? 3. How do mutations to sarcomere proteins, such as
contribute to the “poison peptide” effect, impact their maintenance by chaperones? 4.
Are there functionally distinct PQC mechanisms for the sarcomere? Much like
mitochondria-specific autophagy (mitophagy), is there a sarcomere-specific autophagy
(“sarcophagy”)? Answering these questions with current experimental
systems/techniques is challenging. Adult cardiac and skeletal myocytes are not
amenable to long-term culture, contracting cells present difficulties for live-cell imaging,
and in vitro hypertrophy models require treatment paradigms of multiple days.
Future work may aim at determining how local protein assembly and degradation
are regulated at the sarcomere. How a cardiomyocyte ensures the delivery of new
proteins to its hundreds of sarcomeres with both temporal and spatial accuracy is a
puzzling question. Within a given myocyte, the mechanical strain on individual
sarcomeres is non-uniform [327]. Higher mechanical strain increases the propensity of a
protein to misfold and thus the rate of protein turnover at some sarcomeres must
outpace that at others. In the same vein, the mobilization of protein degradation
pathways to individual sarcomeres must therefore be locally regulated. Recent work by
Lewis et al. made important observations regarding the spatiotemporal maintenance of
the sarcomere [111]. They found ribosomes and sarcomere protein transcripts localize
to the Z-disc, thus allowing for local translation of sarcomere proteins. They propose an
excess synthesis model of sarcomere maintenance where an overabundance of
sarcomere proteins are synthesized and serve as a readily available pool for

50

incorporation into the complex [111]. Evidence also suggests that under increased
stress, autophagy engages in local protein degradation at the sarcomere. In
mechanically stressed myocytes, the autophagic ubiquitin receptor P62/SQSTM1 and
autophagosome membrane protein LC3 localize to the sarcomere, suggesting
sarcomere protein aggregates are engulfed locally by the autophagosome [101,328].
These studies shed some light on the mystery of regulating local PQC at the dynamic
sarcomere and provide an excellent framework for future studies in the years to come.
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CHAPTER 3
SARCOMERE CONTRACTILE FUNCTION IS MAINTAINED BY BAG3-DEPENDENT
PROTEIN TURNOVER2
Abstract
The association between reduced myofilament force-generating capacity (Fmax)
and heart failure (HF) is clear, however the underlying molecular mechanisms are
poorly understood. Here, we show impaired Fmax arises from reduced BAG3-mediated
sarcomere turnover. Myofilament BAG3 expression decreases in human HF and
positively correlates with Fmax. We confirm this relationship using BAG3 haploinsufficient
mice, which display reduced Fmax and increased myofilament ubiquitination, suggesting
impaired protein turnover. We show cardiac BAG3 operates via chaperone-assisted
selective autophagy (CASA), conserved from skeletal muscle, and confirm sarcomeric
CASA complex localization is BAG3/proteotoxic stress-dependent. Using mass
spectrometry, we characterize the myofilament CASA interactome in the human heart
and identify eight clients of BAG3-mediated turnover. To determine if increasing BAG3
expression in HF can restore sarcomere proteostasis/F max, HF mice were treated with
rAAV9-BAG3. Gene therapy fully rescued Fmax and CASA protein turnover after four
weeks. Our findings indicate BAG3-mediated sarcomere turnover is fundamental for
myofilament functional maintenance.

Parts of this chapter represent a published article: Martin TG et al. Cardiomyocyte contractile impairment in heart
failure stems from reduced BAG3-dependent sarcomere protein turnover. Nat. Commun. 2021
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Introduction
Heart failure is the leading cause of morbidity and mortality in the industrialized
world and is characterized by impaired contractility and decreased cardiac output [329].
At the cellular level, several factors have been implicated in the development of heart
failure, including defective calcium handling, neurohormonal imbalance, and functional
decline of the sarcomere – the fundamental molecular unit of contraction [330–332].
The sarcomere is a highly organized protein complex that mediates contraction through
myosin and actin filaments, which engage in the calcium-dependent crossbridge cycle.
Increased myofilament calcium sensitivity and decreased maximum force-generating
capacity (Fmax) are well-documented in heart failure [333–338]. However, while altered
calcium sensitivity is uniformly attributed to changes in site-specific post-translational
modifications, most commonly phosphorylation of troponin I [339], the molecular
mechanisms for decreased Fmax are incompletely understood.
The sarcomere is under constant mechanical strain, which predisposes its
members to denaturation, and yet must maintain optimal mechanical function for
decades in the terminally differentiated adult cardiomyocyte. To preserve function,
stress-denatured sarcomere proteins must be refolded or targeted to degradation
pathways by molecular chaperones so that new proteins can be incorporated [340].
However, sarcomeric protein quality control (PQC) is frequently impaired in heart failure,
leading to toxic aggregation of misfolded/dysfunctional proteins [340]. An arrested
removal of dysfunctional sarcomere proteins in heart failure may thus serve as a
plausible mechanism for the observed decrease in F max. However, the distinct
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mechanisms of sarcomere protein turnover in the adult heart are poorly characterized,
and the functional relevance of sarcomere PQC has not been determined.
Bcl2-associated athanogene 3 (BAG3) is a heat shock protein (HSP) cochaperone that mediates protein degradation through autophagy [306]. Evidence in
recent years indicates an essential role for BAG3 in the heart with numerous clinical
studies finding that BAG3 mutations are associated with dilated cardiomyopathy (DCM)
and myofibrillar myopathy [64–67,69,70,85]. Due to limitations with long-term culture of
adult cardiomyocytes, mechanistic studies of BAG3 have primarily been performed in
immature neonatal myocytes, where BAG3 was shown to stabilize sarcomere structure
through maintenance of the actin capping protein CapZβ [196]. However, the role of
BAG3 at the sarcomere in adult myocytes under mechanical load is less understood
and the association with CapZβ does not appear to be conserved [97]. Moreover,
sarcomere structure is unimpaired at the neonatal stage with germline BAG3 knockout
(KO), but rapidly disintegrates post-natum [99]. These findings suggest separate or
additional sarcomeric roles for BAG3 in the adult.
An important study of BAG3 in the adult heart came from Fang et al. who showed
BAG3 KO in mice caused DCM, destabilized the small HSPs (HSPBs), and resulted in
protein aggregation, indicating impaired protein turnover [54]. Notably, BAG3 KO in
iPSC-derived cardiomyocytes caused reduced contractility and altered expression of
HSPs, suggesting sarcomeric functional relevance for BAG3-dependent PQC [105].
However, iPSC-cardiomyocytes also have immature morphology and are not under
mechanical load, making functional inferences to the adult problematic, especially at the
sarcomere, which only fully matures under chronic load. While little is known regarding
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BAG3’s role in the mature cardiac sarcomere, studies in mature skeletal muscle
identified BAG3 assembles with HSP70 and HSPB8, forming the chaperone-assisted
selective autophagy (CASA) complex which mediates the turnover of the actin crosslinking protein filamin C [47,101,102]. Whether CASA operates at the cardiac
sarcomere, the myofilament functional impact of BAG3, and the effect of heart failure on
these mechanisms are unknown. However, given the near universally observed
depression of Fmax in systolic heart failure, sarcomeric PQC represents an attractive
therapeutic target.
Here, we show that sarcomere protein turnover is impaired in human heart failure
samples with reduced Fmax. We verify the presence of the CASA complex at the
sarcomere in the human heart, confirm its role in filamin C turnover therein, and identify
seven novel clients of BAG3-mediated protein turnover. We further show myofilament
BAG3 expression decreases in human DCM and correlates with functional decline,
where lowest BAG3 expression corresponds to weakest force generation. BAG3 haploinsufficient mice also exhibit this functional deficit and display increased myofilament
protein ubiquitination and reduced CASA protein expression. Finally, increasing BAG3
using adeno-associated virus gene therapy in mice with heart failure restores
myofilament Fmax and sarcomere protein turnover. Our findings indicate that impaired
sarcomere protein turnover contributes to decreased F max in heart failure and highlight
BAG3 as an essential factor for sarcomere functional maintenance.
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Methods
Human Heart Tissue Procurement
Human left ventricular tissue was obtained from the Loyola Cardiovascular
Research Institute Biorepository and Cleveland Clinic Biorepository. Tissue from failing
human hearts with non-ischemic idiopathic dilated cardiomyopathy and left ventricular
dysfunction was collected either at the time of heart explant or at the time of LVAD
implantation. Informed consent was obtained prior to tissue collection. Myocardial tissue
from the non-failing donors with no history of coronary artery disease or heart failure
(EF%, 57.5 ± 3.2) was collected post-mortem with other organs. All tissue was flash
frozen in liquid nitrogen. The patient age and sex distribution were not significantly
different between the non-failing (53.3 ± 8.9 years, 44.4% female) and failing hearts
(55.5 ± 11.5 years, 38.1% female).
Animals
All animal experiments were conducted according to the standards set by the
Loyola University Chicago Health Science Division, Temple University, and Hines VA
Institutional Animal Care and Use Committee (IACUC) in adherence to the US National
Institutes of Health Guide for the Care and Use of Laboratory Animals. Experimental
procedures were approved by the Loyola University Chicago Health Science Division,
Temple University, and Hines VA IACUCs, which are AALAC accredited institutions.
Both mice and rats were maintained in 12-hour light/dark cycles from 6 AM to 6 PM at
65-75 °F/40-50% humidity and had unrestricted access to food and water.
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AAV9-BAG3 Overexpression Mouse Model
The generation of mice with LV dysfunction secondary to a left coronary artery
ligation was described previously [91]. In brief, eight-week old C57/Bl6 mice were
randomized to undergo a left descending coronary artery (LAD) ligation or sham surgery
[341]. Because only half of the mice in which the artery was ligated were alive at oneweek post-surgery, mice were not randomized to treatment group until one-week postsurgery. Eight weeks post-MI, the now randomized sham-operated mice and postinfarction mice received either gene therapy with a recombinant adeno-associated virus9 expressing BAG3 (rAAV9-BAG3) or control (AAV9-GFP) by retro-orbital injection.
Four weeks later mice were sacrificed, tissue was removed, and flash frozen in liquid
nitrogen.
BAG3 P209L Transgenic Mouse Model
The generation of the P209L BAG3 mouse strain was described previously [88].
Transgene positive founders were bred into wild-type C57/Bl6 mice. P209L positive
offspring were identified through PCR of isolated tail DNA obtained during weaning
using primers (F: CATGCCAGAAACCACTCAGC, R: GTAGACAGGTCCCACGTAGC)
for the human bag3 transgene. Wild-type and transgene-positive offspring were pairhoused and aged to 3 or 8 months, at which time they were euthanized, and myocardial
tissue was collected.
BAG3 +/- & -/- Mouse Model
Generation of mice homozygous (-/-) or heterozygous (+/-) for the murine version
of the constitutive (c) deletion of BAG3 (cBAG3-/- or cBAG3+/-) has been described in
detail elsewhere [33]. Mice lacking a single allele of wild type BAG3 developed early LV
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dysfunction by 8 to 10 weeks of age. Mice in which both alleles of BAG3 were deleted
developed LV dysfunction commensurate with that of the heterozygous mice; however,
the BAG3-/- died by 12 to 14 weeks of age with severe LV dysfunction. Hemodynamic
data for the BAG3+/- was reported previously [33]. Hemodynamic data for the BAG3-/was obtained separately. The mice used for data collection in this study were 6 weeks
of age, thus preceding the development of detectable in vivo LV dysfunction.
Neonatal Rat Ventricular Myocyte Studies
Neonatal rat hearts were isolated from 0-1 day old Sprague-Dawley rat pups
(Charles River Laboratories), placed in ice cold Krebs-Henseleit Buffer (KHB)[342], and
rinsed twice. Next, the atria were removed, and the isolated ventricles were digested in
37 °C KHB supplemented with 1g:100mL collagenase type-II (Worthington) and 0.05%
trypsin with intermittent stirring. The buffer solution was then moved to a tube containing
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% fetal
bovine serum (FBS, Millipore Sigma) to stop the digestion reaction. This process was
repeated four times or until the myocardial tissue was fully digested and turned white.
Next, the digested ventricular myocyte solution was centrifuged at 140g for 10 minutes
and the pelleted cells were resuspended in DMEM with 10% FBS and
penicillin/streptomycin, plated, and incubated at 37 °C in a 5% CO 2 incubator for 90
minutes to allow the fibroblasts to stick. After incubation, the plates were softly tapped to
dislodge cardiomyocytes, the supernatant containing the cardiomyocytes was collected
and cultured at 1 million cells per plate on 60 x 15 mm culture dishes coated with 0.1%
gelatin and incubated at 37 °C/5% CO 2. After 48 hours, the media was replaced with
fresh media containing 2 µM MG132 (MedChem Express) dissolved in DMSO to induce
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proteotoxic stress by inhibiting the proteasome, or equal volume of DMSO (Millipore
Sigma) vehicle control. After 24 hours of treatment the cells were collected and enriched
for myofilament proteins.
Skinned Myocyte Force-calcium Experiments
Skinned cardiomyocytes were prepared as described previously [343]. Briefly,
frozen left-ventricular tissue was placed in Isolation solution (Table 3) containing
protease and phosphatase inhibitors (1:100 ratio, Fisher Scientific), 10 mM 1,4dithiothreitol (DTT, Millipore Sigma), and 0.3% (v/v) Triton X-100 (Millipore Sigma). The
tissue was mechanically homogenized in three one-second bursts and left on ice for 20
minutes to permeabilize. Next, the myocyte solution was pelleted by centrifugation at
120g for 2 minutes and resuspended in Isolation solution without triton. For the heat
shock experiment, the myocytes were split into two tubes: one kept at 4 °C and the
other placed on a shaking incubator at 43 °C for three hours. For all other experiments,
the myocytes were kept on ice.
Table 3. Composition of the Isolation, Activation, and Relax Solutions
Activation

Final Conc. (mM)

Relax

Final Conc. (mM)

Isolation

Final Conc. (mM)

Ca2+-EGTA
KPROP
BES
MgCl2
ATP
Creatine P

10
28.1
100
6.2
6.3
10

EGTA
KPROP
BES
MgCl2
ATP
Creatine P

10
47.6
100
6.5
6.2
10

EGTA
KOH
Imidazole
MgCl2
ATP
KCl

2
8.9
10
7.1
5.8
108

To assess function, myocytes were first attached with UV-curing glue (NOA 61,
Thorlabs) to two pins, one attached to a force transducer (AE-801, Kronex) and the
other to a high-speed piezo length controller (Thorlabs). Next, the myocyte was
perfused with a maximal calcium Activating solution to elicit contraction and then
perfusion was switched to 100% Relax solution (Table 3) to facilitate relaxation. This
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process was continued with perfusion of five additional submaximal calcium solutions
containing Activating solution mixed with Relax solution. All measurements were
conducted at room temperature and performed at a sarcomere length of 2.1 µm as
measured by Fast Fourier Transform. Experimenters were blinded to the experimental
groups during the collection of these data.
Myofilament Protein Enrichment
Frozen left ventricular tissue was placed in 1 mL of a standard rigor buffer (SRB)
[344] containing protease and phosphatase inhibitors (1:100 ratio) and 1% Triton X-100.
The tissue homogenized with a mechanical homogenizer and left on ice for 10 minutes.
For NRVMs, the cells were suspended in SRB with Triton and left to permeabilize on ice
for 20 minutes without homogenization. Myofilaments were pelleted by centrifugation at
1,800g for 2 minutes and the supernatant containing soluble proteins was removed. The
myofilament pellet was washed twice in SRB without Triton, resuspended in 9M Urea
(Millipore Sigma), and sonicated. Following sonication, the solution was centrifuged at
12,000g for 10 minutes and the supernatant containing the now solubilized myofilament
proteins was collected.
Immunoblotting
After isolating the myofilament fraction, protein concentration was determined
using a BCA assay (Thermo Fisher). Samples were prepared in SDS Tris-Glycine
Buffer (Life Technologies) supplemented with Bolt Reducing Buffer (Fisher Scientific),
heated for 10 minutes at 95 °C, and run on 4-12% gradient Tris-glycine gels
(Invitrogen). The proteins were transferred onto a nitrocellulose membrane (Thermo
Scientific). Following transfer, membranes were incubated with Revert Total Protein
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Stain (LI-COR Biosciences) for five minutes to assess equal loading and then blocked in
a 1:1 ratio Intercept Blocking Buffer (LI-COR Biosciences) to Tris-Buffered Saline (TBS)
solution for 1 hour at room temperature. The following primary antibodies and dilutions
were used and incubated in blocking buffer with 0.1% Tween overnight at 4 °C with
gentle rocking: BAG3 (Proteintech, 10599-1AP, 1:5,000), BAG3 (Santa Cruz
Biotechnology, sc-136467, 1:500), c-Myc (Cell Signaling Technology, 71D10, 1:1000),
HSPB8 (Proteintech, 15287-1AP, 1:3,000), HSP70 (Proteintech, 10995-1AP, 1:3,000),
Ubiquitin (Cytoskeleton Inc., AUB01, 1:400), CHIP/STUB1 (Santa Cruz Biotechnology,
sc-133083, 1:100), P62 (Proteintech, 18420-1AP, 1:3,000), GAPDH (Cell Signaling
Technology, 14C10, 1:4000), Sarcomeric α-actin (Millipore Sigma, A2172, 1:10000).
Blots were analyzed using the LI-COR Image Studio software.
Co-immunoprecipitation
Dynabeads Protein G (Invitrogen) were incubated with 5 µg of antibody in 200 µl
TBS with 0.1% Tween (TBS-T) for 20 minutes at room temperature with rotation. The
immunocomplex was washed three times with 100 mM sodium borate (pH 9) and then
antibody was crosslinked with 20 mM dimethyl pimelimidate dihydrochloride (DMP) in
100 mM sodium borate for 30 minutes at room temperature. After crosslinking, the
complex was blocked with 200 mM ethanolamine (pH 8) for two hours to limit nonspecific protein binding. After blocking, the immunocomplex was washed three times
with IAP buffer (50 mM MOPS (pH 7.2), 10 mM sodium phosphate, 50 mM NaCl) and
then resuspended in 200 µl of 2 µg/µl myofilament-enriched protein lysates. After
incubation for 10 minutes at room temperature with rotation, the immunocomplex was
washed seven times with TBS-T on a magnetic rack. Immunoprecipitated proteins were
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eluted by suspending the beads in a 0.15% TFA solution for 5 minutes at room
temperature. The eluted proteins were dried by vacuum centrifugation and then
prepared for mass spectrometry or analyzed by western blot.
Client Release Experiment
This protocol was adapted from Arndt et al. with minor modifications [47].
Approximately 500 µg of myofilament-enriched protein from three separate human DCM
LV samples was split into two equal pools and each resuspended in 100 µl of a 20 mM
MOPS, 100 mM KCl, 2 mM ATP, 2 mM MgCl2 buffer. Recombinant BAG3 protein
(Abcam) was then added to the half of the samples at a final concentration of 300 nM,
while the remaining half were left untreated. All samples were then incubated at 30 °C
for 1 hour with constant agitation. After incubation, the myofilaments were pelleted by
centrifugation at 10,000 x g for 10 minutes. The soluble protein fraction containing the
“released” proteins was collected and the myofilament/insoluble protein pellet was
solubilized in 500 µl of 9M urea. To assess ubiquitin in the two fractions, 10 µl of the
released protein and 2.5 µl of the myofilament protein were used for western blot. The
remaining sample underwent in-solution digestion for mass spectrometry as detailed
below. The resulting peptides from the released proteins were reconstituted in 20 µl of
buffer A (3% acetonitrile, 0.1% formic acid) and those from the myofilament pellet were
reconstituted in 2 mL buffer A. For the analysis, this 100-fold difference in the loading
amount was taken into account to allow for appropriate comparison between the
fractions.
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In-solution Digestion Mass Spectrometry
Following immunoprecipitation for BAG3 the co-immunoprecipitated proteins
were reconstituted in 50 mM Tris-HCl (pH 8) and reduced with 5 mM DTT for 45
minutes. Following reduction, the proteins were alkylated by incubation in 10 mM
iodoacetamide for 30 minutes. The proteins were next digested with 5 ug Trypsin/LysC
protease for 18 hours at 37 °C. The reaction was stopped by adding TFA at 0.1% final
volume to bring the pH under 3. Samples were then dried by vacuum centrifugation,
reconstituted in 300 µl of 0.1% TFA, and separated into 12 fractions by basic pH
reverse phase fractionation. The fractions were concatenated, dried, reconstituted in
buffer A (3% acetonitrile, 0.1% formic acid) and analyzed by liquid chromatography
tandem mass spectrometry (LC-MS/MS).
Ubiquitinated Myofilament Peptide Enrichment Mass Spectrometry
This procedure was adopted from Udeshi et al. [345] with minor modifications.
Approximately 3 mg human or 500 µg of mouse myofilament-enriched protein was
incubated in 5 mM DTT at room temperature for 45 minutes to reduce disulfide bonds,
followed by alkylation via incubation with 10 mM IAA for 30 minutes. The protein was
then diluted 1:4 with 50 mM Tris-HCl (pH 9) to reduce the urea concentration and
digested with Trypsin/LysC protease mix (1:50 wt/wt) for 18 hours at 37 °C (pH 8-8.5).
The peptides were next desalted with a 100-mg tC18 SepPak cartridge (Waters), dried
by vacuum centrifugation, and stored at -80 °C until next use. At this stage a small
amount of sample was set aside to be run as a total peptides control on LC-MS/MS
later. Dried peptides were reconstituted in 0.1% TFA and separated into 12 fractions via
high pH reverse phase fractionation (Pierce). The collected fractions were pooled by
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concatenation to maximize LC gradient utilization and then dried by vacuum
centrifugation until next use.
Ubiquitinated peptides were purified using immunoaffinity purification with the
diglycine-lysine ubiquitin remnant motif antibody (Cell Signaling Technology, PTMScan)
crosslinked to Protein A agarose beads. Each pooled fraction was reconstituted in icecold IAP buffer (50 mM MOPS pH 7.2, 10 mM NaPO 4 dibasic, 50 mM NaCl) and
incubated with 30 µg of antibody for 1 hour at 4 °C with gentle rotation. After washing,
the purified peptides were eluted by incubation with 0.15% TFA and concentrated using
the GL-Tip SDB 200 µl C18 tips (GL Biosciences). The collected samples were then
dried by vacuum centrifugation and stored at -80 °C until ready for LC-MS/MS.
Tryptic peptides were reconstituted in 20 µl of buffer A (3% ACN, 0.1% FA) and 5
µl were subjected to high pressure liquid chromatography (HPLC) in a 25 cm PepMap
RSLC C18 column (Thermofisher) coupled to tandem mass spectrometry (MS/MS) on
an LTQ Orbitrap XL mass spectrometer. Upon completion, raw data files were imported
into the Peaks Bioinformatics program and acquired masses were searched against the
Homo sapiens database. The precursor ion mass tolerance was set at 20 ppm and the
MS/MS was set at 1.0 Da. A maximum of three missed cleavages were allowed. The
fixed modification was carbamidomethylated cysteine (+57.02 Da) and the variable
modification was ubiquitinated lysine (+114.04 Da). For comparison between groups,
ubiquitinated peptides were normalized to the corresponding total peptides control for
each sample set aside earlier.
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Immunofluorescence Microscopy
Frozen left ventricular tissue was placed in Isolation solution (Table 3) containing
0.3% Triton X-100, homogenized in 3-4 one-second bursts with a mechanical
homogenizer, and left for 20 minutes on ice to permeabilize. Next, the cells were
pelleted by centrifugation at 120g for 2 minutes, resuspended in Isolation solution
without triton, and seeded on Poly-L-Lysine-coated (Millipore Sigma) chamber slides
(Thermo Scientific). Once settled, the cells were fixed with ice-cold methanol for 1
minute and 4% paraformaldehyde for 3 minutes. For NRVMs, freshly isolated myocytes
were plated on nanopatterned coverslips (Nanosurface Cultureware) to promote adultlike myocyte morphology. Forty-eight hours after plating, the myocytes were treated with
2 µM MG132 or equal volume of DMSO. After 24 hours, the myocytes were fixed with
ice cold methanol for 1 minute, followed by 4% paraformaldehyde for 3 minutes.
Fixed myocytes were incubated in 0.5% Triton solution for 20 minutes, followed
by 0.1% Triton for 30 minutes to permeabilize the sarcolemma. Following
permeabilization, the cells were incubated in 0.1M glycine antigen retrieval solution for
30 minutes, washed three times with PBS, and incubated for one hour in BSA blocking
buffer at room temperature. Next, primary antibodies were added in blocking solution
and incubated for 12-14 hours at 4 °C. Primary antibodies and dilutions used: BAG3
(Proteintech, 10599-1AP, 1:300), HSPB8 (Proteintech, 15287-1AP, 1:300), HSP70
(Proteintech, 10995-1AP, 1:300), CHIP/STUB1 (Proteintech, 55430-1-AP, 1:300), P62
(Proteintech, 18420-1AP, 1:250), α-actinin (Millipore Sigma, A7811, 1:250), oligomer
A11 (Invitrogen, AHB0052, 1:100), Ubiquitin (Cytoskeleton Inc., AUB01, 1:40). After
washing four times with PBS, the cells were incubated for one hour with the appropriate
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secondary antibody conjugated to Alexa-Fluor 488 or Alexa-Fluor 568 (Abcam,
1:1,000). Slides were mounted with Vectashield (Vector Laboratories), sealed with
coverslips, and imaged at 63x magnification on a Zeiss LSM 880 super-resolution
confocal microscope. Images were acquired under constant laser intensity and
photomultiplier gain settings with the Zen Black Software (Zeiss). Quantitative line scan
analysis was performed using ImageJ.
Statistics
All experiments were performed with more than 3 independent biological
replicates. The results are presented as mean ± SEM and were analyzed using
GraphPad Prism 8.0. Datasets containing three or more groups were analyzed by oneway analysis of variance as appropriate. When a significant interaction was identified,
Tukey’s post-hoc test for multiple comparisons was performed. For comparisons of two
groups, data were analyzed by 2-tailed Student’s t test. A p value < 0.05 was
considered as statistically significant.
Results
Human DCM Cardiomyocytes have Reduced Sarcomere Contractile Function and
Impaired Myofilament Protein Turnover.
Decreased contractility in heart failure has been linked to sarcomere dysfunction
[331]. In cases of genetic heart failure, decreased F max may be explained by structural
alterations to proteins involved in the crossbridge cycle, which are detrimental to their
function [346,347]. However, functional deficits have also been observed in non-genetic
heart failure [334,335,337,346], which makes up the majority of cases. We therefore
sought to determine the underlying mechanism for myofilament dysfunction in heart
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failure using left ventricle (LV) samples from patients with idiopathic dilated
cardiomyopathy (DCM) and heart failure (Table 4).
Table 4. Clinical Characteristics for the Human Non-failing (NF) and Dilated
Cardiomyopathy (DCM) Samples
Characteristic
Age, (years), Mean ± SD
Female, (n), %
Ethnicity, (n), %
- White
- Black
- Hispanic
LVEF, (%), Mean ± SD

NF (n = 9)
53.3 ± 8.9
4 (44.4)

DCM (n = 21)
55.5 ± 11.5
8 (38.1)

8 (88.9)
1 (11.1)
0 (0.00)
57.5 ± 3.2

16 (76.2)
4 (19.1)
1 (4.8)
20.3 ± 2.2

p value
0.66

< 0.001

Using skinned myocytes from DCM and non-failing (NF) samples, we first
showed that myofilament Fmax decreased significantly in DCM (Figure 6A-B). Consistent
with prior studies discussed above, the EC50 (calcium concentration required to elicit
half maximal force) also decreased in DCM, indicating increased myofilament calcium
sensitivity (Figure 6C). Since impairment to PQC mechanisms is a common feature of
heart failure [348], we hypothesized that disrupted removal of misfolded/dysfunctional
sarcomere proteins might underly the observed decrease in F max. With functioning PQC,
misfolded proteins are tagged with ubiquitin and then removed through various protein
degradation mechanisms [340]. Thus, increased ubiquitin levels may serve as a readout
for disrupted protein turnover, where proteins are effectively marked for degradation but
fail to be turned over. To determine if sarcomere protein turnover was impaired, we
assessed ubiquitination in myofilament-enriched fractions from the DCM and NF tissue
by western blot. As expected, we found significantly increased ubiquitin at the
myofilament in DCM, suggesting a build-up of misfolded sarcomere proteins in disease
(Figure 6D-E).
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There are two possible explanations for the observed increase in myofilament
ubiquitination in DCM. One is that these ubiquitinated misfolded proteins were removed
from the contractile apparatus, but not degraded properly and thus formed protein
aggregates that are commonly observed in heart failure [348]. However, a second
possibility, which has been suggested in the skeletal muscle sarcomere during atrophy
[285], is that misfolded sarcomeric proteins are not being removed from the contractile
apparatus and remain integrated into the sarcomere. The protein stoichiometry of the
sarcomere is highly conserved [349], and thus the continued integration of these old
sarcomeric proteins which have been marked for degradation would block the
incorporation of newly synthesized proteins, providing an explanation for the decline in
Fmax.
To determine whether these ubiquitinated proteins are imbedded within the
sarcomere itself, we used confocal microscopy on human DCM cardiomyocytes
immunostained for ubiquitin and the protein aggregate marker oligomer A11. As
expected, A11 had diffuse punctate localization with no apparent sarcomere patterning.
However, ubiquitin localized in a cross-striated pattern and was enriched in thick,
regularly repeating bands representative of the sarcomere A-band (Figure 6F). Among
the most abundant A-band proteins are actin, myosin, and myosin binding protein C,
which are fundamental to sarcomere contraction [350]. This indicates that the
ubiquitinated proteins identified in the myofilament fraction, which were found by
western blot to increase in DCM, are in large part incorporated into the sarcomere and
not components of protein aggregates. It further suggests that the primary proteins with
inadequate turnover in DCM are those directly involved in tension generation.
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Figure 6. Human DCM is Characterized by Decreased Myofilament Function
and Impaired Sarcomere Protein Turnover. (A). Skinned myocyte force-calcium
relationship from human non-failing (NF) and dilated cardiomyopathy (DCM)
cardiomyocytes; n = 19 NF from 6 patients, 41 DCM from 12 patients. (B-C).
Summary data for myocyte Fmax (B) and EC50 (C) corresponding to the force-calcium
graph in A. (D). Western blot for ubiquitin in the NF and DCM left ventricle (LV)
myofilament fraction; n = 9 NF samples, 21 DCM. (E). Ubiquitin signal normalized to
total protein; n = 9 NF, 21 DCM. (F). Immunofluorescence image of a human LV
cardiomyocyte immunostained for ubiquitin and oligomer A11; 63X magnification,
scale bar = 10 µm. (G). Force-calcium curves for skinned cardiomyocytes treated at
4 °C (Control) or at 43 °C (Heat Shock) for 3 hours; n = 3 myocytes/treatment from 3
separate non-failing patient samples. (H-I). Summary data for individual myocyte
Fmax (H) and calcium sensitivity (I) corresponding to the force-calcium curves in G.
(J), Western blot for myofilament ubiquitin in the control and heat shock-treated
samples; image is representative of 3 samples/treatment. All data are presented as
mean ± SEM and were analyzed by 2-tailed t-test.
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Next, to confirm the negative functional impact of misfolded proteins remaining
integrated into the sarcomere, we treated NF human skinned cardiomyocytes with heat
shock at 43 °C for 3 hours to cause protein denaturation. Following the heat shock
treatment, we performed force-calcium experiments on these myocytes and found, as
expected, that heat shock caused a prominent reduction in F max (Figure 6G-I). Since the
treatment was of skinned myocytes, which have no intact cellular signaling pathways,
the misfolded proteins denatured by heat shock were not tagged with ubiquitin (Figure
6J). Therefore, while we could not from this data make any claims as to the functional
implications of ubiquitin modifications themselves, we concluded that protein misfolding
alone is sufficient to cause significant functional detriment as we hypothesized.
To determine which specific sarcomere proteins had impaired turnover, we
digested proteins from the myofilament fraction isolated from NF and DCM tissue with
trypsin, enriched for ubiquitinated peptides by immunoprecipitation for the diglycine
lysine ubiquitin remnant motif (K-ε-GG), and identified the peptides via mass
spectrometry (Figure 7A). This technique provided a characterization of the myofilament
ubiquitinome in heart failure and identified several proteins with increased ubiquitination,
suggesting impaired turnover (Figure 7B). The top hits with increased ubiquitination in
DCM included myosin regulatory light chain-2, desmin, myozenin-2, α-actinin-2, and
tropomyosin alpha-1, which had significantly higher ubiquitination when analyzed by
spectral count compared to non-failing (Figure 7C-H). The total peptide amounts of
these proteins were not different between the NF and DCM groups (Figure 7I-N), which
is expected given the specific stoichiometry observed by sarcomere proteins. These
data indicate sarcomere protein turnover is disrupted in DCM resulting in increased
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misfolded proteins incorporated into the sarcomere, which offers a compelling possible
explanation for the decrease in Fmax.

Figure 7. Characterization of the Sarcomere Ubiquitinome in DCM. (A).
Proteomics paradigm for ubiquitinated peptide enrichment. (B). Heat map of the top
20 ubiquitinated proteins identified by LC-MS/MS for NF and DCM human patients
normalized to total peptide input; scale bar = fold change relative to NF, darkest red
color denoting greatest fold change. (C-H). Spectral count data for ubiquitinated
peptides normalized to total peptide input for myosin regulatory light chain (C),
desmin (D), α-actinin (E), tropomyosin (F), filamin C (G), and myozenin-2 (H). (I-N).
Normalized candidate peptides identified by LC-MS/MS in the total peptide input for
myosin regulatory light chain (I), desmin (J), α-actinin (K), tropomyosin (L), filamin C
(M), and myozenin-2 (N). n = 6 NF, 5 DCM. Data are presented as mean ± SEM
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Myofilament Expression of the Co-chaperone BAG3 Decreases in DCM and
Correlates with Fmax
Several studies have implicated the heat shock protein co-chaperone BAG3 in
sarcomere maintenance [75,85,99,105,196], however, the mechanisms of BAG3mediated sarcomere maintenance in adult cardiomyocytes are poorly understood.
BAG3 is involved in PQC by mediating autophagic clearance of misfolded proteins and
has been shown to localize to the sarcomere Z-disc, thus positioning it to mediate
sarcomere protein turnover [1,34]. We used western blot to assess BAG3 expression in
the myofilament protein fraction of human LV samples and found BAG3 levels
decreased significantly in patients with DCM (Figure 8A-B). Strikingly, when we
compared myofilament BAG3 levels with sarcomere functional parameters in the DCM
samples, Fmax was positively associated with BAG3 expression where samples with
reduced BAG3 expression displayed significantly lower Fmax (Figure 8C). As expected,
there was no association between myofilament BAG3 and calcium sensitivity (Figure
8D) Importantly, this relationship appears to be specific to the myofilament pool of
BAG3, as the correlation diminished when Fmax was compared with cytosolic/soluble
BAG3 expression (Figure 8E-G).
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Figure 8. Myofilament BAG3 Decreases in DCM and is Associated with
Decreased Cardiomyocyte Contractile Strength. (A). Western blot for
myofilament BAG3 in NF and DCM humans. (B). Myofilament BAG3 normalized to
total protein; n = 9 NF, 21 DCM; 2-tailed t-test. (C-D). DCM myocyte Fmax (C) and
EC50 (D) grouped by quartile of BAG3 expression; n = 12 DCM samples. E. Western
blot for soluble BAG3 in the DCM LV samples. (F). Myocyte Fmax in the DCM
samples organized by quartile of soluble BAG3 expression; n = 11 DCM samples
(one sample was not prepped for the soluble fraction due to low tissue amount). 1st
quartile = lowest BAG3 levels; 3-4 myocytes per sample for functional assessment;
Data are presented as mean ± SEM; one-way ANOVA, Tukey post-hoc.

To confirm the relationship between reduced BAG3 expression and sarcomere
dysfunction, we next employed a mouse model with cardiomyocyte-restricted
heterozygous BAG3 expression (BAG3+/-). These mice were previously found to have
progressive LV dysfunction starting at 8 weeks of age [33]. In the present study, we
used 6-week-old mice to capture the early effects of BAG3 haploinsufficiency on
myofilament function, rather than the general response to heart failure development. At
6 weeks, the mice displayed a ~20% reduction in myofilament BAG3 compared to wild-
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type, comparable to the reduction in human DCM, and had significantly increased
myofilament protein ubiquitination (Figure 9A-D). Extensive sarcomere structural
abnormalities, which have been identified in BAG3 germline KO mice at 3 weeks [99]
and in BAG3 KO iPSC-cardiomyocytes [105], were not observed in the BAG3+/- mice at
this time-point (Figure 9E). We next assessed myofilament function using force-calcium
experiments on skinned myocytes from the BAG3+/- and WT mice and found
cardiomyocytes from BAG3+/- mice had reduced Fmax but no change in calcium
sensitivity (Figure 9F-H). Together, these data indicate BAG3 is required for optimal
contractile function of the sarcomere and for maintaining sarcomere proteostasis.
Additionally, sarcomere dysfunction due to BAG3 haploinsufficiency arises despite
normal sarcomere morphology, suggesting impaired sarcomere protein turnover – not
structural disarray – may be the initial insult that leads to contractile dysfunction and
ultimately heart failure. It further agrees with our finding that the ubiquitinated proteins
remain integrated in the sarcomere and induce dysfunction but not necessarily disarray.
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Figure 9. Cardiomyocyte Specific BAG3 Haploinsufficiency in Mice is
Associated with Increased Myofilament Protein Ubiquitination and Reduced
Maximal Contractile Force. (A). Representative western blot for myofilament BAG3
in WT and BAG3+/- mice. (B). BAG3 signal normalized to total protein; n = 6 WT, 7
BAG3+/-. (C). Representative western blot for myofilament ubiquitin in WT and
BAG3+/- mice. (D). Ubiquitin signal normalized to total protein; n = 6 WT, 7 BAG3 +/-.
(E). Immunofluorescence image of WT and BAG3+/- cardiomyocytes immunostained
for α-actinin and BAG3; 63X magnification, scale bars = 5 µm. (F). Skinned myocyte
force-calcium relationship from WT and BAG3+/- cardiomyocytes; n = 9 WT from 3
mice, 10 BAG3+/- from 3 mice. (G-H). Summary data for myocyte Fmax (G) and EC50
(H) corresponding to the force-calcium curves in F. All data were analyzed by twoway t-test and are presented as mean ± SEM.
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A particularly penetrant BAG3 mutation, that results from a single amino acid
substitution of proline at 209 for leucine (P209L), precludes ubiquitinated substrate
targeting to the autophagy pathway and causes protein aggregation and myofibrillar
myopathy [75,82,85]. Earlier work found that mice with cardiomyocyte-restricted
expression of the human P209L bag3 transgene developed restrictive cardiomyopathy
by 32 weeks of age, which was accompanied by elevated whole LV ubiquitin levels and
protein aggregation [88]. We found that protein ubiquitination also increases in the
myofilament-specific fraction of the P209L mice by 12 weeks of age (Figure 10A-E).
Therefore, we employed this model to directly assess the impact of disrupted BAG3mediated protein degradation on myofilament function. Using skinned myocyte forcecalcium experiments on cardiomyocytes from 12-week-old P209L mice, we did not find
any significant differences in myofilament functional parameters, though F max appeared
to trend toward a decrease (Figure 10F-H). However, when we assessed myofilament
function in 32-week-old P209L mice, the age at which in vivo cardiac dysfunction
manifests, we found Fmax was significantly reduced compared with aged-matched
littermate controls (Figure 10I-K). Taken together, the relationship between
decreased/dysfunctional BAG3 and reduced force-generating capacity identified in the
human DCM samples, the BAG3+/- mice, and the P209L mice suggests BAG3 is
essential for maintaining sarcomere function.
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Figure 10. Cardiomyocyte-specific Expression of the Human BAG3 P209L
Transgene Impairs Myofilament Protein Turnover and Contractile Function in
Mice. (A) Representative western blots for myofilament BAG3, HSP70, HSPB8, and
ubiquitin in the WT and P209L mice. (B-E). Myofilament expression of BAG3 (B),
HSP70 (C), HSPB8 (D), and ubiquitin (E) normalized to total protein; n = 10 WT, 14
P209L. n = 10 WT and 14 P209L for BAG3, HSP70, and HSPB8; n = 12 WT and 22
P209L for ubiquitin. (F). Skinned myocyte force-Ca2+ relationship for 12-week-old
WT and P209L myocytes; n = 21 WT myocytes from 7 mice, 24 P209L from 8 mice.
(G-H). Summary data for individual myocyte Fmax (G) and calcium sensitivity (H)
corresponding to the force-calcium curves in F. (I). Skinned myocyte force-Ca2+
relationship for 32-week-old WT and P209L myocytes; n = 18 WT myocytes from 6
mice, 15 P209L from 5 mice. (J-K). Summary data for individual myocyte Fmax (J)
and calcium sensitivity (K) corresponding to the force-calcium curves in I. All data
are presented as mean ± SEM and were analyzed by 2-tailed t-test.

The Chaperone-assisted Selective Autophagy (CASA) Complex Localizes to the
Sarcomere Z-disc and is Upregulated in Response to Proteotoxic Stress
Having established that BAG3 is functionally significant for the sarcomere, we
next sought to identify the underlying mechanism. To begin, we explored the BAG3
interactome in the human LV myofilament fraction using immunoprecipitation and mass
spectrometry. Mass spectrometry analysis identified numerous sarcomere members,
which may represent clients of BAG3-mediated protein turnover, as well as two heat
shock proteins: HSP70 and HSPB8 (Table 5). Mass spectrometry analysis of the
HSP70 and HSPB8 myofilament interactomes further confirmed the association of these
three proteins (Tables 6-7). These two binding partners are noteworthy, as together with
BAG3 they were previously shown to engage in chaperone-assisted selective
autophagy (CASA) in skeletal muscle [47,101]. In the canonical CASA pathway, the
BAG3/HSP70/HSPB8 complex associates with misfolded proteins, which are
ubiquitinated by the E3 ligase c-terminus of HSP70 interacting protein (CHIP) and
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targeted to the autophagosome for degradation [102]. Others have shown that this
complex localizes to the sarcomere Z-disc in skeletal muscle [47,101], which we also
confirm in mouse gastrocnemius myocytes (Figure 11).

Figure 11. Localization of the CASA Complex Members in Skeletal Myocytes.
(A). Representative immunofluorescence image of a skeletal myocyte stained for
BAG3 and α-actinin. (B). Line-scan showing overlay of α-actinin and BAG3
fluorescence intensity. (C). Representative immunofluorescence image of a skeletal
myocyte stained for HSP70 and α-actinin. (D). Line-scan showing overlay of αactinin and HSP70 fluorescence intensity. (E). Representative immunofluorescence
image of a skeletal myocyte stained for HSPB8 and α-actinin. (F). Line-scan showing
overlay of α-actinin and HSPB8 fluorescence intensity. Images were acquired at 63X
magnification; scale bars = 10 µm.
To confirm the presence of the CASA complex at the cardiac sarcomere, we used
immunofluorescence microscopy on human LV cardiomyocytes and found BAG3,
HSP70, HSPB8, and CHIP each localized to the sarcomere Z-disc, as evident from their
co-localization with α-actinin (Figure 12A-B). We further confirmed this localization was
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sarcomeric using western blot for the CASA members in human whole LV, soluble, and
myofilament fractions (Figure 12C) and confirmed their association therein using coimmunoprecipitation (Figure 12D-E).
Table 5. Top 30 Protein Hits in the Myofilament BAG3 Interactome Identified by
Mass Spectrometry
Protein Accession
O95817|BAG3_HUMAN
P12883|MYH7_HUMAN
P17661|DESM_HUMAN
Q14896|MYPC3_HUMAN
P35609|ACTN2_HUMAN
Q9UJY1|HSPB8_HUMAN
P15924|DESP_HUMAN
P09669|COX6C_HUMAN
Q13423|NNTM_HUMAN
P12235|ADT1_HUMAN
Q14315|FLNC_HUMAN
P21796|VDAC1_HUMAN
A7E2Y1|MYH7B_HUMAN
Q15149|PLEC_HUMAN
Q09666|AHNK_HUMAN
P40939|ECHA_HUMAN
P02511|CRYAB_HUMAN
P18859|ATP5J_HUMAN
P12111|CO6A3_HUMAN
P11142|HSP7C_HUMAN
P24539|AT5F1_HUMAN
P06732|KCRM_HUMAN
P20674|COX5A_HUMAN
P0DMV8|HS71A_HUMAN
P54652|HSP72_HUMAN
P68431|H31_HUMAN
P62805|H4_HUMAN
P52179|MYOM1_HUMAN
P08590|MYL3_HUMAN
Q9NPC6|MYOZ2_HUMAN

Coverage (%)
73
41
39
14
16
32
3
47
7
32
3
28
4
1
1
6
22
32
1
7
12
8
15
6
6
15
29
2
20
12

# of Peptides
63
113
22
16
13
10
8
7
7
12
8
6
11
5
5
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3

Unique Peptides
63
36
19
16
13
10
8
7
7
6
6
6
5
5
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
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Table 6. Top 30 protein Hits in the Myofilament HSP70 Interactome Identified by
Mass Spectrometry
Accession
P12883|MYH7_HUMAN
Q14896|MYPC3_HUMAN
P35609|ACTN2_HUMAN
P35555|FBN1_HUMAN
P54296|MYOM2_HUMAN
P12111|CO6A3_HUMAN
P0DMV8|HS71A_HUMAN
Q13423|NNTM_HUMAN
P25705|ATPA_HUMAN
P52179|MYOM1_HUMAN
Q13813|SPTN1_HUMAN
P17661|DESM_HUMAN
P15924|DESP_HUMAN
P16615|AT2A2_HUMAN
P06576|ATPB_HUMAN
Q14315|FLNC_HUMAN
P08590|MYL3_HUMAN
P06732|KCRM_HUMAN
Q02978|M2OM_HUMAN
Q5VTT5|MYOM3_HUMAN
P55084|ECHB_HUMAN
P10916|MLRV_HUMAN
Q16891|MIC60_HUMAN
Q9NPC6|MYOZ2_HUMAN
O75746|CMC1_HUMAN
P02452|CO1A1_HUMAN
P20674|COX5A_HUMAN
P40939|ECHA_HUMAN
Q99959|PKP2_HUMAN
P02511|CRYAB_HUMAN

Coverage (%)
71
51
77
15
28
12
53
27
52
15
11
54
7
26
48
10
83
48
59
13
34
68
24
67
23
11
66
18
18
66

# of Peptides
222
57
69
33
33
30
31
25
23
23
22
23
21
21
20
24
22
18
17
16
16
17
16
14
14
13
13
13
15
12

Unique Peptides
74
56
43
33
31
30
26
25
23
22
22
21
21
21
20
18
18
17
17
16
16
15
15
14
13
13
13
13
12
12
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Table 7. Top 30 Protein Hits in the Myofilament HSPB8 Interactome Identified by
Mass Spectrometry
Accession
P12883|MYH7_HUMAN
Q14896|MYPC3_HUMAN
O76041|NEBL_HUMAN
P35609|ACTN2_HUMAN
P52179|MYOM1_HUMAN
Q86VF7|NRAP_HUMAN
P17661|DESM_HUMAN
O15061|SYNEM_HUMAN
P02511|CRYAB_HUMAN
P06576|ATPB_HUMAN
P54296|MYOM2_HUMAN
P06732|KCRM_HUMAN
P25705|ATPA_HUMAN
P15924|DESP_HUMAN
P40939|ECHA_HUMAN
O94875|SRBS2_HUMAN
Q9UJY1|HSPB8_HUMAN
Q14315|FLNC_HUMAN
O95817|BAG3_HUMAN
P45379|TNNT2_HUMAN
P08670|VIME_HUMAN
Q99959|PKP2_HUMAN
P63316|TNNC1_HUMAN
P08123|CO1A2_HUMAN
P04075|ALDOA_HUMAN
P31930|QCR1_HUMAN
P04792|HSPB1_HUMAN
P12111|CO6A3_HUMAN
P84243|H33_HUMAN
P14923|PLAK_HUMAN

Coverage (%)
67
57
52
79
28
20
66
15
81
53
19
67
35
8
23
18
68
10
37
29
37
15
55
12
44
30
53
3
54
15

#Peptides
242
67
49
87
38
30
33
24
22
20
20
23
19
18
17
16
15
19
14
13
17
13
12
11
12
10
10
9
9
9

#Unique
69
64
49
47
37
30
29
24
22
20
19
18
18
18
16
15
15
14
14
13
12
12
12
11
10
10
10
9
9
9
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Figure 12. The CASA Complex Localizes to the Sarcomere Z-disc in
Cardiomyocytes. (A). Representative immunofluorescence images of human LV
cardiomyocytes immunostained for BAG3, HSP70, HSPB8, and CHIP and
counterstained for α-actinin; 63X magnification, scale bars = 5 µm. (B). Line scan of
fluorescence intensity by distance from the corresponding green and red channels in
panel A. (C). Western blot for the CASA complex proteins in the whole LV, tritonsoluble, and myofilament fractions. (D). Western blot showing results of reciprocal
co-immunoprecipitation for BAG3 and HSP70 in myofilament fraction. (E). Western
blot showing results of reciprocal co-immunoprecipitation for BAG3 and HSPB8 in
myofilament fraction.
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These data indicate that the CASA complex is present at the cardiac sarcomere in
humans. It should be noted that HSP70 sarcomeric localization differs between the
skeletal and cardiac myocytes. While in both cell types it was found to localize to the Zdisc, there was also prominent localization to the sarcomere A-band in skeletal
myocytes that was not found in cardiomyocytes. This may represent a greater
involvement of HSP70 in its previously described roles in maintenance of myosin or
myosin binding protein C (MYBPC3) in skeletal muscle [254,351].
Protein chaperones and co-chaperones are regulated by cell stress, advanced
levels of which stimulate increased chaperone protein expression. This was previously
shown for BAG3 in a fibroblast-like cell line, where treatment with the proteasome
inhibitor MG132 caused an upregulation of BAG3 expression [40]. To determine if the
CASA complex exhibited proteotoxic stress-dependent localization to the sarcomere,
we isolated neonatal rat ventricular myocytes (NRVMs) and maintained them in culture.
To cause proteotoxic stress, the NRVMs were treated with 2 µM MG132 for 24 hours.
MG132 treatment caused a pronounced upregulation of BAG3, HSP70, HSPB8, and
CHIP expression in the myofilament fraction, indicating that CASA localizes to the
sarcomere in response to proteotoxic stress (Figure 13A-G). This finding was
substantiated further by confocal imaging of DMSO and MG132-treated NRVMs, which
showed BAG3 localization to the Z-disc increased in response to MG132 (Figure 13HK).

84

Figure 13. The CASA Complex is Targeted to the Sarcomere in Response to
Proteotoxic Stress. (A-B). Representative western blots for myofilament BAG3,
HSP70, HSPB8, ubiquitin, and CHIP in neonatal rat ventricular myocytes (NRVMs)
treated with vehicle (DMSO) or the proteasome inhibitor MG132. (C-G).
Quantification of myofilament protein expression normalized to total protein for BAG3
(C), HSP70 (D), HSPB8 (E), CHIP (F), and ubiquitin (F); n = 6 DMSO, 6 MG132 from
3 independent experiments; 2-tailed t-test. All data are presented as mean ± SEM.
(H-K). Immunofluorescence images for NRVMs treated with DMSO (H) or MG132 (J)
immunostained for BAG3 and α-actinin, with quantitative line scan of fluorescence
intensity (I,K); 63X magnification, scale bars = 10 µm.
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3.4.4. HSPB8 and CHIP Display BAG3-dependent Association with the
Myofilament
We next asked whether BAG3 was required for localization of the other CASA
members to the myofilament. To test this, we used mouse models of cardiomyocytespecific heterozygous and homozygous BAG3 deletion. Using western blot
in myofilament-enriched LV tissue from wild-type, BAG3+/-, and BAG3-/- mice, we
found myofilament levels of HSPB8 and CHIP were reduced in the partial and complete
absence of BAG3 (Figure 14A-D). However, myofilament HSP70 expression was not
impacted by decreased BAG3, suggesting it requires different mechanism for targeting
to the sarcomere. This finding is not surprising as HSP70 is a general chaperone for
numerous protein clients and operates in many arms of cellular protein folding and
degradation [352]. Nevertheless, that myofilament CHIP was reduced with decreased
BAG3 is significant for HSP70-mediated degradation processes as CHIP is the primary
E3 ligase for HSP70 clients. However, it should be noted that other E3 ligases have
been shown to mediate ubiquitination of HSP70 substrates [353,354], and our mass
spectrometry analysis of the CASA protein myofilament interactomes identified the E3
ligases MYCBP2, MIB2, and BRE1A. We expect these ubiquitin ligases and others
contribute to the increased myofilament ubiquitination we observed in the BAG3 +/- mice
despite the reduction in CHIP.
Since myofilament BAG3 expression decreases in human DCM, we next sought
to determine whether expression of the other CASA members is altered in disease.
Using western blot for HSP70, HSPB8, and CHIP in NF and DCM myofilament samples,
we found no significant differences in expression for any protein between the two

86

groups (Figure 14E-H). Myofilament BAG3 displayed broad variability in expression in
DCM. Therefore, while general myofilament protein expression of HSP70, HSPB8, and
CHIP were not changed in disease, we hypothesized that the expression of HSPB8 and
CHIP would be reduced in samples with lowest BAG3 expression, as in the BAG3+/mice. The BAG3+/- mice had ~80% of the wild-type myofilament BAG3, which we found
to be a functionally significant decrease in expression. Therefore, we separated the
human samples into two groups: those with “high” BAG3 expression (≥80% of the mean
NF BAG3) and those with “low” BAG3 expression (<80% of the mean NF BAG3). As in
the mice, HSP70 did not display BAG3-dependent localization to the myofilament
(Figure 14I). However, patients with lowest BAG3 expression had significantly reduced
myofilament HSPB8 levels (Figure 14J). Myofilament CHIP expression was highly
variable and not significantly decreased in the low BAG3 expressors (Figure 14K). Our
data in the BAG3-deficient mice indicate BAG3 is required for assembly of HSPB8 and
CHIP at the sarcomere, which is further supported for HSPB8 in the human
comparisons. These effects may be through directly mediating HSPB8/CHIP localization
to the myofilament or stabilizing these proteins to prevent their degradation, which is
supported for HSPB8 by a previous study [54].
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Figure 14. BAG3 is Required for Full Assembly of CASA Complex Members in
the Myofilament Fraction. (A). Representative western blots for myofilament BAG3,
HSP70, HSPB8, and CHIP in WT, BAG3+/-, and BAG3-/- mice. (B-D). Quantitative
densitometry for HSP70 (B), HSPB8 (C), and CHIP (D) normalized to total protein; n
= 6 WT, 7 BAG3+/-, 3 BAG3-/-; one-way ANOVA, Tukey post-hoc. (E). Representative
western blots for myofilament HSP70, HSPB8, and CHIP in human NF and DCM left
ventricular samples. (F-G). Quantitative densitometry analysis for HSP70, (F),
HSPB8 (G), and CHIP (H) normalized to total protein; n = 9 NF, 21 DCM for
HSP70/HSPB8; n = 9 NF, 17 DCM for CHIP; 2-tailed t-test. (I-K). HSP70 (I), HSPB8
(J), and CHIP (K) expression grouped by high (>80% of mean NF expression) or low
(<80% of mean NF expression) myofilament BAG3 level; n = 18 high, 12 low for
HSP70/HSPB8; n = 15 high, 11 low for CHIP.
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Identification of the BAG3/CASA Clients at the Cardiac Sarcomere in Humans
Now that we had confirmed the CASA complex localizes to the sarcomere and
does so in response to proteotoxic stress, we next sought to identify the sarcomere
proteins that are degraded by this pathway. To begin we analyzed the myofilament
interactomes of BAG3, HSP70, and HSPB8 identified earlier (Tables 5-7) anticipating
that CASA clients would be included in the interactome of each CASA member. We
identified 52 proteins by this approach, the three primary CASA members and 49
potential clients, that were included in each protein’s interactome (Figure 15A-B). These
potential CASA client candidates were primarily sarcomere constituents, with a large
proportion having roles at the thin filament (Figure 15B). While this approach does not
ensure that these proteins are CASA clients, it does help to narrow the pool of potential
substrates.
As discussed above, previous work in skeletal muscle showed that the actin
cross-linking protein filamin C is degraded by CASA when it becomes denatured due to
mechanical strain. The initial characterization of CASA was by Arndt et al. who showed
filamin C was a client by incubating the cytoskeletal fraction from C2C12 skeletal
myocytes with recombinant BAG3, which resulted in filamin C being released to the
soluble fraction as identified by western blot [47]. We modified this approach to identify
the CASA clients in the heart, and incubated myofilament fractions from human DCM
samples with 300 nM recombinant BAG3 for 1 hour. We then collected the
released/soluble and myofilament/insoluble fractions. Western blot analysis of these
fractions indicated that ubiquitinated proteins were released from the myofilament in
response to BAG3 treatment (Figure 15C-E).
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Figure 15. Identification of the Sarcomeric CASA Clients in the Human Heart.
(A). Quantitative Venn diagram of the BAG3, HSP70, and HSPB8 myofilament
interactomes identified by bottom-up mass spectrometry of immunoprecipitated
proteins. (B). List of the 49 shared proteins identified in the myofilament interactome
of each CASA complex member; bold = previously identified CASA clients (FLNC)
and new CASA clients identified in this study. (C). Western blot for myofilament
ubiquitin and ubiquitinated proteins released from the myofilament in response to
increased BAG3 expression; image is representative of 3 hearts/group. (D-E).
Quantitative densitometry for myofilament (D) and released (E) ubiquitin normalized
to α-actin; n = 3 control, 3 +BAG3. (F-P). Spectral count analysis of the proteins
identified by mass spectrometry to increase in the released protein fraction with
increased BAG3 expression. For all, n = 3 control and 3 recombinant BAG3
treatment (+BAG3), from the same 3 human LV samples. All data are presented as
mean ± SEM and were analyzed by 2-tailed t-test.

To identify which specific proteins were released from the myofilament with increased
BAG3, we proceeded to trypsin digestion upstream of peptide identification by bottomup mass spectrometry. Mass spectrometry analysis revealed eight sarcomere proteins
that increased in the released pool with BAG3 treatment compared with untreated
(Figure 15F-M). Our findings confirm filamin C as a client of BAG3-mediated turnover in
the human heart and identify seven new candidates: α-actinin, desmin, myosin binding
protein C, myomesin-1, myozenin-2, spectrin alpha, and XIRP1. Mass spectrometry
analysis also identified increased HSP70 and HSPB8 in the released protein pool with
BAG3 treatment (Figure 15N-P), perhaps suggesting restored clearance of these
chaperones and their cargo. Analysis of the myofilament protein pool for each of these
clients largely showed slight decreases in the proposed CASA clients, as expected
(Figure 16).
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Figure 16. Spectral Count Analysis for the Myofilament Pool of CASA Clients in
the Client Release Experiment. (A-H). Analysis of the 8 CASA clients in the
myofilament/insoluble protein fraction of three DCM human samples after 1 hour of
treatment with control or 300 nM recombinant BAG3 protein. For all: n = 3 control, 3
+BAG3 from the sample 3 human LV tissue samples. All data are presented as the
mean ± SEM and were analyzed with 2-tailed t-test.

BAG3 Gene Therapy in Heart Failure Restores Myofilament Fmax and CASA Protein
Turnover
Having established BAG3 is critical for maintaining sarcomere function,
identifying CASA as the mechanism, and showing that increasing BAG3 levels causes
release of ubiquitinated proteins from the sarcomere, we next hypothesized that
increasing BAG3 expression in heart failure would rescue F max through restored CASA.
Eight-week-old mice received either a myocardial infarction produced by permanent
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coronary artery ligation (HF) or sham surgery (Sham). Eight weeks post-surgery, the
mice were randomly assigned to receive a recombinant adeno-associated virus
serotype 9 (rAAV9) vector expressing the mouse bag3 gene or control (rAAV9/GFP) via
retro-orbital injection. After four weeks of adenovirus expression the mice
were euthanized, and the LV tissue was collected. BAG3 overexpression in heart
failure restored in vivo cardiac function, which was reported previously for this cohort
[91].
We first assessed whether CASA protein localization to the sarcomere was
altered in HF or HF/BAG3 by immunofluorescence microscopy. As in the human heart,
BAG3, HSP70, and HSPB8 each displayed localization to the sarcomere Z-disc in the
Sham mice (Figures 17-18). Interestingly, again, as in the mouse gastrocnemius,
HSP70 appeared to localize both at the Z-disc and between them, which was not
observed in human myocytes. There were no overt differences in localization of BAG3,
HSP70, or HSPB8 in the HF or HF/BAG3 groups compared to Sham mice (Figures 1718). Next, to determine the impact of HF and BAG3 gene therapy on sarcomere
function, we used force-calcium experiments on skinned myocytes from the infarct
border zone. As in human DCM, cardiomyocytes from mice in the HF group displayed
significantly reduced Fmax. However, Fmax was fully rescued in the HF mice that received
rAAV9/BAG3 (Figure 19A-B). Changes in myofilament calcium sensitivity were not
observed, which may be attributed to the relatively early stage of disease progression
we studied (Figure 19C). We hypothesized that the rescue of Fmax with BAG3
overexpression was due to restoration of CASA client clearance. Therefore, we next
assessed expression of the CASA members in the myofilament fraction.
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Using western blot, we found that HSP70, HSPB8, and CHIP levels each had
increased expression at the myofilament in the HF mice (Figure 19D-I). BAG3
expression also displayed a mild, though non-significant increase in the HF group.
These results indicate that targeting of the complex to the myofilament in response
to proteotoxic stress is not hindered in the early progression to heart failure, whereas in
the end-stage of heart failure (human data) the stress-responsiveness of BAG3/CASA
becomes dysregulated. At this stage, the clearance of the CASA complex and its
ubiquitinated clients appears to be either stalled or occurring at an inadequate rate for
the level of protein misfolding. However, the issue of CASA clearance was ameliorated
by BAG3 gene therapy, which returned CASA expression to Sham levels, supporting
restored turnover (Figure 19D-I). This finding agrees with our client release experiment,
where increasing BAG3 protein levels resulted in release of HSP70, HSPB8, and eight
sarcomere proteins from the myofilament. Notably, myofilament levels of the autophagic
ubiquitin receptor P62/SQSTM1, an essential adaptor protein for autophagy that
mediates the targeting of ubiquitinated proteins to the autophagosome [300], also
increased in the HF mice and were returned to baseline with BAG3 gene therapy
(Figure 19H), further indicating restored clearance.
To determine the impact of BAG3 gene therapy on sarcomere proteostasis, we
assessed myofilament protein ubiquitination between the three groups by western blot.
As identified in human DCM, we found myofilament protein ubiquitination increased
significantly in the HF mice, indicating impaired protein turnover. However, in the HF
mice that received four weeks of BAG3 gene therapy, myofilament ubiquitination was
significantly reduced (Figure 19J). These data and our preceding data together support
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that the mechanism by which increasing BAG3 expression in heart failure rescues
myofilament Fmax is through restoring sarcomere protein turnover, where old/misfolded
proteins are removed from the structure by CASA and thus allow newly synthesized
proteins to be incorporated.

Figure 17. Localization of BAG3 in Sham, HF, and HF/BAG3 Cardiomyocytes.
(A). Representative immunofluorescence images immunostained for α-actinin and
BAG3 in the Sham, HF, and HF/BAG3 groups. (B). Line scan of fluorescence
intensity by distance for α-actinin and BAG3.

95

Figure 18. Localization of HSP70 and HSPB8 in Sham, HF, and HF/BAG3
Cardiomyocytes. (A). Representative immunofluorescence images immunostained
for α-actinin and HSP70 in the Sham, HF, and HF/BAG3 groups. (B). Line scan of
fluorescence intensity by distance for α-actinin and HSP70. (C). Representative
immunofluorescence images immunostained for BAG3 and HSPB8 in the Sham, HF,
and HF/BAG3 groups. (D). Line scan of fluorescence intensity by distance for BAG3
and HSPB8.
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Figure 19. BAG3 Gene Therapy in Heart Failure Restores Myofilament Function
and Sarcomeric CASA Turnover. (A). Skinned myocyte force-calcium relationship
for mouse cardiomyocytes from sham, heart failure (HF), and HF treated with AAV9BAG3 (HF/BAG3); n = 12 sham from 4 mice, 9 HF from 3 mice, and 9 HF/BAG3
from 3 mice. (B-C). Summary data for myocyte Fmax (b) and EC50 (c) corresponding
to the force-calcium curves in a. (D). Representative western blots for myofilament
BAG3, myc-BAG3, HSP70, HSPB8, P62, CHIP, and ubiquitin in the sham, HF, and
HF/BAG3 mice; n = 6 Sham, 5 HF, 4 HF/BAG3. (E-J). Quantitative densitometry
analysis for protein expression of BAG3 (E), HSP70 (F), HSPB8 (G), P62 (H), CHIP
(I) and ubiquitin (J) normalized to total protein. All data are presented as mean ±
SEM and were analyzed via one-way ANOVA with Tukey post-hoc test for multiple
comparisons.

Discussion
Decreased contractility is a hallmark feature of systolic heart failure. At the
cellular level, this may be attributed to structural and functional changes at the
sarcomere, the molecular unit of contraction in striated muscle [331]. However, the
mechanisms underlying decreased sarcomere tension generation in heart failure are
incompletely understood. In this study, we asked whether inadequate sarcomeric
protein turnover in heart failure could serve as an explanation for functional impairment
and, if so, to identify the key players involved. We show sarcomere protein turnover is
impaired in human DCM samples with reduced myofilament force-generating capacity
(Fmax), where elevated ubiquitinated (and thus presumably misfolded/dysfunctional)
proteins remained integrated into the sarcomere. We found decreased myofilament
localization of the co-chaperone BAG3, such as occurs in heart failure, is directly related
to the Fmax decline and show that increasing BAG3 expression in heart failure restores
both function and sarcomere proteostasis through CASA. This study indicates BAG3 is
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critically important for functional maintenance of the cardiac sarcomere through
mediating sarcomere protein turnover.
Disrupted proteostasis has long been associated with sarcomere structural
abnormalities and heart failure [302,303,340,355]. However, mechanisms of sarcomere
protein turnover and the myofilament functional significance of individual molecular
chaperones involved in sarcomere PQC are not known. BAG3 is key to PQC in many
different cell types and has been shown to target already ubiquitinated proteins to
autophagy and to directly facilitate the ubiquitination of other misfolded proteins, leading
to their autophagic clearance [103,356]. Interestingly, BAG3 had previously been shown
to localize to the sarcomere Z-disc, positioning it as a potential mediator of sarcomere
protein turnover through autophagy [34]. However, relatively little was known regarding
BAG3’s role at the cardiac sarcomere. Mechanistic studies in neonatal myocytes
showed BAG3 was required for sarcomere structural organization through stabilization
of the actin-capping protein CapZ [196]. However, neonatal myocytes are structurally
and functionally distinct from the adult cardiomyocyte and are not under any mechanical
load, making inferences from this study to the adult difficult. Indeed, it is apparent that
BAG3’s role in adult cardiomyocytes differs from the neonatal as BAG3 was found
dispensable for sarcomere structural maintenance in utero, but loss of BAG3 caused
rapid sarcomere disintegration once the heart was under mechanical load [99].
Moreover, recent studies in the adult heart failed to identify CapZ as a BAG3-interacting
protein, suggesting the stabilization of CapZ by BAG3 is specific to sarcomere assembly
[97]. Our mass spectrometry analysis of the myofilament BAG3 interactome also failed
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to identify CapZ as a binding partner, further suggesting this association is specific to
development.
An important advance in our understanding of BAG3’s role in the adult heart
came from Fang et al. who showed that cardiomyocyte-restricted BAG3 KO caused a
DCM phenotype in mice, was associated with reduced stability of the HSPBs, and
increased toxic protein aggregation [54]. The authors also showed that a DCMassociated BAG3 mutation impaired BAG3 binding to HSP70 and was associated with
reduced stability of HSPBs and protein aggregation. Together, these findings strongly
indicate BAG3 is required for protein turnover in the adult heart. However, while this
study identified prominent protein aggregation with decreased/dysfunctional BAG3, it
did not assess whether misfolded proteins remained incorporated into the sarcomere. In
the present study, we found that sarcomere-specific expression of BAG3 decreased in
human DCM and levels were particularly low in samples with the weakest myofilament
force-generating capacity. We therefore hypothesized that impaired BAG3-mediated
turnover of sarcomere proteins might contribute to decreased sarcomere contractile
function. Using cardiomyocyte-restricted heterozygous deletion of BAG3, we found
elevated sarcomere protein ubiquitination, suggesting inadequate turnover, and reduced
myofilament force-generating capacity. Importantly, these ubiquitinated proteins were
not members of protein aggregates, but were still imbedded within the sarcomere
complex and did not cause overt structural disarray, thus offering a compelling
explanation for the observed functional deficit.
To further clarify the functional importance of BAG3-mediated protein turnover,
we used a transgenic mouse model expressing the human P209L mutation. The P209L
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BAG3 mutation is highly penetrant and is associated with myofibrillar myopathy and
elevated toxic protein aggregation [75,85]. Recent work in cell culture systems identified
P209L BAG3 impairs release of ubiquitinated substrates to the macroautophagy system
[82,83]. We chose transgenic expression of the human P209L bag3 as a recent study of
the analogous mouse mutation (P215L) showed no cardiac phenotype, which was
attributed to the pathogenicity of this variant being specific to the human BAG3 isoform
[89]. Previous work with the human P209L transgenic mouse found mice developed
restrictive cardiomyopathy by 8 months, mimicking the human phenotype [88]. In the
present study, we found expression of the P209L BAG3 mutant increased myofilament
ubiquitin levels and caused a significant reduction in F max by 8 months of age. Instead of
mediating sarcomere stability as in the neonatal myocyte, our data identify a converse
role for BAG3 in the adult myocyte, where BAG3 is required for sarcomere protein
turnover.
Studies in skeletal muscle previously identified BAG3 mediates chaperoneassisted selective autophagy (CASA), a macroautophagy pathway involving HSP70 and
HSPB8 [47,101]. In skeletal muscle, CASA mediates the turnover of the actin crosslinking protein filamin C when it is denatured due to mechanical strain [47,101].
Misfolded filamin-C is bound by HSP70/HSPB8 which form a complex with BAG3. The
HSP70-bound misfolded client is then ubiquitinated through the actions of the E3
ubiquitin ligase CHIP, which associates with the HSP70 c-terminus [102]. We found that
CASA is conserved in cardiomyocytes and that the complex assembles at the
sarcomere in a BAG3- and proteotoxic stress-dependent manner in cardiomyocytes.
Using several mass spectrometry-based approaches, we also confirmed that filamin C
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is a client of CASA in the human heart and identified seven additional clients of
structural and functional significance for the sarcomere. Notably, five of the eight clients
identified are known to associate with the thin filament and engage in regulating thin
filament structure and dynamics. Thus, CASA emerges as a mechanism of thin filament
maintenance.
In the canonical CASA pathway, the client (filamin C) was thought to be first
bound by the BAG3/HSP70/HSPB8 complex and then ubiquitinated by CHIP and
degraded [102]. However, our data indicates that BAG3 can assist in the removal of
proteins that are already ubiquitinated and suggests that ubiquitination of
HSP70/HSPB8 clients in CASA may occur prior to the association of BAG3 with the
complex, though BAG3 is fundamental for clearance of the complex/clients. It is also
suggested from our data that CHIP is not the only E3 ligase involved in ubiquitinating
CASA clients as myofilament ubiquitination increased, despite a 50% reduction in CHIP
in the BAG3+/- mice. This finding is not surprising as multiple E3 ligases have been
identified for HSP70 clients and our proteomics data indicates several other E3 ligases
associate with the CASA members.
An earlier study had shown that BAG3 gene therapy restored in vivo cardiac
function in a mouse model of heart failure secondary to coronary artery ligation [91].
Employing this same model, we found that BAG3 gene therapy fully rescued
myofilament Fmax and reduced sarcomere ubiquitination. Notably, the stressresponsiveness of CASA at this early stage in heart failure progression was intact as
suggested by significant increases in HSP70, HSPB8, and CHIP at the myofilament.
This suggests that at this stage of heart failure, either clearance of the CASA complex
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stalls or occurs at an inadequate rate. Regardless, CASA protein expression returned to
baseline after increasing BAG3, indicating that gene therapy rescued clearance of the
complex and its clients. This restoration of CASA clearance with increased BAG3 is
supported by our client release experiment in the myofilament fraction from DCM
patients, where addition of BAG3 resulted in release of HSP70 and HSPB8 to the
soluble fraction along with the ubiquitinated proteins.
Under conditions of elevated stress, such as are present at the sarcomere,
proteins are predisposed to misfolding. In the healthy state, misfolded proteins are
removed from the sarcomere and swapped with functional replacements. However,
protein degradation mechanisms are dysregulated in heart failure. Our data identify
inadequate sarcomere protein turnover as a mechanism of sarcomere functional decline
in heart failure. Moreover, our findings show decreased BAG3-mediated sarcomere
protein degradation is a primary contributor to this observed decrease in myofilament
contractile function. This study indicates impaired PQC at the sarcomere in heart failure
has a direct effect on myofilament function. Furthermore, our results show that BAG3 is
required for maintaining sarcomere proteostasis and optimal tension generation in
cardiomyocytes and demonstrate that the potential therapeutic benefits of BAG3 gene
therapy in heart failure include improving myofilament function by restoring sarcomeric
protein turnover.

CHAPTER 4
PHARMACOLOGICAL DISRUPTION OF THE BAG3-HSP70 COMPLEX IS TOXIC IN
CARDIOMYOCYTES3
Abstract
The co-chaperone Bcl2-associated athanogene-3 (BAG3) maintains cellular
protein quality control through regulation of heat shock protein 70 (HSP70). Cancer cells
manipulate BAG3-HSP70-regulated pathways for tumor initiation and proliferation,
which has led to the development of promising small molecule therapies, such as JG98, that inhibit the BAG3-HSP70 interaction and mitigate tumor growth. However, it is
not known how these broad therapies impact cardiomyocytes, where the BAG3-HSP70
complex is a key regulator of protein turnover and contractility. Here we show that JG98 exposure is toxic in neonatal rat ventricular myocytes (NRVMs). Using
immunofluorescence microscopy to assess cell death, we found that apoptosis
increased in NRVMs treated with JG-98 doses as low as 10 nM. JG-98 treatment also
reduced autophagy flux and altered expression of BAG3 and several binding partners
involved in BAG3-dependent autophagy, including SYNPO2 and HSPB8. We next
assessed protein half-life with disruption of the BAG3-HSP70 complex by treating with
JG-98 in the presence of cycloheximide and found that BAG3, HSPB5, and HSPB8 halflives were reduced, indicating complex formation with HSP70 is important for their

Parts of this chapter represent a published article: Martin TG, et al. Pharmacological inhibition of BAG3-HSP70 with
the proposed cancer therapeutic JG-98 is toxic in cardiomyocytes. J. Cell. Biochem. 2021.
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stability. Next, we assessed sarcomere structure using super-resolution microscopy an
found that disrupting the interaction with HSP70 lead to sarcomere structural
disintegration. To determine if the effects of JG-98 could be mitigated by
pharmacological autophagy induction, we co-treated NRVMs with rapamycin, which
partially reduced the extent of apoptosis and sarcomere disarray. Finally, we
investigated whether the effects of JG-98 extended to skeletal myocytes using C2C12
myotubes and found again increased apoptosis and reduced autophagic flux. Together,
our data suggest that non-specific targeting of the BAG3-HSP70 complex to treat
cancer may be detrimental for cardiac and skeletal myocytes.
Introduction
The co-chaperone Bcl2-associated athanogene-3 (BAG3) helps to maintain cell
survival through regulation of protein quality control (PQC). The involvement of BAG3 in
PQC stems from its association with heat shock protein 70 (HSP70), for which BAG3 is
a nucleotide exchange factor, regulating client handling and connection with autophagy
[306]. However, increased activity of BAG3-HSP70 in cancer is associated with tumor
grade, metastasis, and chemotherapy resistance [357]. A considerable effort has
therefore been made to develop therapies that inhibit BAG3 and its modulation of
HSP70 activity [107,358]. The small molecule JG-98, which binds an allosteric pocket in
the nucleotide binding domain of HSP70 and disrupts the interaction with BAG3,
displays potent anti-cancer effects [108,109]. Importantly, the toxic effects of JG-98 also
appear to be cancer cell-specific as healthy fibroblasts were viable with similar
treatment [108]. However, while these studies highlight therapeutic promise for targeting
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BAG3-HSP70 in cancer, little is known regarding the impact of JG-98 on other tissues,
such as the heart, where the BAG3-HSP70 interaction is crucial for function [54,196].
The highest expression of BAG3 in healthy tissues is in striated muscle, which
experiences constant stress from the mechanical strain of muscle contraction. Previous
work in skeletal myocytes found that the BAG3-HSP70 complex was essential for
maintaining the sarcomere – the fundamental contractile unit in muscle cells – through
chaperone-assisted selective autophagy (CASA) [47,101]. In this process, BAG3 and
HSP70 form a complex with small heat shock proteins (HSPBs) and synaptopodin-2 to
target misfolded proteins to autophagy [102]. We have recently shown that CASA
extends to cardiac muscle and is essential for maintaining cardiomyocyte contractile
function [308]. Given the significance of BAG3-HSP70 for PQC and contractile function,
it is necessary to determine whether disrupting this complex to treat cancer with
compounds like JG-98 will have detrimental off-target effects in cardiomyocytes.
In this study, we show exposure of neonatal rat ventricular myocytes (NRVMs) to
JG-98 has severe consequences. Disrupting the BAG3-HSP70 complex with JG-98
caused apoptosis, reduced autophagy flux, and altered expression and protein stability
of BAG3 and its binding partners. JG-98 also caused sarcomere structural disintegration
and impaired stress-responsive sarcomere maintenance. The negative impact of JG-98
on cell viability and sarcomere structure could be partially rescued by co-treatment of
NRVMs with the autophagy inducing compound rapamycin. Finally, using C2C12
myotubes we show the toxic effects of JG-98 may extend to skeletal muscle. Our data
support previous findings that the BAG3-HSP70 complex is fundamental for
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cardiomyocytes and suggest that targeting this interaction to treat cancer will have
negative consequences in the heart.
Methods
NRVM Isolation and Culture
Hearts were isolated from one-day-old Sprague-Dawley rats and placed in
Krebs-Henseleit Buffer (KHB). Tissue was digested in KHB containing collagenase type
II (Worthington, Lot #: 49A19003) and 0.05% trypsin at 37 °C for 15 minutes. The
solution was then added to isolation medium (DMEM, 4.5 g/L glucose, +L-glutamine, pyruvate, 10% FBS, 1X ITS-X, 100 U/mL penicillin-streptomycin) to stop the digestion
reaction. This was repeated five times. The isolated cells were resuspended in fresh
isolation medium and added to a cell culture dish for 90 minutes to remove fibroblasts.
The dish was tapped to dislodge myocytes, which were collected, resuspended in
maintenance medium (DMEM, 4.5 g/L glucose, +L-glutamine, -pyruvate, 18.5% M199
medium, 5% horse serum, 1% FBS, 1X ITS-X, 100 U/mL penicillin-streptomycin,
10 µM BrdU to prevent proliferation of contaminating fibroblasts) and plated at ~80%
confluency.
C2C12 Culture and Differentiation
C2C12 myoblasts were grown to ~100% confluency in growth medium (DMEM,
4.5 g/L glucose, +L-glutamine, -pyruvate, 10% FBS). The media was then switched to
differentiation media (DMEM, 2% horse serum), which was changed every 24 hours.
Experiments were performed on days 5-7 post-differentiation.
Immunoprecipitation
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Dynabeads protein G (Thermo Fisher Scientific) were incubated with an antiHSP70 antibody (Proteintech 10995-1AP) for 30 minutes and then crosslinked with 20
mM dimethyl pimelimidate dihydrochloride for 30 minutes. The crosslinking reaction was
quenched by incubation with 200 mM ethanolamine for 2 hours. Cell lysates were
collected in Igepal lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1% Igepal) and
precleared by incubation with Dynabeads for 20 minutes. The antibody-beads complex
was then incubated with 300 µg protein for 1 hour at 4 °C. The complex was washed
four times with lysis buffer for 5 minutes each at 4 °C. Immunoprecipitated protein was
eluted with 0.15% trifluoroacetic acid.
Western Blotting
Cell lysates were collected in 8M urea/0.2% SDS. A BCA assay (Pierce) was
used to determine protein concentration. 5 µg of protein was separated on 4-12% bistris gradient gels (Invitrogen) and transferred onto nitrocellulose membrane. Revert
Total Protein Stain (LI-COR Biosciences) was used to assess protein loading. The
following primary antibodies/dilutions were used: BAG3 (Proteintech 10599-1AP,
1:4000), HSP70 (Proteintech 10995-1AP, 1:4000), HSPB8 (Proteintech 15287-1AP,
1:2500), HSPB5 (15808-1AP, 1:2500), SYNPO2 (Proteintech 25453-1AP, 1:2500), LC3
(Cell Signaling Technology 2775s, 1:1000). Secondary antibodies: LICOR IRDye
680RD and 800CW, 1:8000. Membranes were imaged on an Azure c600. Protein
densitometry was quantified using ImageStudio (LI-COR Biosciences).
Quantitative RT-PCR
Cells were lysed in Trizol and the RNA was extracted using the RNeasy RNA
extraction kit (Qiagen) with on-column DNase I treatment. cDNA was synthesized using
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Superscript IV Reverse Transcriptase (Thermo Fisher Scientific). Quantitative RT-PCR
was performed with Quant Studio 3 using SYBR green mastermix and the primers listed
in Table 8. Candidate mRNA expression was normalized to β-actin using the ΔΔCT
method.
Table 8. Primer Sequences for Target Genes
Cell Type
NRVM

Gene
bag3

NRVM

hspa1a

NRVM

hspb8

NRVM

hspb5

NRVM

synpo2

NRVM

β-actin

C2C12

bag3

C2C12

hspa1a

C2C12

hspb8

C2C12

hspb5

C2C12

synpo2

C2C12

β-actin

Primer Nucleotide Sequences
F: CTTGTTTGGGAGCCCTTTCT
R: TCCTGTAACTCTCTGCCTATCC
F: CCATCGAGGAGGTGGATTAGA
R: GAACTCCGGAGAGAAGGAGTAA
F: GTCAGCCTTGGTCCTTCTTT
R: AGGGATGGTCATTTGGTTCTC
F: GTGGACAGAGAGCTAGTGAAAC
R: GGGACTTGTGATCAGGGATTT
F: CCTCTCAGCCCAACTTCTTT
R: GGATGTGGAGGTCGTTTCTT
F: CTTCCTTCCTGGGTATGGAATC
R: CTGTGTTGGCATAGAGGTCTT
F: TCTGGATGGGACCAGAAGT
R: GGGTGGAAGTGTCTGGAAATAG
F: TGGTGCTGACGAAGATGAAG
R: CGCTGAGAGTCGTTGAAGTAG
F: CCGGAAGAGCTGATGGTAAAG
R: CTTCTGCAGGGAGCTGTATTT
F: TCTTCTCAACAGCCACTTCC
R: TCCTTCTCCAAACGCATCTC
F: CAGGTGACAAGGACGAGATAAG
R: CCAGTCCAGAATCCCAATCAA
F: GAGGTATCCTGACCCTGAAGTA
R: CACACGCAGCTCATTGTAGA

NCBI RefSeq
NM_001011936.1
NM_031971.2
NM_053612.2
NM_012935.4
NM_001191963.1
NM_031144.3
NM_013863.5
NM_010479.2
NM_030704.3
NM_001289782.1
NM_001388502.1
NM_007393.5

Measurement of Autophagy Flux
The culture medium was replaced with fresh medium containing 1 µM JG-98
(MedChem Express) or DMSO, with or without 10 mM NH4Cl, and incubated for 18
hours. Following treatment, the cells were lysed in 8M urea/0.2% SDS. Western blotting
for LC3-II was performed to assess autophagic flux.
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Measurement of Apoptosis
The Apoptosis/Necrosis Detection Kit (Abcam, ab176749) was used according to
the manufacturer protocol. Briefly, myocytes were incubated in assay buffer containing
Apopxin Green indicator for apoptosis and CytoCalcein indicator for healthy cells and
incubated for one hour at room temperature. The cells were washed with assay buffer
and imaged using a Zeiss LSM 880 at 10X magnification. Excitation/emission
parameters: Apopxin Green – 488/525nm, CytoCalcein – 405/450nm. Image scoring
was performed by an experimenter blinded to the treatment groups.
Measurement of Protein Half-life
Cells were treated with either DMSO or 1 µM JG-98 in the presence of 50 µM
cycloheximide to block protein translation. Cell lysates were collected in 8M urea/0.2%
SDS at the start of treatment (t = 0) and at 2-, 4-, 8-, 12-, and 24-hours post-treatment.
Protein expression across the time points was assessed by western blot.
Assessment of Sarcomere Structural Disarray
Myocytes were incubated with DMSO or 1 µM JG-98 for 18 hours or for 1 hour
followed by 2-hour heat shock at 42 °C. Cells were then washed with PBS and fixed in
ice-cold methanol for 1 minute, followed by 4% paraformaldehyde for 3 minutes.
Permeabilization was performed with 0.5% triton for 20 minutes, followed by 0.1% triton
for 30 minutes. 100 mM glycine (pH 7.4) for 30 minutes was used for antigen retrieval.
The slides were washed with PBS and blocked with 1:1 PBS to BSA blocking solution
(1% BSA, 1% gelatin, 1% tween-20, 0.001% NaN3) for one hour. Primary antibodies
were added in blocking buffer and incubated overnight at 4 °C. Antibodies/dilutions:
BAG3 (Proteintech 10599-1AP, 1:250), α-actinin (Millipore Sigma A7811, 1:150).
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Following overnight incubation, the slides were washed with PBS, and alexa-fluor
secondary antibodies (Abcam) were added in blocking buffer at 1:1000 dilution for 1
hour at room temperature. Slides were washed with PBS, mounted with Vectashield
containing DAPI (Vector Laboratories), and imaged at 63X magnification on a Zeiss
LSM 880 microscope with Airyscan. Sarcomere scoring was performed as previously
described[105], blinded to the treatment groups.
Statistical Analysis
All experiments were replicated with myocytes from 3 or more separate
isolations. The data are presented as the mean ± SEM and were analyzed using
GraphPad Prism 9. For analyses of three or more groups, a one or two-way ANOVA
was performed as annotated in the figure legends. If a significant interaction was
identified, Tukey’s post-hoc test was used. For all comparisons of two groups, the data
were analyzed using Student’s two-tailed t test. A p value of < 0.05 was considered
statistically significant.
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Results
Disrupting the BAG3-HSP70 Complex Causes Cardiomyocyte Apoptosis

Figure 20. Disrupting the BAG3-HSP70 Complex with JG-98 Causes Apoptosis
in Cardiomyocytes. (A). Representative immunofluorescence images for NRVMs
treated with DMSO and 1 nM to 10 µM JG-98; green – extracellular membrane
phosphatidylserine (apoptotic), blue – healthy; scale bars = 100 µm. (B).
Quantification of apoptosis in the immunofluorescence images; n = 18 images per
treatment from 3 separate experiments; data were analyzed by one-way ANOVA
with Tukey’s post-hoc test. (C). Representative western blot for HSP70 and BAG3 in
HSP70 immunoprecipitation experiments from cells treated with DMSO or 1 µM JG98. (D). Quantitative densitometry analysis of the BAG3 signal intensity normalized
to HSP70; n = 9 per group from 3 separate experiments; data were analyzed by twotailed t-test. All data are presented as the mean ± SEM.
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To determine the impact of JG-98 on cardiomyocyte viability, we treated NRVMs
with doses of JG-98 ranging from 1 nM to 10 µM for 18 hours and assessed apoptosis
using immunofluorescence microscopy for extracellular membrane-expressed
phosphatidylserine. JG-98 treatment significantly increased cardiomyocyte apoptosis at
doses from as low as 10 nM (15.95 ± 2.75%) up to 10 µM (92.97 ± 2.09%) compared to
DMSO control (1.34 ± 0.32%) (Figure 20A-B). Based on the results of this assay, we
chose to use 18 hours of 1 µM JG-98 for the remainder of the study as it caused
moderate apoptosis (63.5 ± 2.7%) and is comparable to dose/duration used in cancer
cell studies [108,109]. To confirm that 1 µM JG-98 reduced the association of BAG3HSP70, we used immunoprecipitation (Figure 20C) and found that JG-98 significantly
reduced their association as quantified by BAG3 signal normalized to HSP70 (1.00 ±
0.07 DMSO vs. 0.54 ± 0.05 JG-98, Figure 20D).
Autophagy Flux is Impaired with JG-98
Since the BAG3-HSP70 complex had previously been identified to mediate
autophagy in myocytes [103], we next investigated whether inhibition of the BAG3HSP70 complex with JG-98 affects autophagy flux. To measure flux, we treated NRVMs
with DMSO or JG-98 in the presence or absence of 10 mM ammonium chloride (NH 4Cl),
which prohibits lysosome acidification and thus blocks autophagy. After 18 hours, cell
lysates were collected and autophagy flux was assessed by western blotting for LC3-II
(Figure 21A). LC3-II protein expression significantly increased in both the DMSO and
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JG-98 groups treated with NH4Cl, however, the extent of increase was reduced with JG98 (2.09 ± 0.22 vs. 3.26 ± 0.29 DMSO) indicating impaired autophagy flux (Figure 21B).

Figure 21. JG-98 Treatment Reduces Autophagy Flux. (A). Representative
western blot for LC3 in NRVMs treated with DMSO or JG-98 in the presence or
absence of the autophagy inhibitor NH 4Cl. (B). Quantification of LC3-II expression
normalized to total protein; n = 9 per group from 3 separate experiments; data were
analyzed with two-way ANOVA (interaction, p = 0.023) with Tukey’s post-hoc test.
Data are presented as the mean ± SEM.

JG-98 Alters Expression of BAG3 Binding Partners
To gain insight into the toxic effects of JG-98, we next assessed its impact on
protein and gene expression of BAG3, HSP70, and several other BAG3-binding
proteins that assemble with this complex to mediate autophagy: the small heat shock
proteins HSPB8 and HSPB5, which mediate client recognition and connection with
HSP70, and synaptopodin-2 (SYNPO2), which assists in autophagosome formation
[340]. Using western blot and qPCR, we found no changes in BAG3 and HSP70 at the
protein level with JG-98 (Figure 22A-D), while protein levels of HSPB8, HSPB5, and
SYNPO2 decreased with JG-98 treatment (Figure 22E-G).
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Figure 22. Inhibition of BAG3-HSP70 Alters Expression of Proteins Involved in
BAG3-dependent Autophagy Pathway. (A-B). Representative western blots for
BAG3, HSPB8, SYNPO2, HSP70, HSPB5 in NRVMs treated with DMSO or JG-98.
(C). Quantification of BAG3 (C), HSP70 (D), HSPB8 (E), HSPB5 (F), and SYNPO2
(G) protein expression normalized to total protein loading control. (H-L). qPCR
analysis of bag3 (H), hspa1a (I), hspb8 (J), hspb5 (K), and synpo2 (L) mRNA
expression normalized to β-actin. All treatments were with 1 µM JG-98 for 18 hours.
For all, n = 9 per group from 3 separate experiments; data were analyzed by twotailed t-test and are presented as the mean ± SEM.
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At the transcript level we found a significant decrease in bag3 expression, no change in
hspa1a and hspb8, and decreases in hspb5 and synpo2 expression (Figure 22H-L).
These findings suggest that the interaction of BAG3 with HSP70 regulates expression of
BAG3 and its binding partners.
Maintaining Protein Stability of BAG3, HSPB8, and HSPB5 Requires the BAG3HSP70 Complex
Previous work on a pathogenic BAG3 mutation that disrupts binding to HSP70
found that the BAG3-HSP70 interaction is required for stabilizing the HSPBs [54]. We
therefore next investigated whether JG-98 alters protein stability of HSPB5 and HSPB8,
along with SYNPO2, HSP70, and BAG3. NRVMs were treated with DMSO or JG-98 in
the presence of 50 µM cycloheximide (CHX) to block protein translation, cell lysates
were collected at 0, 2, 4, 8, 12, and 24 hours post-CHX treatment, and protein
expression was assessed by western blot (Figure 23A-B). JG-98 reduced the stability of
BAG3, HSPB8, and HSPB5 (Figure 23C-E), while HSP70 and SYNPO2 stability were
unaffected. Protein half-life decreased significantly for BAG3 (28.0 ± 0.3 to 3.04 ± 0.5
hours), HSPB8 (25.7 ± 4.3 to 4.0 ± 0.9 hours), and HSPB5 (14.0 ± 3.2 to 2.1 ± 0.6
hours) (Figure 23F), supporting that the BAG3-HSP70 interaction is fundamental for
maintaining stability of these proteins.
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Figure 23. The BAG3-HSP70 Interaction is Required for Maintaining BAG3,
HSPB8, and HSPB5 Protein Stability. (A-B). Representative western blots for
BAG3, HSPB8, SYNPO2, HSP70, HSPB5 in NRVMs treated with DMSO or 1 µM
JG-98 in the presence of cycloheximide (CHX) for 0-24 hours. (C-E). Quantification
of BAG3 (C), HSPB8 (D), and HSPB5 (E) protein expression normalized to total
protein over the time-course of CHX treatment with DMSO or JG-98; n = 3 for each
time point from 3 separate experiments; data were plotted using one-phase decay
equation; data were analyzed by two-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001.
(F). Presentation of protein half-life for BAG3, HSPB8, and HSPB5 obtained from the
preceding graphs; each point for a given protein represents a separate experiment;
data were analyzed by two-tailed t-test. All data are presented as the mean ± SEM.
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Figure 24. BAG3-HSP70 is Required for Maintaining Sarcomere Structure. (A).
Representative immunofluorescence images of NRVMs treated with DMSO or 1 µM
JG-98 for 18 hours and immunostained for BAG3 and α-actinin. (B). Quantification of
sarcomere disarray in the DMSO and JG-98 groups; n = 36 cells per group from 3
separate experiments. (C). Representative immunofluorescence images of NRVMs
treated with DMSO or 1 µM JG-98 for 1 hour, followed by heat shock (HS) at 42 °C
for two hours, then fixed and immunostained for BAG3 and α-actinin. (D).
Quantification of sarcomere disarray in the DMSO/HS and JG-98/HS groups; n = 24
cells per group from 3 separate experiments. Images were acquired at 63X
magnification; scale bars = 10 µm. Data were analyzed by two-tailed t-test.

118

JG-98 Treatment Causes Sarcomere Structural Disintegration and Impairs
Cardiomyocyte Stress Response
We recently identified BAG3-dependent PQC at the cardiac sarcomere is
required for maintaining cardiomyocyte contractile capacity [308]. Since the interaction
with HSP70 is integral to this process, we hypothesized that JG-98 treatment in NRVMs
would be detrimental for sarcomere structure. Using immunofluorescence microscopy
for BAG3 and the Z-disc protein α-actinin, we found a significant increase in sarcomere
disarray with JG-98 (72.5 ± 5.6% vs. 25.0 ± 2.6% DMSO) (Figure 24A-B). To ensure
this effect was directly due to impaired stress-responsive sarcomere maintenance and
not a byproduct of apoptosis at the late time-point, we next treated NRVMs with JG-98
for just 1 hour followed by a 2-hour heat shock at 42 °C to induce stress. We again
found significantly more sarcomere disarray in the JG-98 group (82.3 ± 4.6%) compared
to DMSO (37.5 ± 4.0%) (Figure 24C-D), supporting that the BAG3-HSP70 complex is
required for stress-responsive maintenance of the sarcomere.
To further explore the impact of JG-98 on the stress response in cardiomyocytes,
we treated NRVMs with DMSO or JG-98 for 1 hour, followed by 1 hour heat shock at 42
°C. After heat shock, the cells were allowed to recover for 3 hours at 37 °C, during
which time induction of the stress response proteins should occur. To determine if JG98 altered the expression of stress-responsive proteins following heat shock, cell
lysates were collected and western blots performed for BAG3, HSP70, HSPB8, HSP90,
and HSF-1 (Figure 25A). In the DMSO group, 1 hour heat shock and 3 hour recovery
resulted in either no change (BAG3, HSPB8, HSP90), increased (HSP70), or decreased
(HSF-1) expression. The decrease in HSF-1 expression with heat shock is expected
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and has been previously characterized [359]. However, with JG-98, there was
decreased expression of HSPB8, HSF-1, and HSP90 at baseline and a further
decrease of these proteins and BAG3, HSP70 with heat shock, indicating the stress
response was impaired (Figure 25B-F). These data further indicate that the BAG3HSP70 complex is important for regulating the stress response in cardiomyocytes.
Autophagy Induction with Rapamycin Partially Rescues Toxic Effects of JG-98
Earlier work in zebrafish with BAG3 loss-of-function mutations found protein
aggregation was reduced with autophagy induction by rapamycin and with genetic
haplo-insufficiency of mTOR [71,86,87]. We therefore investigated whether co-treatment
with rapamycin could mitigate the cardiotoxicity of JG-98. We first assessed apoptosis
by immunofluorescence with DMSO and 1 µM JG-98 with and without 30 nM rapamycin
for 18 hours (Figure 26A). The extent of cell death caused by JG-98 (57.8 ± 4.1%) was
partially rescued with rapamycin (42.8 ± 2.6%) (Figure 26B). We next assessed the
effect of rapamycin on sarcomere structure and found it significantly reduced the
negative impact of JG-98 (85.2 ± 3.3% disarray JG-98 vs. 67.2 ± 4.8% JG98/rapamycin) (Figure 26C-D). These data support the earlier findings that rapamycin
may be a potential therapeutic option when BAG3 function is compromised.
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Figure 25. JG-98 Treatment in NRVMs Causes Decreased Expression of Stress
Response Proteins Following Heat Shock. (A). Representative western blots for
BAG3, HSPB8, HSP70, HSF-1, and HSP90 in NRVMs treated with DMSO or JG-98
for 1 hour, followed by 1 hour heat shock at 42 °C, and 3 hours of recovery at 37 °C.
(B-F). Quantitative densitometry analysis of BAG3 (B), HSPB8 (C), HSP70 (D), HSF1 €, and HSP90 (F) protein expression normalized by total protein; n = 9 per group
from 3 separate experiments; data were analyzed by two-way ANOVA with Tukey’s
post-hoc test and are presented as the mean ± SEM.
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Figure 26. Rapamycin Co-treatment Partially Reduces Toxic Effects of JG-98
on NRVMs. (A). Representative immunofluorescence images of NRVMs treated with
DMSO or 1 µM JG-98 with or without 30 nM rapamycin; green – extracellular
membrane phosphatidylserine (apoptotic), blue – healthy; scale bars = 100 µm. (B).
Quantification of apoptosis; n = 23 images per group from 3 separate experiments;
data are presented as the mean ± SEM and were analyzed by two-way ANOVA
(interaction = 0.0039) with Tukey’s post-hoc test. (C). Representative
immunofluorescence images of NRVMs treated with DMSO or 1 µM JG-98 with or
without 30 nM rapamycin for 18 hours and immunostained for BAG3 and α-actinin;
images were acquired at 63X magnification; scale bars = 10 µm. (D). Quantification
of sarcomere structural disarray; n = 32 cells per group from 3 separate experiments;
data were analyzed by two-way ANOVA (interaction = 0.0075), Tukey post-hoc.
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JG-98 Toxicity Extends to Skeletal Myotubes
The importance of BAG3-dependent autophagy in myocytes has been well
described in skeletal muscle [4,47,101]. Therefore, we next investigated whether the
toxic effects of JG-98 extend to skeletal myocytes. Using C2C12 skeletal myotubes, we
assessed apoptosis with JG-98 doses from 1 nM to 10 µM (Figure 27A).

Figure 27. JG-98 Treatment in C2C12 Skeletal Myotubes Causes Apoptosis and
Reduces Autophagic Flux. (A). Representative immunofluorescence images of
C2C12s treated with DMSO or increasing concentrations of JG-98. Images were
acquired using the 10X objective; scale bars = 100 µm. (B). Quantification of
apoptosis; one-way ANOVA, Tukey post-hoc. (C). Representative western blot for
LC3 in C2C12s treated with DMSO or JG-98 in the presence or absence of NH4Cl.
(D). Quantification of LC3-II expression normalized to total protein; n = 9 per group
from 3 separate experiments; two-way ANOVA, Tukey post-hoc.
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Figure 28. Effect of JG-98 on Expression of BAG3 and its Binding Partners in
C2C12 Skeletal Myotubes. (A-B). Representative western blots for BAG3, HSPB8,
SYNPO2, HSP70, and HSPB5 in C2C12s treated with DMSO or JG-98 for 18 hours.
(C-G), Quantification of BAG3 (C), HSP70 (D), HSPB8 (E), HSPB5 (F), and
SYNPO2 (G) protein expression normalized to total protein; n = 9 per group from 3
separate experiments. (H-L). qPCR analysis of bag3 (H), hspa1a (I), hspb8 (J),
hspb5 (K), and synpo2 (L) expression normalized to β-actin; n = 9 per group from 3
separate experiments; all data was analyzed by two-tailed t-test and is presented as
the mean ± SEM.
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Figure 29. Disrupting BAG3-HSP70 with JG-98 in C2C12s does not Affect
BAG3, HSPB8, or HSPB5 Protein Half-life. (A). Representative western blots for
BAG3, HSPB8, SYNPO2, HSP70, and HSPB5 in C2C12s treated with DMSO or 1
µM JG-98 in the presence of cycloheximide (CHX). (B-D). Quantification of BAG3
(B), HSPB8 (C), and HSPB5 (D) expression normalized to total protein over the timecourse of CHX treatment; n = 3 for each time point from 3 separate experiments;
data were plotted using one-phase decay equation. Data are presented as the mean
± SEM.

As in the cardiomyocytes, JG-98 caused significant apoptosis at 1 µM (59.2 ± 6.8%)
and 10 µM (88.6 ± 3.3%), however, myotubes were viable at doses of 100 nM and lower
(Figure 27B). We next measured autophagy flux with NH4Cl and found JG-98 reduced
autophagy flux as indicated by decreased LC3-II expression (3.51 ± 0.12) compared to
DMSO (4.12 ± 0.19) (Figure 27C-D). Using western blot to assess protein expression of
BAG3 and its binding partners, we found BAG3 and SYNPO2 decreased with JG-98,
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HSP70 expression increased, and HSPB5/HSPB8 expression did not change (Figure
28A-G). At the transcript level, hspa1a expression increased, synpo2 and hspb8
decreased, and no changes were found for bag3 and hspb5 (Figure 28H-L). We
assessed protein half-life using DMSO and JG-98 in the presence of cycloheximide and,
unlike in NRVMs, found no differences in protein stability with JG-98 (Figure 29).
Together, our findings in C2C12s suggest that JG-98 exposure may be toxic for skeletal
myocytes.
Discussion
The multifunctional co-chaperone BAG3 maintains PQC through regulation of
autophagy [306]. The role of BAG3 in PQC stems from its interaction with HSP70,
where BAG3 binds in the nucleotide binding domain and connects HSP70 with
misfolded protein aggregates and the macroautophagy pathway [40,360]. Unfortunately,
the BAG3-HSP70 complex is co-opted in various cancers to promote cell survival and
tumor proliferation [29,106]. This has led to the development of promising small
molecule inhibitors of BAG3-HSP70, which display anti-proliferative effects in cancer
models both in vitro and in vivo [29,108,109,361]. However, it is not clear if these
proposed therapeutics have detrimental effects on other cell types, such as
cardiomyocytes, which rely on BAG3-mediated macroautophagy for function [362].
Here, we studied the effects of the BAG3-HSP70 inhibitor JG-98 on cardiomyocytes in
vitro and found that disrupting the complex caused apoptosis, reduced autophagic flux,
and ablated sarcomere structure.
As terminally differentiated cells that must survive for decades while experiencing
constant stress from the strain of contraction, cardiomyocytes critically rely on PQC
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systems [298]. When these systems are compromised, as often occurs with heart
disease, cardiomyocytes exhibit increased apoptosis and contractile dysfunction
[363,364]. BAG3 has emerged in recent years as a key player in cardiac PQC and both
mutations to BAG3 [64,65,67,75] and its decreased expression [70,365] are associated
with heart failure. Interestingly, pathogenic BAG3 mutations are commonly found in the
C-terminal BAG domain, which mediates binding to HSP70 [37], and thus compromise
BAG3-dependent protein turnover [54]. In this study, we show that the effects of JG-98
in cardiomyocytes are similar to BAG domain mutants, causing apoptosis, reducing
autophagy, and destabilizing the small heat shock proteins. Additionally, we show that
the interaction with HSP70 is critical for BAG3’s protein stability. The BAG3-HSP70
association may also be important for regulating gene expression of bag3, synpo2, and
the hspbs, which decreased at the transcript level with JG-98. The mechanism of this
decrease it not clear, but previous work has shown that both BAG3 and HSP70
modulate the stress response through regulation of heat shock factor-1 [366,367].
However, whether the BAG3-HSP70 complex is involved in gene expression regulation
remains to be elucidated.
BAG3 localization in cardiomyocytes is predominantly to the sarcomere Z-disc.
Our earlier work, informed by studies in skeletal myocytes [47,101], found that
sarcomere-localized BAG3 orchestrates chaperone-assisted selective autophagy
(CASA) of sarcomeric proteins to maintain contractile function in the mouse heart [308].
Others have shown that BAG3 maintains myocyte contractile force in zebrafish [71] and
human iPSC-cardiomyocytes [105], clearly delineating the importance of BAG3mediated PQC for contractile function. Our findings with JG-98 exposure in NRVMs
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show that disrupting the BAG3-HSP70 complex causes sarcomere structural
disintegration and suggest that JG-98 impairs stress responsive sarcomere turnover.
These findings complement earlier work using NRVMs, which showed that siRNA
knockdown of BAG3 caused sarcomere structural disarray in the context of mechanical
strain [196]. While functional readouts are difficult to obtain from immature
cardiomyocyte models like NRVMs, our data on the sarcomeric structural effects of JG98 strongly suggest this compound will impair cardiomyocyte contractile function.
Due to the importance of PQC for their survival, cardiomyocytes engage
numerous semi-overlapping processes to maintain proteostasis. Thus, if one fails, its
effects may be ameliorated by upregulating a different arm. Indeed, studies in zebrafish
showed administration of autophagy inducing compounds such as metformin and
rapamycin restore clearance of protein aggregates when BAG3-mediated autophagy is
compromised by pathogenic mutations or haplo-insufficiency [86,87]. In this study, we
investigated if co-treatment of NRVMs with JG-98 and rapamycin could reduce the toxic
effects of the compound and found that a 30 nM dose of rapamycin, chosen based on
previous work in NRVMs [368,369], reduced apoptosis and sarcomere disarray by 15
and 20%, respectively. While these effects were modest, future studies should explore
the optimal doses of JG-98 and rapamycin co-treatment that effectively reduce tumor
proliferation while minimizing effects on cardiomyocytes.
Another tissue where BAG3-HSP70 mediates protein turnover is skeletal muscle,
where CASA mediates the degradation of denatured filamin C [47] and BAG3 knockout
causes sarcomere structural disintegration [99]. We used C2C12 myotubes to assess
whether the detrimental effects of JG-98 extend to skeletal myocytes and found that,
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while less affected at low doses, 1 µM JG-98 caused significant apoptosis and reduced
autophagic flux in these cells. Future studies on the effects of JG-98 and similar
compounds are warranted in skeletal muscle and in nervous tissue where BAG3-HSP70
has also been shown to regulate macroautophagy [19,44,370].
In summary, we show that the proposed cancer therapeutic JG-98 is harmful for
cardiomyocytes and support careful consideration of cardiotoxicity before advancing
such compounds to the clinic. Our data also suggest that the detrimental impact of JG98 may extend to skeletal muscle. However, it is important to note several limitations
with this study. First, adult cardiomyocytes are not equipped for long-term culture, which
leads to immature cardiomyocyte models such as NRVMs and iPSC-CMs being the
only methods to do so. While NRVMs share many aspects of mature cardiomyocytes, it
is possible that immature myocytes are more sensitive to the effects of disrupting
BAG3-HSP70. Second, C2C12 skeletal myotubes are a stable cell line, which may not
fully represent the physiology of skeletal muscle. Additionally, while JG-98 has been
shown to reliably prevent the BAG3-HSP70 interaction, the specificity of JG-98 for this
complex is not clear and earlier work suggests it may elicit effects on other processes
[109]. Future studies should investigate the effects of JG-98 in vivo on adult
cardiomyocytes and skeletal muscle and characterize its effects on BAG3-dependent
and independent processes.

CHAPTER 5
MYOFILAMENT BAG3 EXPRESSION IS LINKED TO HEAT SHOCK FACTOR-1 AND
DECREASES IN MALES WITH DILATED CARDIOMYOPATHY4
Abstract
Mutations to the sarcomere-localized co-chaperone protein Bcl2-associated
athanogene 3 (BAG3) are associated with dilated cardiomyopathy (DCM) and display
greater penetrance in male patients. Decreased protein expression of BAG3 is also
associated with heart failure, however, the factors regulating cardiac BAG3 expression
are unknown. Using left ventricular (LV) tissue from non-failing and DCM human
samples we found that whole LV BAG3 expression was not significantly impacted by
DCM or sex, however, myofilament localized BAG3 was significantly decreased in
males with DCM. DCM females displayed no changes in BAG3 compared with nonfailing. This sex-difference appears to be estrogen independent as estrogen treatment
in ovariectomized female rats had no impact on BAG3 expression. BAG3 gene
expression in non-cardiac cells is primarily regulated by the heat shock transcription
factor-1 (HSF-1). We show whole LV HSF-1 expression and nuclear localized/active
HSF-1 each displayed a striking positive correlation with whole LV BAG3 expression.
We further found that HSF-1 localizes to the sarcomere Z-disc in cardiomyocytes and
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that this myofilament-associated HSF-1 pool decreases in heart failure. The decrease of
HSF-1 was more pronounced in male patients and tightly correlated with myofilament
BAG3 expression. Together our findings indicate that cardiac BAG3 expression and
myofilament localization are differentially impacted by sex and disease and are linked to
HSF-1.
Introduction
Bcl-2-associated athanogene-3 (BAG3) is a multifunctional co-chaperone protein
expressed at varying levels in all human tissues. Through various protein interactions
BAG3 mediates numerous cellular processes, including cell survival, protein quality
control, cytoskeleton maintenance, and development [1]. Notably, BAG3 protein
expression is highest in cancer cells, where it enhances tumor pathogenesis by
inhibiting apoptosis/activating autophagy [5], and in striated muscle, where it mediates
turnover of sarcomere proteins via selective macroautophagy [47,101,308]. In cardiac
muscle, BAG3 mutations and decreased BAG3 protein expression are associated with
increased apoptosis and sarcomere structural disarray [33,99]. Understandably, both
inhibiting and inducing BAG3 expression/activity, in cancer and myopathy respectively,
have been proposed as therapeutic strategies for treating human diseases
[1,31,91,109,371]. However, while the factors that regulate BAG3 protein expression in
cancer cells are well established, relatively little is known regarding the regulation of
BAG3 expression in cardiomyocytes.
BAG3 mutations, which commonly cause dilated cardiomyopathy (DCM), are
among the leading genetic causes of heart failure [65] and have higher penetrance in
male patients [64]. Preclinical models of heart failure provide evidence that altered
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BAG3 protein expression is also involved in the progression of heart failure and show
BAG3 levels decrease in heart failure secondary to pressure overload and myocardial
infarction [54,91,307]. Additionally, diminished BAG3 expression was found in LV tissue
from patients with end-stage heart failure compared with non-failing donor hearts [70]
and we recently showed the myofilament-specific pool of BAG3 also decreases in DCM
[308]. However, these studies were not powered to examine potential sex differences in
cardiac BAG3 expression and myofilament localization, such as have been observed
with BAG3 mutation penetrance. That the disease pathogenesis of DCM differs
between male and female patients is well established [372] and earlier studies in cancer
cells suggest that biological sex impacts BAG3 expression [373,374]. An assessment of
the impact of sex on BAG3 expression in the heart is thus warranted.
The primary cellular factor regulating BAG3 expression in cancer cells is the heat
shock transcription factor-1 (HSF-1) [306]. HSF-1 regulates the gene expression of a
myriad of chaperone and co-chaperone proteins, which are upregulated in response to
elevated cell stress conditions [375,376]. A previous study of HSF-1 in the human heart
found that HSF-1 activity decreases substantially in the end-stage of heart failure [377],
the effects of which likely contribute to the general proteotoxicity observed in heart
disease [348]. Interestingly, HSF-1 deficiency in mice accelerated the transition from
pressure-overload-induced cardiac hypertrophy to heart failure [378], further delineating
the importance of the HSF-1-mediated stress response for heart function. Given the
similar effects of BAG3 and HSF-1 deficiency on cardiac function, it is plausible that the
observed phenotype with HSF-1 deficiency is due at least in part to reduced HSF-1-
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mediated BAG3 expression. However, the relationship between HSF-1 and BAG3 in
cardiomyocytes has not been examined.
In this study, we demonstrate that the previously observed decrease in BAG3
expression in DCM is more exaggerated for the myofilament-specific fraction compared
to the whole LV. We further show that the decrease in BAG3 associated with DCM is
specific to males, as expression in female patients was unchanged compared to nonfailing. We show this sex difference in expression cannot be explained simply by
differences in estrogen signaling. We further demonstrate that cardiac BAG3 expression
is tightly linked with HSF-1 expression and nuclear localization, suggesting the
regulation of cardiac BAG3 expression by HSF-1 is conserved from other cell types.
Finally, we show that HSF-1 localizes to the sarcomere Z-disc and that this myofilament
pool decreases in males with DCM and positively correlates with myofilament BAG3.
Collectively, our findings support that the decrease in myofilament BAG3 observed in
DCM is specific to disease pathogenesis in male patients and suggest that altered HSF1 expression and localization may be the root cause.
Methods
Human Heart Tissue Procurement
Human LV samples were obtained from the Cleveland Clinic and Loyola
University Chicago Cardiovascular Research Institute biorepositories. The non-failing
(NF) samples were obtained from donor hearts without history of coronary artery
disease and with normal left ventricular function (n = 19, 52.6% female; Age = 56.1 ±
11.6; LV Ejection Fraction = 62.3 ± 8.5; Table 9) that were deemed unsuitable for
transplant due to blood type, age, or size incompatibility. The failing heart LV tissue was
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obtained from explanted failing hearts of patients with non-ischemic dilated
cardiomyopathy (DCM) (n = 25, 32.0% female; Age = 52.2 ± 12.1; LV Ejection Fraction
= 22.1 ± 13.4). Tissue samples were flash frozen in liquid nitrogen and stored at -80 °C.
All patients provided written informed consent prior to tissue procurement and patient
identifiers associated with the tissue were removed at the time of biobanking. The
institutional review boards of the Cleveland Clinic and Loyola University Chicago
approved the tissue experimentation. This tissue procurement procedure adheres to the
ethical practices in biomedical research involving human subjects laid out by the 1975
Declaration of Helsinki.
Ovariectomy Rat Model
The experimental procedures used in this study were approved by the Loyola
University Chicago Health Science Division Institutional Animal Care and Use
Committee (IACUC). The Loyola University Chicago Health Science Division is an
AAALAC accredited institution.
This experimental paradigm has been previously described in detail [379]. In
brief, 18-month-old female Fisher 344 rats were obtained from the National Institute of
Aging (NIA) colony (Taconic Biosciences). The rats were pair-housed and given ad
libitum access to standard chow and water. To ensure circulating E2 levels were
minimized, one week after arrival the rats were anesthetized and received bilateral
ovariectomy (OVX) surgery in which the ovaries and uterine horns were removed [379].
One week after OVX surgery, the rats were assigned to receive a subcutaneous
injection of either vehicle (safflower oil) or E2 (2.5 µg/kg) dissolved in vehicle once a day
for three consecutive days. Twenty-four hours after the final injection, the rats were
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euthanized, and the heart and plasma were collected. The hearts were flash frozen in
liquid nitrogen and stored at -80 °C. The plasma was analyzed to determine the
circulating levels of 17β-estradiol using an ELISA kit and were previously reported for
this paradigm [379].
Immunofluorescence Microscopy
Glass chamber slides (Nunc Lab Tek) were coated with poly-D-lysine (Millipore
Sigma) and left to incubate at room temperature for 30 minutes. The poly-D-lysine was
then aspirated, and the slides were left to air dry.
Approximately 25 mg of frozen human LV tissue was placed in a glass vial
containing isolation solution (2 mM EGTA, 8.9 mM KOH, 10 mM imidazole, 7.1 mM
MgCl2, 5.8 mM ATP, 108 mM KCl) supplemented with 0.3% final volume Triton X-100
and protease and phosphatase inhibitor cocktails (Fisher Scientific). The tissue was
homogenized at 7000 RPM with a mechanical homogenizer, passed through a 100 µm
filter, and left to incubate on ice. After 20 minutes, the filtered homogenate was
centrifuged at 120g to pellet the myocytes. The cell pellet was resuspended in isolation
solution free of Triton and pipetted onto the now dry poly-D-lysine-coated chamber slide
and incubated at room temperature. The solution was aspirated after one hour and
slides were washed with PBS.
Myocytes were fixed with ice-cold methanol for 1 minute, followed by cold 4%
paraformaldehyde for 3 minutes. To further permeabilize the cells, 0.5% Triton was
added to each chamber and incubated for 20 minutes at room temperature, followed by
two 15-minute incubations with 0.1% Triton. A 0.1M glycine solution (pH 7.4) was used
for antigen retrieval by incubating the slides for 30 minutes at room temperature. The
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slides were next washed with PBS and incubated in blocking solution (1:1 vol/vol PBS
to BSA solution (% BSA, 1% Gelatin, 1% Tween-20, 0.001% NaN3). After one hour, the
primary antibodies (1:300 sarcomeric α-actinin, Millipore Sigma A7811; 1:300 BAG3,
Proteintech 10599-1AP; 1:150 HSF-1, Proteintech 51034-1AP) were added in blocking
solution and slides were incubated for 12-14 hours at 4 °C.
Following incubation with primary antibody, the slides were washed with PBS
and incubated with blocking solution containing secondary antibody (Abcam, AlexaFluor
488 or 568, 1:1000) for 50 minutes at room temperature. The slides were mounted with
Vectashield containing DAPI (Vector Laboratories), coverslipped, sealed with nail
polish, and imaged at 63X magnification on a Zeiss LSM 880 microscope under
constant laser intensity and photomultiplier gain settings.
Whole Tissue Sample Preparation
Frozen left ventricular tissue (human and rat) was homogenized in lysis buffer
(9M Urea, 1 % w/v CHAPS) supplemented with protease and phosphatase inhibitor
cocktails (Fisher Scientific). The samples were then briefly sonicated and centrifuged at
10,000g for 10 minutes. The supernatant contained the proteins of interest and protein
concentration was determined by BCA assay (Pierce).
Myofilament Protein Enrichment
The protocol for myofilament enrichment was described previously [343]. In brief,
frozen left ventricular tissue was added to a glass vial containing a standard rigor buffer
(SRB) [344], supplemented with 0.5% vol/vol Triton X-100 and protease/phosphatase
inhibitors, and homogenized at 7,000 RPM. The homogenates were transferred to
Eppendorf tubes and incubated on ice. After 20 minutes, the samples were centrifuged
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at 1,800g for 2 minutes at 4 °C and the supernatant containing the cytosolic and Tritonsoluble proteins was discarded. The pellet containing the myofilament proteins was
washed in SRB without Triton by resuspension and centrifugation. The pellet was then
resuspended in 9M Urea to solubilize the myofilament proteins and sonicated. After
sonication, the protein solution was centrifuged at 10,000g for 10 minutes and the
supernatant containing the myofilament fraction was collected. Protein concentration
was determined by BCA assay (Pierce).
Nuclear Fractionation
This protocol was adapted from Dimauro et al [380] with some minor
modifications. LV tissue was placed in a glass sample vial containing STM buffer (50
mM Tris-HCl (pH 7.4), 250 mM sucrose, 5 mM MgCl2, and 1:100 protease/phosphatase
inhibitors) and minced with surgical scissors for 2 minutes. The sample was next placed
into the pestle of a 15 mL Dounce homogenizer (Pyrex) and homogenized for
approximately 1 minute, after which it was added to an Eppendorf tube and left on ice
for 30 minutes. The homogenate was then vortexed and centrifuged at 500g for 15
minutes at 4 °C to pellet the nuclei. The supernatant was saved for later and the nuclear
pellet was washed three times by resuspension in STM and centrifugation at 800g. To
isolate the nuclear proteins, the pellet was next resuspended in 1 mL NET buffer (20
mM HEPES (pH 7.9), 1.5 mM MgCl2, 0.5M NaCl, 0.2 mM EDTA, 10% glycerol, 1%
triton, 1:100 protease/phosphatase inhibitors), vortexed, and left on ice for 30 minutes.
The solution was then sonicated and centrifuged at 10,000g for 20 minutes at 4 °C. The
nuclear fraction was collected in the supernatant. To purify the cytosolic fraction, the
initial supernatant set aside earlier was centrifuged at 21,000g for 15 minutes 4 °C.
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Measurement of BAG3 and HSF1 Protein Expression
Protein samples (15 µg) from whole tissue lysis and myofilament enrichment
were prepared for western blot in equal volume SDS Tris-Glycine Buffer (Life
Technologies) supplemented with Bolt Reducing Buffer (Fisher Scientific) and heated at
95 °C for 10 minutes. The proteins were then separated electrophoretically on 4-12%
gradient Tris-glycine gels (Invitrogen) and transferred onto nitrocellulose membranes
(Thermo Scientific). The membranes containing the separated proteins were briefly
rinsed with ddH2O and incubated with Revert Total Protein Stain (LI-COR Biosciences)
to assess equal loading. Total proteins were imaged at this point on an Azure c600
imager (Azure Biosystems) and the membrane was then blocked for one hour at room
temperature in 1:1 (vol/vol) 1X tris-buffered saline (TBS) and Intercept Blocking Buffer
(LI-COR Biosciences). The blots were incubated overnight with primary antibodies in
blocking buffer. Primary antibodies and dilutions: BAG3 rabbit polyclonal (Proteintech,
10599-1AP, 1:5000), HSF-1 rabbit polyclonal (Proteintech, 51034-1AP, 1:2500),
GAPDH rabbit monoclonal (Cell Signaling, 2118, 1:2000), Histone H3 rabbit monoclonal
(Cell Signaling, 9715, 1:2000). For visualization, IRDye 700CW anti-rabbit secondary
antibodies (LI-COR) were added in blocking solution without Tween for 1 hour at room
temperature with agitation. The blots were imaged on an Azure c600 and analyzed with
the LI-COR Image Studio software.
Statistical Analysis
Statistical analyses were performed by 2-way ANOVA with Tukey’s Post-Hoc test
for multiple comparisons in cases where a significant interaction was identified.
Comparisons of only two groups were performed with a 2-tailed Student’s t-test for
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unpaired samples, as annotated in the figure legends. All analyses were performed
using GraphPad Prism 8.0. All data are presented as mean ± the standard error of the
mean (SEM). A p value of < 0.05 was considered as statistically significant.
Table 9. Non-failing (NF) and Dilated Cardiomyopathy (DCM) Patient Clinical
Characteristics.
Characteristic
Age, (years), Mean ± SD
Female, n, (%)
Ethnicity, n, (%)
Non-Hispanic origin
Hispanic origin
LVEF, (%), Mean ± SD

Non-failing (n = 19)
56.1 ± 11.6
10 (52.6)

DCM (N = 25)
52.2 ± 12.1
8 (32.0)

18 (94.8)
1 (5.2)
62.3 ± 8.5*

23 (92.0)
2 (8.0)
22.1 ± 13.4**

*LVEF was not determined for 5 NF patients

P value
0.30

< 0.0001

**LVEF was not determined for 1 DCM patient

Results
To ensure our myofilament protein fractions were free of cytosolic contaminants,
we first performed a western blot for BAG3, sarcomeric α-actin, and GAPDH in the
whole LV, triton-soluble, and myofilament fractions. The result confirmed that BAG3 is
present in both the cytosolic and myofilament fraction, with a greater proportion being
observed in the myofilament fraction (Figure 30A). BAG3 had previously been described
to localize in a striated pattern in muscle cells, which resembles sarcomere Z-disc
patterning [34,54]. To confirm this localization in the human samples analyzed in this
study, we used immunofluorescence microscopy on LV cardiomyocytes and found
BAG3 co-localized with the Z-disc protein α-actinin (Figure 30B). While such striated
patterns are also observed for t-tubule and sarcoplasmic reticulum-localized proteins,
due to BAG3 being so highly expressed in the myofilament protein fraction we interpret
this localization to represent the sarcomere Z-disc.
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Figure 30. Confirmation of the Purity of Myofilament Enrichment and Example
of BAG3 Localization in Human Cardiomyocytes (A). Western blot for BAG3,
sarcomeric α-actin, and GAPDH in human whole LV lysate, soluble fraction, and
myofilament fraction. (B). Representative immunofluorescence microscopy image of
a human LV cardiomyocyte immunostained for BAG3 and the Z-disc protein αactinin; 63x magnification, scale bar = 10 µm.

Whole LV BAG3 Expression is not Significantly Impacted by Dilated
Cardiomyopathy or Sex
One earlier study of nine New York Heart Association (NYHA) class IV heart
failure patient samples found a significant reduction in LV BAG3 expression compared
with non-failing donors [70]. However, due to limited samples, this study was not
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powered to assess whether sex differences in BAG3 expression exist. We sought to
determine the impact of sex and disease on BAG3 expression in an age-matched
cohort of 19 non-failing LV samples and 25 with heart failure stemming from nonischemic DCM (Table 9). Using western blot to assess protein expression in whole LV
tissue lysates, we did not identify a significant difference in BAG3 levels between the
non-failing and DCM hearts (p = 0.092, Figure 31A-B). This result was unexpected
given the results of the previous study. However, BAG3 was clearly reduced among a
subset of the DCM samples we analyzed and there was considerable variation in both
the non-failing and DCM groups. Our samples represent a spectrum of heart failure
severity and systolic dysfunction (22.1 ± 13.4), while the earlier study included only
NYHA class IV patients with mean LV ejection fraction of ~13%. Therefore, we next
assessed whether decreased BAG3 expression correlated with in vivo cardiac
dysfunction. To do so, we compared BAG3 protein levels with LV ejection fraction from
these patients by linear regression but found no correlation, indicating that systolic
dysfunction does not correlate with BAG3 levels (Figure 31C). Next, we assessed if our
data could be explained by differential expression of BAG3 in males and females but
found no significant differences (Figure 31D-E).
Myofilament BAG3 Expression Decreases in Male Patients with DCM
Since BAG3 localizes to the sarcomere Z-disc and BAG3 expression in the
myofilament fraction decreased with DCM in our recent work on a different patient
cohort [308], we next sought to determine whether the myofilament pool of BAG3
displays differential regulation by sex and disease compared with the whole LV.
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Figure 31. Whole LV BAG3 Expression is not Significantly Altered by Sex or
Dilated Cardiomyopathy. (A). Representative western blot of BAG3 and total
protein loading control for human whole LV lysates in DCM and NF samples. (B).
Quantitative densitometry analysis for BAG3 normalized to total protein input and
separated by disease; n = 19 NF, 25 DCM; data are mean ± SEM, 2-tailed Student’s
t-test. (C). Linear regression analysis of whole LV BAG3 vs. LVEF. (D). Quantitative
densitometry analysis for BAG3 normalized to total protein input and separated by
sex; n = 26 males, 18 females; data are mean ± SEM, 2-tailed Student’s t-test. (E).
Normalized whole LV BAG3 separated by sex and disease; n = 9 NF male, 17 DCM
male, 10 NF female, 8 DCM female; 2-way ANOVA (interaction: p = 0.69, sex: p =
0.36, disease: p = 0.13).
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Figure 32. Myofilament BAG3 Expression Decreases in Males with Dilated
Cardiomyopathy, while Female Sex is Associated with Higher Myofilament
BAG3 Levels (A). Representative western blot of BAG3 and total protein loading
control for human myofilament fractions in DCM and NF samples. (B). Quantitative
densitometry analysis for BAG3 normalized to total protein input and separated by
disease; n = 19 NF, 25 DCM; data are mean ± SEM, 2-tailed Student’s t-test. (C).
Linear regression analysis of myofilament BAG3 vs. LVEF. (D). Normalized
myofilament BAG3 expression separated by sex and disease; n = 9 NF male, 17
DCM male, 10 NF female, 8 DCM female; 2-way ANOVA, (interaction: p = 0.18, sex:
p = 0.09, disease: p = 0.005), Tukey post-hoc. (E). Quantitative densitometry
analysis for myofilament BAG3 normalized to total protein input and separated by
sex; n = 26 males, 18 females; data are mean ± SEM, 2-tailed Student’s t-test.
As in our earlier study, in the present study we found that myofilament BAG3 was
significantly decreased in DCM (p = 0.001, Figures 32A-B). As before, we investigated
whether LVEF correlated with BAG3 in the myofilament-specific fraction and found a
significant correlation by linear regression (p = 0.003, Figure 32C). We next analyzed
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these samples after separating them by sex and disease, we found BAG3 expression in
male patients was impacted more by DCM (p = 0.009) than females. DCM females did
not display a significant reduction in myofilament BAG3 compared to non-failing (p =
0.694, Figure 32D), suggesting a potential sex difference. Notably, when sex was
considered as the only variable, female samples also had significantly higher
myofilament BAG3 expression than males (p = 0.028, Figure 32E). These results
indicate the myofilament pool of BAG3 correlates with systolic function and is
differentially affected by sex and disease compared with whole LV BAG3 expression.
Acute Estrogen Treatment in Ovariectomized Female Rats does not Impact BAG3
Expression
Since the decrease of myofilament BAG3 in DCM was only observed in the male
samples and previous evidence identified elevated BAG3 levels with increased ERα
expression in cancer cells [374], we hypothesized that estrogen might regulate BAG3
expression in the heart, thus explaining the observed sex difference. To test the effects
of estrogen on cardiac BAG3 expression and myofilament localization, we used a rat
ovariectomy model with estrogen replacement therapy.
Eighteen-month-old female rats were ovariectomized (OVX) to remove circulating
estrogen. One week after surgery, the rats were randomized to receive either 17βestradiol (E2) or vehicle once a day for three days. Twenty-four hours after the last
dose, the rats were euthanized, and the hearts and blood were collected (Figure 33A).
Previous work with this cohort showed circulating estrogen levels were significantly
reduced in the OVX-veh group compared to the OVX-E2 group [379].
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Figure 33. Acute Effects of Estrogen Replacement Therapy on BAG3
Expression in Ovariectomized Female Rats. (A). Treatment paradigm: 18-monthold ovariectomized (OVX) female rats were treated once a day for three days with
vehicle or E2 starting one-week after OVX. At day 10, the rats were euthanized and
LV tissue was collected. (B). Western blot of BAG3 and total protein loading control
for whole LV lysate from OVX-V and OVX-E rats. (C). Quantitative densitometry
analysis for BAG3 normalized to total protein input. (D). Western blot of BAG3 and
total protein loading control for myofilament fraction. (E). Quantitative densitometry
analysis for myofilament BAG3 normalized to total protein input. (F). Western blot of
HSF-1 and total protein loading control for whole LV lysate. (G). Quantitative
densitometry analysis for HSF-1 normalized to total protein input. All data are mean
± SEM; n = 5 OVX-V, 4 OVX-E; 2-tailed Student’s t-test.
We used western blot to assess BAG3 protein expression in whole LV tissue lysates
and myofilament fractions from the two groups and found no significant differences (p =
0.20, Figure 33B-E). We also assessed expression of heat shock factor-1 (HSF-1) but
found no change with E2 treatment (p = 0.21, Figures 33F-G). These data suggest that
E2 levels do not affect whole LV BAG3 expression or localization to the myofilament in
the healthy heart.
Whole LV BAG3 Expression Positively Correlates with Heat Shock Factor-1
Protein Expression and Nuclear Translocation
While the factors regulating BAG3 expression in the heart are poorly understood,
several factors have been identified as regulators of BAG3 expression in non-cardiac
cells [11,381]. Foremost among these is HSF-1, which in cancer cells localizes to the
nucleus under cell stress conditions and upregulates the expression of several
chaperones including BAG3 [10,382]. We therefore sought to determine whether HSF-1
protein expression was impacted in DCM and to assess its relationship with BAG3
levels. Using western blot of whole LV tissue lysates from the human samples, we
found that HSF1 expression displayed high variability in both groups and was not
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significantly different in DCM hearts compared with non-failing (Figure 34A-B). We
further studied whether HSF-1 expression was impacted by biological sex in the nonfailing and DCM samples and found no differences (Figure 34C). When sex was
considered as the only variable there was also no difference in HSF-1 expression (p =
0.139, Figure 34D).
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Figure 34. Heat Shock Transcription Factor 1 (HSF-1) Expression is not
Impacted by Dilated Cardiomyopathy or Sex but Correlates with BAG3 Protein
Expression. (A). Representative western blot of HSF-1 and total protein loading
control for human whole LV lysates in DCM and NF samples. (B). Quantitative
densitometry analysis for HSF-1 normalized to total protein input and separated by
disease; n = 19 NF, 25 DCM; data are mean ± SEM, 2-tailed Student’s t-test. (C).
Normalized HSF-1 expression separated by sex and disease; n = 9 NF male, 17
DCM male, 10 NF female, 8 DCM female; 2-way ANOVA (interaction: p = 0.90, sex:
p = 0.12, disease: p = 0.59). (D). Quantitative densitometry analysis for HSF-1
normalized to total protein input and separated by sex; n = 26 males, 18 females;
data are mean ± SEM, 2-tailed Student’s t-test. (E). Linear regression analysis of
whole LV HSF-1 vs. whole LV BAG3. (F). Linear regression analysis of whole LV
HSF-1 vs. myofilament BAG3.

To determine if BAG3 expression correlated with whole LV HSF-1 expression in
these samples, we performed linear regression analysis and found a strong positive
correlation for HSF-1 with whole LV (r2 = 0.686, p < 0.0001) and a weakly significant
relationship with myofilament BAG3 (r2 = 0.228, p = 0.001, Figures 34E-F). These
findings suggest a link between HSF-1 and BAG3 expression in the heart, however, we
could not verify HSF-1 activity by the method used. To determine the impact of active
HSF-1 on BAG3 expression, we selected 11 DCM samples with varying BAG3 protein
levels (Figure 35A) and performed subcellular fractionation on these samples to collect
the cytosolic and nuclear fractions (Figure 35B). Using western blot, we determined
HSF-1 expression in the cytosolic and nuclear fractions of these (Figure 35C). When
compared with BAG3 expression, cytosolic and nuclear HSF-1 each displayed a strong
positive correlation with whole LV BAG3 levels (Figures 35D-E). Myofilament BAG3 did
not significantly correlate with HSF-1 levels (Figures 35F-G). These results suggest that
human cardiac BAG3 expression is linked to HSF-1 expression and activity, while the
myofilament BAG3 expression likely requires additional factors.
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Figure 35. Whole LV BAG3 Expression Correlates with HSF-1 Nuclear
Translocation in Human Dilated Cardiomyopathy Samples. (A). Western blots for
BAG3 in whole LV lysate (top) and myofilament fraction (bottom) from 11 DCM
samples with varying BAG3 expression. (B). Western blot for HSF-1, GAPDH
(cytosol control), and histone H3 (nucleus control) from subcellular fractionation. (C).
Western blot for HSF-1 in cytosol and nuclear fractions from the same 11 samples
used in A. (D). Linear regression analysis of nuclear HSF-1 expression vs. whole LV
BAG3. (E). Linear regression analysis of cytosolic HSF-1 expression vs. whole LV
BAG3. (F). Linear regression analysis of nuclear HSF-1 expression vs. myofilament
BAG3 expression. (G). Linear regression analysis of cytosolic HSF-1 expression vs.
myofilament BAG3 expression.
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HSF-1 Localizes to the Myofilament Fraction and Correlates with Myofilament
BAG3 Expression
While studying HSF-1 localization in these samples, we discovered by
immunofluorescence microscopy that while having strong cytosolic and nuclear
localization, HSF-1 was also prominently localized to the sarcomere Z-disc as evident
from its co-localization with α-actinin (Figure 36A). To our knowledge, this is the first
description of sarcomere-localized HSF-1. Given the Z-disc localization of HSF-1, we
next sought to determine whether HSF-1 expression in the myofilament fraction was
impacted by disease. Using western blot in myofilament-enriched LV tissue lysates, we
found HSF-1 was significantly decreased in DCM compared with non-failing samples (p
< 0.0001, Figures 36B-C). Myofilament HSF-1 did not display any significant difference
between male and female samples (p = 0.116, Figure 36D), but – like BAG3 – was
more impacted by disease in male DCM patients (p = 0.0004) than in female (p = 0.274,
Figure 36E). Lastly, when compared with myofilament BAG3 by linear regression, we
found a strong correlation for myofilament HSF-1 (r2 = 0.661, p < 0.0001, Figure 36F).
Together these data show the transcription factor for many sarcomere chaperones
localizes to the sarcomere Z-disc, decreases in male patients with DCM, and this
myofilament HSF-1 pool is tightly linked to myofilament expression of at least one of its
canonical downstream gene targets, BAG3.
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Figure 36. HSF-1 Myofilament Localization Decreases in Males with Dilated
Cardiomyopathy and Tightly Correlates with Myofilament BAG3 Expression.
(A). Representative immunofluorescence microscopy image of a human LV
cardiomyocyte immunostained for BAG3 and the Z-disc protein α-actinin; 63x
magnification, scale bar = 10 µm. (B). Representative western blot for HSF-1 in
myofilament-enriched LV tissue. (C). Quantitative densitometry analysis of
myofilament HSF-1 expression normalized to total protein loading control; n = 19 NF,
25 DCM; Student’s 2-tailed t test. (D). Normalized HSF-1 expression separated by
sex; n = 26 males, 18 females; Student’s 2-tailed t test. (E). Normalized myofilament
HSF-1 expression separated by sex and disease; n = 9 NF male, 17 DCM male, 10
NF female, 8 DCM female; 2-way ANOVA (interaction: p = 0.13, sex: p = 0.38,
disease: p = 0.0001), Tukey post-hoc. (F). Linear regression analysis of myofilament
HSF-1 vs. myofilament BAG3.
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Discussion
Dilated cardiomyopathy (DCM) accounts for up to 40% of all heart failure cases
and is characterized by systolic dysfunction and dilation/enlargement of one or both
ventricles [252]. Mutations and decreased expression of the heat shock protein cochaperone protein BAG3 have been linked to DCM pathogenesis through numerous
clinical studies [64,66,67,69,70]. In recent years, several mechanistic studies have
identified diverse roles for BAG3 in the heart, highlighting its fundamental roles in
regulating cardiac function. A study by Fang et al., using BAG3 knockout and a DCMassociated BAG3 mutation in mice, identified BAG3 mediates cardiac protein quality
control through stabilizing interactions with heat shock proteins [54]. Through a separate
pathway, BAG3 also directly modulates cardiomyocyte contractility via interactions with
the β1-adrenergic receptor and L-type calcium channel [91,97]. Perhaps the most
prominent localization of BAG3 in striated muscle is to the Z-disc of the sarcomere – the
molecular unit of muscle contraction. Skeletal myocyte studies identified the Z-disc
localized BAG3 was essential to turnover of the actin scaffolding protein filamin C
through autophagy [47,101], and we recently showed that this myofilament-associated
BAG3 decreases in cardiomyocytes from human DCM left ventricle samples [308].
However, despite the clear importance of BAG3 for maintaining cardiac function, the
factors regulating BAG3 expression and myofilament localization in cardiomyocytes
have not been explored [383]. In the present study, we sought to identify factors
regulating cardiac BAG3 expression in human cardiomyocytes from non-failing donor
hearts and in patients with DCM.
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A previous assessment of BAG3 expression in the end-stage failing heart found
BAG3 levels decreased sharply in disease [70]. In the present study, with a much larger
cohort, we observed a trend toward decreased BAG3 in DCM. However, this difference
was not statistically significant. Comparing the two studies, in Feldman et al. whole LV
BAG3 decreased by almost three-fold in heart failure, while we observed only a ~20%
decrease with considerable variability in the DCM group. One possible explanation was
that our DCM cohort represented a spectrum of cardiac dysfunction, while the earlier
study included only samples from NYHA class IV/end-stage heart failure. The NYHA
classification system is based on patient symptoms and places patients into four
categories based upon their limitations in physical activity, with stage IV being the worst
[384]. Unfortunately, the NYHA class diagnosis was not available for all the de-identified
patient samples used in our study and we were thus unable to compare BAG3
expression in each class.
A common cardiac functional parameter not included in NYHA classification is
the LV ejection fraction, which is a measure of systolic function. Given the apparent
influence of disease severity on BAG3 expression levels, we expected BAG3
expression would decrease with progressing systolic dysfunction. However, when we
compared whole LV BAG3 expression with LV ejection fraction we did not find a
significant correlation and some samples with the lowest LV ejection fractions (<10%)
had BAG3 levels comparable to non-failing. Therefore, we conclude that decreased
whole LV BAG3 expression in the very end-stage of heart failure may be explained by
the overall disease severity or the poor response to physical activity but is not directly
linked to systolic dysfunction. Of note, another potentially important difference between
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ours and the previous study is the etiology of heart failure studied. We included only
samples with non-ischemic DCM, while the earlier study included patients with both
ischemic and non-ischemic DCM. Future studies are needed to determine the impact of
different heart failure etiologies on BAG3 expression in humans.
The disease pathogenesis of DCM frequently differs between males and
females, due in part to sex differences in the regulation of gene and protein expression
[372]. Divergence with biological sex is apparent in the incidence, severity, and often
the response to treatment for heart failure [385]. The results of two earlier studies in
cancer cells suggest that BAG3 expression and functions may not be uniform between
males and females [373,374]. Sex differences in BAG3 expression in the heart have not
been explored, however, a retrospective study of 129 BAG3 mutation carriers found that
DCM disease penetrance of BAG3 mutations was significantly worse for male patients
[64]. This finding suggests that in some cases BAG3 may be dispensable for healthy
cardiac function in females. We show in this study that whole LV BAG3 expression is
not different between males and females.
We had previously identified that BAG3 localized to the cardiac sarcomere
decreased in a separate cohort of human samples with non-ischemic DCM [308]. In the
present study we also assessed expression of myofilament BAG3, given its apparent
functional significance. As we previously showed, when myofilament BAG3 was
measured in the present study we identified a significant decrease of ~40% in DCM
compared with non-failing. While sex differences in myofilament localized BAG3 were
not identified in non-failing samples, this pool of BAG3 decreased significantly in males
with DCM but not in female DCM samples. These results suggest a decrease in BAG3-
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mediated functions may contribute to the disease pathogenesis more frequently for
male patients than for females, as does the disease penetrance of BAG3 mutations
[64]. Notably, when we assessed the impact of 17β-estradiol treatment on BAG3
expression in a cohort of ovariectomized female rats we did not observe a change in
either the whole LV or myofilament expression levels. These results suggest the sex
difference is not estrogen mediated, or, if it is, may only present in the disease state.
Future studies focused on this question are warranted.
The primary factor regulating bag3 gene expression identified in non-cardiac
cells is the heat shock transcription factor-1 (HSF-1). Studies in cancer cell lines
showed HSF-1 binds to two heat shock response elements in the bag3 gene promoter
to modulate its expression [8–10,386]. In the heart, decreased HSF-1 activity has been
linked to end-stage human heart failure [377] and is implicated in the transition from
compensatory to pathological cardiac remodeling [378]. The underlying mechanisms
are not well established, however given its role as a central mediator of cellular protein
quality control, it is probable that this cardiac dysfunction stems from reduced HSF-1
mediated proteostasis. In this study, we found whole LV HSF-1 expression was not
affected in humans with DCM. However, HSF-1 expression and nuclear localization
were positively correlated with whole LV BAG3 expression in both the healthy and
failing hearts, suggesting HSF-1 regulates BAG3 expression in the human heart.
While investigating the localization of HSF-1 in human LV cardiomyocytes we
discovered HSF-1 unexpectedly had prominent localization to the sarcomere Z-disc.
Sarcomeric localization of HSF-1 has not previously been described to our knowledge
and may represent a chaperone transcription factor that is positioned to rapidly respond
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to stress conditions experienced at the sarcomere specifically, such as those presented
by the mechanical strain of contraction. Sarcomere-associated transcription factors
have previously been identified in skeletal muscle to mediate sarcomere-nucleus
crosstalk [387,388]. However, we are not aware of such a link for sarcomere protein
quality control processes being previously identified in the heart. We show in this study
that the myofilament pool of HSF-1 is impacted in DCM, where it decreased significantly
in male patients compared to non-failing. Again, like BAG3, such a decrease was not
found in DCM females. Importantly, myofilament HSF-1 displayed a striking positive
correlation with myofilament BAG3 expression, further supporting BAG3 expression –
even in specific cellular compartments – is regulated by HSF-1. Previous studies have
identified therapeutic promise for increasing HSF-1 activity to prevent cardiac
dysfunction in ischemia- and pressure-overload-induced cardiac hypertrophy
[377,389,390]. Further studies are warranted to characterize the therapeutic potential
for increasing BAG3 and other chaperone expression at the sarcomere through HSF-1
activation, particularly in the context of dilated cardiomyopathy.
There are several limitations in the present study that must be noted. First, due to
the limited clinical information at our disposal from the DCM and NF samples, we
cannot rule out the impact of different medications or cardiovascular comorbidities on
BAG3 expression. Additionally, while we conducted a robust analysis of non-ischemic
DCM-associated heart failure, future studies are needed to determine the impact of
other heart failure etiologies on BAG3 and HSF-1 expression/localization, including
ischemic cardiomyopathy (ICM) and hypertrophic cardiomyopathy (HCM). Regarding
the impact of estrogen on BAG3 expression, while we did not see an effect in healthy
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rats, this study did not test whether there is an estrogen-dependent impact on BAG3 in
heart failure. With respect to the relationship between transcription factors and BAG3
expression, while HSF-1 is the primary transcription factor for BAG3 our study did not
assess the relationship of BAG3 expression with its other identified transcription factors
NFκB [11] and JNK [14]. Lastly, the nature of the relationship between myofilament
localized HSF-1 and BAG3 on a mechanistic level is not clear from the present study.
BAG3 is a multi-faceted co-chaperone protein. Previous studies have identified
that both decreased protein expression of BAG3 and BAG3 mutations are associated
with dilated cardiomyopathy and heart failure. In the present study, we show that HSF-1
expression also impacts BAG3 expression, which may have implications in disease
where protein quality control mechanisms are frequently impaired. We also assess the
expression of BAG3 in the myofilament protein fraction and show that this pool of BAG3
is differentially impacted by heart failure in male and female patients and is also linked
to myofilament HSF-1 localization. Understanding the factors that regulate cardiac
BAG3 expression is an important consideration for those focused on BAG3 as a
therapeutic target for both inherited BAG3 mutation-associated cardiovascular disease
and non-genetic heart failure.

CHAPTER 6
SUMMARY & FUTURE DIRECTIONS
Summary of Thesis Work
BAG3 Maintains Sarcomere Contractile Function
Despite an abundance of evidence from clinical studies indicating that BAG3
mutations are a definitive cause of genetic dilated cardiomyopathy (DCM), relatively few
mechanistic studies had been performed to determine the role of BAG3 in
cardiomyocytes. The earliest suggestion that BAG3 had a role in sarcomere
maintenance came in 2006 when the first study of whole-body BAG3 knockout (KO)
was performed in mice [99]. The BAG3 KO mice developed normally in utero, however,
they displayed growth defects after birth and died by 3 weeks-of-age [99]. Assessment
of skeletal muscle found that while sarcomere structure by electron microscopy
appeared normal at embryonic day 18.5, severe disarray was evident by just 4 days
after birth suggesting a role for BAG3 in sarcomere maintenance [99]. The sarcomeric
structural significance of BAG3 was further indicated in a study of DCM-causing BAG3
mutations expressed in neonatal rat ventricular myocytes (NRVMs), where the
mutations (R258W and L462P) caused sarcomere disarray [34]. More recently, a study
of BAG3 KO in iPSC-cardiomyocytes suggested that BAG3 was also important for
cardiomyocyte contractility [55]. Together, these studies suggested that BAG3 has an
important role in structural and functional maintenance of the cardiac sarcomere.
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However, whether this extended to adult cardiomyocytes, which are structurally and
functionally distinct from these immature cardiomyocyte models, was not clear.
In Chapter 3, we used human left ventricular tissue, cardiomyocyte-specific
BAG3 haplo-insufficient mice, cardiomyocyte-specific BAG3 P209L transgenic mice,
and a mouse heart failure model with BAG3 gene therapy to investigate the functional
significance of BAG3 at the mature sarcomere. Numerous previous studies had
identified that maximum calcium-activated sarcomere contractile force (Fmax) is reduced
in both animal heart failure models and in explanted failing human hearts [331,333–
338,346,347,391]. This was corroborated in our own data with left ventricular
cardiomyocytes from human DCM samples and a mouse heart failure model secondary
to coronary artery ligation. Notably, in the human samples we found that
cardiomyocytes from DCM samples with the highest relative myofilament BAG3 levels
had preserved function, while lowest myofilament F max was associated with the lowest
BAG3 expression. While this relationship is purely correlation, it suggested that BAG3
might be functionally significant at the sarcomere in humans. We went on to validate the
functional significance of BAG3 in our mouse models and found that F max was reduced
both with BAG3 haplo-insufficiency and with the P209L BAG3 mutation. Importantly,
four weeks of BAG3 gene therapy in the mouse heart failure model partially rescued
sarcomere contractile function. Building on previous studies in NRVMs and iPSCcardiomyocytes, our findings using human and mouse myocardium in Chapter 3
indicate that BAG3 is indeed functionally significant for the mature cardiomyocyte
sarcomere and suggest that sarcomere dysfunction in human heart failure may be at
least partially explained by reduced BAG3 levels.
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BAG3 Associates with HSP70 and HSPB8 in the Cardiac Sarcomere to Regulate
Protein Turnover
The most well-characterized cellular role of BAG3 is regulation of the
macroautophagy pathway through its interaction with HSP70. In this process, BAG3
acts as a co-chaperone for HSP70 to facilitate its association with misfolded protein
clients and target them to the autophagosome/lysosome for removal [306]. Previous
studies in skeletal myocytes identified a muscle-specific macroautophagy pathway at
the sarcomere mediated by BAG3, termed chaperone-assisted selective autophagy
(CASA) [102]. In the CASA pathway, BAG3 interacts with both HSP70 and the small
heat shock protein HSPB8. These chaperones bind to misfolded protein substrates,
which are ubiquitinated and then the entire complex is targeted to the forming
autophagosome by the ubiquitin adaptor protein P62 and another BAG3 associated
protein synaptopodin-2 (SYNPO2) [47,101]. P62 facilitates the association of the
ubiquitinated client protein with LC3 proteins on the nascent autophagosome
membrane, while SYNPO2 assists with autophagosome maturation and complex
engulfment [340]. While CASA had not been identified in cardiac muscle, recent studies
had shown that, in addition to HSP70, BAG3 interacted with the HSPBs and mediated
their stability [54–56]. Thus, all the necessary pieces appeared to be present and to
interact in cardiomyocytes.
In Chapter 3, we sought to determine whether the CASA complex was present in
cardiomyocytes from the human left ventricle and to characterize its role therein. Using
BAG3 immunoprecipitation and mass spectrometry, we first determined the BAG3
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protein interactome at the sarcomere and found that HSP70 and HSPB8 coimmunoprecipitated with BAG3. This finding suggested the CASA complex was
conserved in the human heart and we further validated the association of these proteins
using co-immunoprecipitation and western blot. Next, using immunofluorescence
microscopy on human left ventricular cardiomyocytes, we further showed that these
CASA complex members co-localized with α-actinin at the sarcomere Z-disc. Notably,
the CASA members displayed proteotoxic stress- and BAG3-dependent localization to
the sarcomere, indicating that BAG3 is the essential nucleating factor for localization of
the other chaperones.
The earlier work in skeletal myocytes identified the actin cross-linking protein
filamin C as a CASA client. We expected that many more clients likely existed given the
number of protein substrates HSP70 is known to associate with. To determine which
sarcomere proteins might be clients of CASA in the human heart, we characterized the
sarcomere interactome of each BAG3, HSP70, and HSPB8, anticipating the potential
clients would be conserved across the three interactomes. By this method we narrowed
down the potential client pool to 49 proteins. The identification of filamin C as a CASA
client by Jörg Höhfeld’s lab was in part through a client release assay where
cytoskeletal fractions from myocytes were incubated with recombinant BAG3 protein
and filamin C was released into the soluble pool [47]. Using the same assay with
myofilament fractions from the human heart paired with mass spectrometry, we
identified 8 sarcomere proteins that were solubilized with the addition of BAG3. These
included the previously identified filamin C and 7 other sarcomere proteins, suggesting
CASA may be a more general protein turnover mechanism for the sarcomere.
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Cancer Therapeutics Targeting BAG3-HSP70 may be Cardiotoxic
In addition to its role in regulating autophagy in various cell types, the BAG3HSP70 complex mediates cell survival by inhibiting the intrinsic apoptosis pathway
[2,392]. In response to harmful stimuli, the cytosolic proteins Bax and Bak oligomerize
and co-localize to the outer mitochondrial membrane [393]. This localization stimulates
release of cytochrome c from the mitochondria, which activates downstream apoptosis
pathways [394]. The protein B-cell lymphoma-2 (Bcl-2) prevents the oligomerization of
Bax and Bax and thus prohibits apoptosis [395,396]. Studies have shown that BAG3HSP70 is important for stabilizing Bcl-2 and preventing its degradation by the
proteasome [371]. Thus, BAG3 acts as an anti-apoptotic protein. In some cancers,
BAG3 levels and activity increase and lead to cancer cell survival and tumor
proliferation [106,357,397–399]. As a result, BAG3 and its anti-apoptotic effects have
become a focus for cancer therapies [27,107,357]. One promising approach is through
pharmacological inhibition of the BAG3-HSP70 complex and small molecules that
disrupt this interaction have proven effective in cell models and in vivo cancer models
[108,109,400,401]. While the effects of such therapies are beneficial for cancer
treatment, we hypothesized that broadly administering these treatments would have
detrimental effects on cardiomyocytes.
In Chapter 4, we studied the effects of the small molecule JG-98, which disrupts
BAG3-HSP70, using NRVMs. At doses similar to and lower than those used in cancer
cell models, we found that JG-98 caused a significant increase in cardiomyocyte cell
death. In addition, disrupting BAG3-HSP70 in NRVMs resulted in reduced autophagy
flux, which at least in part contributed to the increased apoptosis. Given our earlier
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findings of the importance of CASA in cardiomyocytes, we assessed CASA gene and
protein expression with JG-98 and found that bag3, synpo2, and hspb5 gene
expression were reduced, while SYNPO2, HSPB5, and HSPB8 protein levels
decreased. In agreement with previous studies, this decrease in HSPB protein
expression was shown to result from reduced protein stability when the BAG3-HSP70
complex was disrupted [54–56]. Interestingly, JG-98 treatment also caused a reduction
in BAG3 protein stability, indicating for the first time that BAG3 stability requires the
interaction with HSP70. We assessed sarcomere structure in the NRVMs treated with
JG-98 and found that disrupting BAG3-HSP70 by this method caused stress-dependent
sarcomere disintegration, supporting earlier work that this complex is required for
structural maintenance of the sarcomere [34,104]. Finally, using C2C12 skeletal
myotubes we found that some of the toxic effects of JG-98 extended to skeletal
myocytes. Our data on JG-98 in NRVMs suggests this compound and its analogs will
have toxic effects on the heart and skeletal muscle if broadly administered as a cancer
therapy.
Sex Differences in Myofilament BAG3 Expression in Patients with Dilated
Cardiomyopathy
Multiple studies had shown that BAG3 protein levels decreased in both animal
heart failure models and end-stage human heart failure [54,70,91,307]. However, work
by Feldman et. al. and our own unpublished work showed that the mRNA expression
was unchanged or even increased [70]. Thus, the decrease in BAG3 at the protein level
appears to arise from either reduced stability/increased degradation of BAG3 in heart
failure. Additionally, our work in Chapter 3 showed that this decrease in BAG3 extended
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to the sarcomere-specific protein pool as well. In Chapter 5, we used a large cohort of
non-failing (n = 19) and DCM (n = 25) human left ventricle samples to examine the
factors that regulate BAG3 protein levels and localization to the sarcomere.
We began by examining potential sex differences in whole LV and myofilament
BAG3 expression. Previous work by Dominguez and colleagues had shown that BAG3
mutations have increased disease penetrance in male patients [64], and we thus
hypothesized that BAG3 expression also would have sex-dependent differences. At the
whole LV level, protein expression of BAG3 was not obviously different between males
and females. However, while myofilament BAG3 decreased by ~50% in males with
DCM, females with DCM did not display the same decrease. In fact, when disease was
removed as a variable and only sex was considered, the female group had significantly
higher BAG3 expression compared to the males. This finding is important as most
animal models studying BAG3 to-date (including our own) have been performed using
only male mice. Future studies should include comparisons in adequately powered male
and female cohorts. The mechanism by which females maintain higher BAG3 levels at
the sarcomere remains unclear, though it does not appear to require estradiol signaling
as acute estrogen replacement therapy in a rat ovariectomy model did not affect BAG3
expression. We also explored the relationship between BAG3 and one of its known
transcription factors, HSF1 [10]. Protein expression of HSF-1 and BAG3 in the whole LV
and myofilament fractions were tightly correlated and nuclear localized HSF-1
expression correlated with higher BAG3 levels. However, it is not clear whether this
nuclear HSF-1 bound to heat shock elements in the bag3 promoter or if it correlated
with increased mRNA transcripts.
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Future Directions
Regulation of BAG3 Protein Stability in the Healthy and Failing Heart
It is clear from several studies that protein expression of BAG3 decreases in
heart failure, and this appears to be due to protein level regulation, as our own data and
others shows the mRNA levels are unchanged or even increased (Figure 37) [70]. What
factors regulate BAG3 protein stability and how do these change in heart failure? This is
perhaps the most important question regarding BAG3 in the heart and the answer
remains elusive. However, the data presented in this dissertation may shed some light.
For one, our study of JG-98 suggests that in addition to the BAG3-HSP70 complex
being required for stability of the HSPBs, the interaction of BAG3 with HSP70 is also
required for BAG3’s stability. Whether BAG3 protein levels decrease with DCM-causing
mutations that disrupt HSP70 binding, such as the E455K, L462P, or P470S, is not
known. However, based on our findings with JG-98, one might expect BAG3 protein
half-life to be reduced with these mutations. Even so, this would not explain how in nongenetic cases of heart failure BAG3 is also reduced at the protein level. It could be that
HSP70 is sequestered away from BAG3 in heart failure leading to reduced BAG3, but
this question requires further exploration. Additionally, our finding of myofilament BAG3
levels decreasing in males with DCM but not females suggests that the mechanism
mediating BAG3 protein stability may remain active in females with heart failure. This
apparent sex difference could serve as a useful tool to determine which
proteins/pathways are dysregulated specifically in the failing heart of males, which may
expose the mechanisms regulating BAG3 stability.
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Figure 37. bag3 Gene Expression Increases in
the Left Ventricle of Patients with Dilated
Cardiomyopathy. Quantitative real-time PCR
data for bag3 mRNA expression in left ventricle
samples from NF and DCM humans. n = 10 NF,
21 DCM; expression was normalized to gapdh
using the ΔΔCt method; data were analyzed with
2-tailed t-test; primers: Forward:
TGCCAGAAACCACTCAGCCAGA, Reverse:
TGAGGATGAGCAGTCAGAGGCA

Factors Regulating BAG3 Localization to the Sarcomere
We have shown that BAG3 is important for maintaining sarcomere function
through CASA, which displays proteotoxic stress-dependent localization to the
sarcomere. However, the specific mechanisms regulating BAG3’s localization to the
sarcomere remain unknown. Determining this mechanism is an important step toward
developing potential therapies that can specifically target the sarcomeric pool of the
protein and the CASA pathway, while avoiding disruption of other BAG3-regulated
processes in the cytosol. Again, the sex-dependent differences in myofilament BAG3 in
human heart failure may indicate that the mechanism targeting BAG3 to the sarcomere
is sustained in females. Additionally, our unpublished data on BAG3 post-translational
modifications in the cytosolic and sarcomeric fractions from human myocardial samples
shows that BAG3 T285 phosphorylation may be enriched at the sarcomere (Figure 38).
Future studies should fully assess the regulation of BAG3 post-translationally as this
may shed light on both BAG3 localization and protein stability mechanisms.
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Figure 38. BAG3 T285 Phosphorylation is
Enriched in the Myofilament Protein Fraction.
Mass spectrometry spectral count analysis of
phosphorylated T285 BAG3 peptides normalized to
total BAG3 peptides in the soluble and myofilament
protein fractions from the human left ventricle; n = 6
soluble, 6 myofilament; data were analyzed by 2tailed t-test.

BAG3-dependent Regulation of the Stress Response in Cardiomyocytes
The studies presented in this dissertation, building on insightful work by other
groups, delineate the importance of BAG3 for mediating protein degradation through the
autophagy pathway and shows that BAG3-dependent protein turnover is functionally
significant for the sarcomere. Interestingly, our work in Chapter 4 suggests that the
BAG3-HSP70 complex is not only important for mediating turnover of misfolded clients,
but also potentially for regulation of the general stress response as protein and gene
expression of stress response chaperones were reduced with JG-98. Our recent
unpublished work corroborates these findings and shows that BAG3 is important for
maintaining protein stability of HSF-1, the primary stress-responsive transcription factor.
In response to stresses such as heat shock, hypoxia, and oxidation, HSF-1 translocates
to the nucleus and activates expression of chaperone proteins [10,402,403]. Our data
show that when BAG3 levels are reduced, either through genetic haploinsufficiency in
mice or by siRNA knockdown in NRVMs, HSF-1 protein expression decreases,
suggesting BAG3 is required for its stability (Figure 39).
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Figure 39. BAG3 is Required for Maintaining HSF-1 Protein Stability in
Cardiomyocytes. (A). Representative western blot for HSF-1 in NRVMs transfected
with control (scramble) or BAG3 siRNA and treated with cycloheximide to assess
protein half-life. (B). Quantification of HSF-1 expression at each time point
normalized to total protein; n = 1 per treatment for each time point; data were fit
according to one-phase decay kinetics. (C). Representative western blot for HSF-1 in
NRVMs treated with DMSO or 1 µM JG-98 and cycloheximide to assess protein halflife. (D). Quantification of HSF-1 expression at each time point normalized to total
protein; n = 3 per treatment for each time point from 3 separate experiments; data
were fit according to one phase decay kinetics and were analyzed by 2-tailed t-test;
*p< 0.05. (E). Western blots for BAG3, ubiquitin, and HSF-1 in whole tissue LV
lysates from 44-week-old WT and BAG3+/- mice. (F-H). Quantification of BAG3 (F),
ubiquitin (G), and HSF-1 (H) protein expression normalized to total protein; n = 3 per
group; 2-tailed t-test. Data are presented as the mean ± SEM.
Using JG-98 treatment in NRVMs with cycloheximide to assess HSF-1 protein half-life,
we also found that the stability of HSF-1 requires the interaction of BAG3 with HSP70
(Figure 39). We expect this is similar to the previously described regulation of Bcl-2,
where the BAG3-HSP70 complex binds to and stabilizes Bcl-2 to prevent its
degradation by the proteasome [371]. This finding may also explain why HSF-1
overexpression in iPSC-CMs with a pathogenic BAG3 mutation rescued sarcomere
structure in the context of proteotoxic stress [56]. Future work should build on these
findings to determine the specific regulatory mechanisms BAG3-dependent HSF-1
protein stability. Moreover, in vivo studies should be performed to determine if and how
the HSF-1-mediated stress-response is impaired in the BAG3 haplo-insufficient mouse
model and to determine if these findings extend to human disease.
In addition to being a transcription factor for BAG3, HSF-1 had previously been
shown to require BAG3 for its shuttling between the cytosol and nucleus in response to
stress in HeLa cells [366]. Our data indicate this is also the case in cardiomyocytes
where BAG3 knockdown prevented nuclear translocation of HSF-1 (Figure 40A-B).
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Figure 40. BAG3 Regulates Stress-responsive Nuclear Translocation of HSF-1
in Cardiomyocytes. (A). Representative western blots for HSF-1 and BAG3 in the
nuclear and cytosolic fractions following 1 hour of heat shock at 42 °C in NRVMs
transfected with control or BAG3 siRNA. (B). Analysis of nuclear HSF-1 normalized
to total protein in the four groups; n = 2 per group from 2 separate isolations (C).
Representative western blots for HSF-1 and BAG3 in the nuclear and cytosolic
fractions with 1 hour JG-98 exposure followed by 1 hour of heat shock at 42 °C in
NRVMs. (D). Analysis of nuclear HSF-1 normalized to total protein in the four
groups; n = 3 per treatment for each group from 3 separate experiments; data were
analyzed by 2-way ANOVA with Tukey’s post-hoc test. Data are presented as the
mean ± SEM.
Importantly, this regulation may also depend on HSP70 as acute exposure to JG-98
prior to heat shock also reduced the nuclear translocation of HSF-1 (Figure 40C-D).
Based on these data, BAG3 emerges as a potentially important regulator of the stress
response, not only at the level of autophagic protein degradation but also at the gene
level through modulation of HSF-1 stability and localization. Future studies should
expand on this work to determine the mechanisms that regulate BAG3 partitioning into
its two distinct cellular locations/pathways in response to stress: the nucleus to regulate
HSF-1 dependent chaperone gene expression and the sarcomere to regulate protein
turnover through CASA.
Concluding Remarks
In summary, this dissertation explored the role and regulation of the HSP70 cochaperone protein BAG3 in cardiomyocytes. At the onset of this project, we knew BAG3
was relevant for human disease and for in vivo cardiac structure and function
[33,54,70,307]. We hypothesized that the functional significance of BAG3 for the heart
stemmed from a role at the sarcomere, where the protein was shown to localize and
where BAG3 mutations were associated with disarray [34,47]. Based on these
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assumptions, we endeavored to define the sarcomere functional significance of BAG3
and to determine the mechanism(s) of BAG3-dependent sarcomere maintenance. Upon
the completion of this work, we conclude that BAG3 is functionally relevant for the
mature sarcomere and maintains sarcomere protein turnover through CASA. Moreover,
we show that sarcomeric BAG3 is relevant in human disease as sarcomere-associated
BAG3 decreased in males with DCM and correlated with functional decline. Importantly,
a proposed heart failure therapy using adeno-associated virus to express BAG3 in mice
after myocardial infarction rescued sarcomere function and restored CASA. However,
our data show that proposed cancer therapies that disrupt binding of BAG3 to HSP70
are likely cardiotoxic and prevent CASA in cell models, resulting in cardiomyocyte
death, reduced autophagy, and sarcomere disarray. A more detailed understanding of
the mechanisms regulating BAG3’s stability, sarcomeric localization, and regulation of
the stress response through autophagy and HSF-1 may lead to targeted therapeutic
opportunities for heart failure. We hope that future studies will build on our findings to
achieve this goal.
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